Non-conventional polymers as matrix excipients for hot melt extruded oral-release formulations by Claeys, Bart
  
  
 
Ghent University 
Faculty of Pharmaceutical Sciences 
 
 
 
NON-CONVENTIONAL POLYMERS AS MATRIX EXCIPIENTS 
FOR HOT MELT EXTRUDED ORAL-RELEASE FORMULATIONS  
 
Bart Claeys 
Pharmacist 
 
 
Thesis submitted to obtain the degree of doctor in Pharmaceutical Sciences 
2015 
 
Promoters: 
Prof. Dr. C. Vervaet 
Prof. Dr. J.P. Remon 
 
 
Laboratory of Pharmaceutical Technology 
Ghent University 
 
 
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
  
   
Acknowledgements 
 
 
 
ACKNOWLEDGEMENTS 
 
This doctoral thesis would not have been possible without the endless support and 
encouragement of numerous people, therefore thank you:  
Prof. Jean Paul Remon, for giving me the opportunity to start this PhD. I will never 
forget one of my last classes at the institute of Pharmaceutical Sciences were you asked at the 
end of your lecture if ‘Bart’ was present in the audience. At first, I thought that I did 
something wrong as I was co-organizing some events for our graduation-party. The fact that 
you offered me a position as PhD-student at the lab of Pharmaceutical Technology came as a 
surprise for me, but really changed a lot for me. It had a profound impact on me as a scientist 
and as a person. I also thank you for the interesting and productive discussions that we often 
had, as well as our brainstorming sessions. 
Prof. Chris Vervaet, for believing in me and giving me the opportunity to start this 
PhD. Especially thank you for your patience and revising all of my manuscripts. I realize that 
scientific writing is not my strongest point, which often resulted in first drafts with chaotic 
structures and spelling errors, but you really kept your patience and revised all my 
manuscripts carefully. This doctoral thesis would have been impossible without your support 
and input. 
Prof. Thomas De Beer and prof. Bruno De Geest, for the pleasant collaborations and 
the scientific discussions. We should definitely go cycling again next year! 
 
Acknowledgements 
 
 
Prof. Peter Adriaensens, prof. Robert Carleer and dr. Sam Possemiers for the 
constructive collaborations: thank you for your help with the FTIR-experiments and the 
SHIME (Simulator Human Intestinal Microbial Ecosystem). 
Katharine Wullaert, Ilse Dupon, Christine Geldhof and Daniël Tensy, for all the 
administrative work and assistance with in vivo experiments. 
My colleagues of the lab, thank you for the nice working atmosphere, your support, 
the many scientific discussions we had, but definitely also our coffee breaks, enjoyable lunch 
meetings and after-work drinks. Thank you for 4 years of unforgettable experiences and 
memories. All the best with your future careers. Special thanks go to Lien, Lieselot, and 
Anouk, my colleagues from -without a doubt- the best office of the third floor. Lien, you have 
an amazing voice, your singing was amazing at our wedding. I could not have imagined a 
better neighbor. Lieselot, I knew you already from the student union, and I got to know you 
now as a colleague. You are a great and really fun person to be around. I really appreciate 
your lively, enthusiastic, and energetic character. Anouk(ske), thank you for the constructive 
and helpful scientific discussions. Our (M)DSC-talks really were pleasant, you have a lot of 
knowledge and your ambition is endless, you were a great colleague. 
The PhD students of the chemistry labs of Prof. Richard Hoogenboom and Prof. Filip 
Du Prez: Victor R. de la Rosa and Xander Hillewaere. Thank you for your help and assistance 
with SEC-analysis, analyzing my NMR-data and your input from a chemical standpoint. 
My thesis students, for their support with the experiments, their scientific input and 
assistance: Reinout Vandeputte, Ruben De Coen, and Sander De Bruyn. 
 
Acknowledgements 
 
 
All my friends, for our enjoyable moments that made me forget my doctoral thesis and 
the work associated with it. Thank you for all the amazing parties, get-together-drinks, 
memorable holidays and mind-blowing weekends.  
My deepest gratitude goes out to my family, and in particular to my parents, my 
brothers Wim and Peter, my sister Katrien, my mother- and father-in-law, Marleen and 
Francis, my sister-in-law Sabine and my grandparents. Thank you for your everlasting 
support, confidence and encouragements. I really am lucky to have such a loving family. 
Mom, dad, especially thank you for the many opportunities you have given me! 
And last but definitely not least I want to thank, my girl, my wife, Anne-Sophie. This 
doctoral thesis shatters into nothing when I compare it with you. I am living the dream with 
you by my side. You are the greatest thing that ever happened to me. I love you.
  
Table of Contents 
 
 
 
TABLE OF CONTENTS 
 
LIST OF ABBREVIATIONS 1 
OUTLINE AND AIMS 3 
 
INTRODUCTION Ι Hot melt extrusion and injection molding: a critical review 5 
CHAPTER 1 I The creation of a pH-independent immediate release polymethacrylate formulation via 
quaternization of the polymer or the addition of acids 45 
CHAPTER 2 I Structural modifications of polymethacrylates: impact on thermal behaviour and release 
characteristics of glassy solid solutions 61 
CHAPTER 3 I Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation via hot melt extrusion 
and injection molding 91 
CHAPTER 4 I Thermoplastic polyurethanes for the manufacturing of highly dosed oral sustained 
release matrices via hot melt extrusion and injection molding 113 
CHAPTER 5 I Release characteristics of polyurethane tablets containing dicarboxylic acids as release 
modifiers – a case study with diprophylline 143 
 
GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 171 
SUMMARY  175 
SAMENVATTING 179 
CURRICULUM VITAE  185 
  
List of abbreviations 
 
 1 
 
LIST OF ABBREVIATIONS 
1
H-NMR 
1
H-Nuclear Magnetic Resonance  
AIBN Azoisobutyronitrile  
API Active Pharmaceutical Ingredient  
ATR Attenuated total reflectance  
BSA Bovine serum albumin  
CEL Celecoxib 
DAD Diode Array Detector  
DMAEMA Dimethylaminoethylmethacrylate  
DMF Deuterated Dimethylformamide  
Dyph Diprophylline 
EC Ethylcellulose 
ENG Etonorgestrel 
EudrE Eudragit
®
 E  
EudrE-Q Quaternized Eudragit
®
 E  
EVA Ethylene Vinylacetate 
FBT Fenofibrate  
FTIR Fourier-transform infrared  
HME Hot Melt Extrusion 
HPC Hydroxypropyl Cellulose 
HPMC Hydroxylpropyl Methyl Cellulose 
HS Hard Segment 
HSM Hot Stage Microscopy  
IBP Ibuprofen 
IM Injection Molding 
iso-BMA Isobornylmethacrylate 
IUD Intrauterine Device 
IVR Intravaginal Rings 
LCST Lower Critical Solution Temperature  
MCR Multivariate Curve Resolution  
MDI 4,4’-Methylene Diphenyl Diisocyanate  
MDSC Modulated Differential Scanning Calorimetry 
MMA Methylmethacrylate 
MPT Metoprolol Tartrate  
n-BMA n-Butylmethacrylate  
PCL Polycaprolactone  
PDI Polydispersity Index  
PEG Polyethylene Glycol 
PEO Polyethyleneoxide 
PEtOx Poly(2-ethyl-2-oxazolin)e 
List of abbreviations 
 
 2 
 
PLGA Poly D,L-Lactic-co-Glycolic Acid 
PVA Polyvinylacetate  
PVP Polyvinylpyrrolidone 
PVPVA Polyvinylpyrrolidone/Vinyl Acetate  
R&D Research & Development 
RID Refractive Index Detector  
SCFA Shortchain Fatty Acids  
SDS Sodium Dodecyl Sulfate  
SEC Size Exclusion Chromatography  
SEM Scanning Electron Microscopy  
SHIME Simulator of the Human Intestinal Microbial Ecosystem  
SR Sustained Release 
SS Soft Segments  
t-BMA tert-Butylmethacrylate  
Tg Glass Transition Temperature 
TGA Thermogravimetric Analysis  
Th Theophylline 
Tm Melting point Temperature 
TPUR Thermoplastic Polyurethanes 
TPR Tamper Resistant Formulation 
XRD X-ray Diffraction  
 
 
 
Outline and aims 
 
 3 
 
 
OUTLINE AND AIMS 
 
Hot melt extrusion (HME) is an established process that has been used for almost a 
century. The combination with injection molding (IM) enables the processing of materials 
with high dimensional precision. These techniques rely on obtaining a homogeneous system 
by converting raw materials into a product of uniform shape via a substantial energy input, 
provided by elevated temperature, high shear force, and pressure. HME and IM are widely 
used for a plethora of applications as they allow the continuous processing (replacing 
traditional batch processing), as well as the implementation of process analytical technology 
to understand and control the manufacturing process. In the pharmaceutical field, on the other 
hand, research valorization has been disappointing.  
The objective of this doctoral thesis was, therefore, to evaluate the use of several non-
conventional polymers as matrix excipients for hot melt extruded oral-release formulations. 
Expanding the range of polymers currently used for HME/IM could potentially solve the 
problems associated with the current formulations: pH dependent release profiles, stability 
issues, and low drug loaded dosage forms. Also, formulations containing 3 components 
(active pharmaceutical ingredient (API), polymer and other additional excipient) have been 
extensively described in literature. If the characteristics of an extrudate containing API and 
polymer does not meet the requirements, a third component (plasticizer, drug release 
modifier, swelling agent, etc.) is often added to improve the formulation its performance. This 
doctoral thesis has the intention to emphasize the importance of the polymer. Try to ‘keep it 
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simple’. The focus should first be on the polymer rather than on the addition of a third 
component. To this end, the process of HME could be simplified as a combination of 2 
components requires less quality control, process control and decreases the complexity of 
formulation characterization. Overall, this doctoral thesis accentuates the need for a more 
rational design of polymer matrix excipients for drug formulation via HME and IM. 
The objectives of this study were: 
1. To create a pH independent immediate release formulation via the modification of a 
conventional polymer: polymethacrylates  
 
2. To alter the polymer composition of a conventional polymer to increase a 
formulation’s mechanical unstabiliy: polymethacrylates 
 
3. To evaluate the use of a new non-conventional polymer as immediate and/or sustained 
release matrix excipient: polyoxazolines 
 
4. To evaluate the use of a new non-conventional polymer to produce high drug loaded 
sustained release formulations: polyurethanes 
  
INTRODUCTION 
 
 
Hot-melt extrusion and injection molding: 
a critical review 
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Introduction 
 
Hot melt extrusion (HME) is an established process that has been used for almost a 
century. It was introduced in the plastics manufacturing industry, quickly followed by the 
food processing industry as it allows the continuous manufacturing of a wide variety of forms 
and shapes at a low cost. Over the last three decades, the pharmaceutical industry also started 
to recognize the potential of HME with a boost in HME-related research and patents [1], as a 
consequence. HME is defined as a process that transforms raw materials into a homogeneous 
melt (the extrudate) under controlled conditions, such as temperature, feed rate, screw speed 
and pressure.  
 
The basic extrusion set-up (Figure 1) consists of three parts: a feeding device, a 
temperature-controlled barrel containing one or two screws (co-rotating or counter-rotating) 
and a die to shape the extrudate in a final form. The function of the feeding device is to 
transport the raw materials, most likely a powder blend containing API, thermoplastic 
polymer and other additional excipients, into the barrel under controlled conditions. The 
barrel, heated to the desired temperature, provides the energy needed for the powder blend to 
melt, while the screws in the barrel are responsible for the kneading, mixing and 
transportation of the blend towards the die. The friction generated by the rotating screws 
provides additional energy input to transform the powder blend into a homogeneous 
extrudate. The die, located at the end of the extrusion barrel, shapes the extrudate into a 
distinct form, which is then subjected to further downstream processing. 
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Figure 1. Hot melt extrusion equipment 
 
 Several downstream processing devices are available to transform the homogeneous 
extrudate into its final product form: (a) the extrudates can be cooled on conveying rolls [2]; 
(b) cutting the extrudates into small pellets can be done via a pelletizer (fast spinning short 
knives) immediately at the die exit (die-face pelletizing) or after cooling (strand pelletizing) 
[3]; (c) forcing the extrudates through chilled rolls (chill rolling) results in the continuous 
manufacturing of films; (d) calendering using chilled rolls with tablet-shaped cavities allows 
the continuous shaping of the extrudates into tablets [4]; (e) grinding of the hot melt 
extrudates yields a powder which can be filled into capsules or compressed into tablets; (f)  
shaping the extrudates into a final product form via injection molding.  
 
Injection molding (IM) is one of the most versatile downstream processing techniques 
available. It allows the production of complex final product forms with high dimensional 
precision. IM has three basic components: the injection unit, the mold and the clamping 
system. The injection unit prepares the homogeneous melt to be transferred to the mold, while 
the clamping system is responsible for the opening and closing of the mold. The molten 
material is transferred by means of a pressure-controlled injection step into a closed and 
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shape-specific mold cavity, basically duplicating the cavity of the mold. Maintaining the 
injected material under pressure for a specified time (post-pressure) is necessary to prevent 
back flow of the melt and to compensate for the decrease in volume during hardening of the 
melt. Upon complete solidification, the final drug product is obtained by opening the mold. 
The mold basically consists of a sprue, a runner and a cavity. The sprue is the opening, 
located at the beginning of the mold that is responsible for an appropriate connection between 
the die of the HME device and the runner of the mold. The runner is the transport channel of 
the mold. Hence, the molten material flows through the die, sprue and runner in order to reach 
the mold cavity. Variations in final drug product form can be easily obtained by varying the 
complexity or the shape of the mold cavity. Molds can consist of a single cavity or multiple 
cavities to increase the production capacity. In multiple cavity molds, each cavity can be 
identical (mass production) or can be unique with special selected geometries. This range of 
design considerations and possibilities endorses the versatility of the injection molding 
technique. 
 
The first injection molding device was build and patented in 1872 by John Wesley 
Hyatt [5]. It consisted of a needle-like plunger that injected plastic through a heated cylinder 
into a mold. About seventy years later (1946), the first screw injection molding machine was 
created by James Watson Hendry, introducing a more precise and controlled injection step, 
thereby increasing the quality of the produced products. Although injection molding found its 
origin in the plastic processing industry (nowadays consuming approximately 32 wt.% of all 
plastics [6]), the pharmaceutical industry has recently become interested in IM as a versatile 
processing technology.  
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HME in combination with IM offers several advantages compared to conventional 
pharmaceutical production processes: a) it is a solvent-free process, avoiding time-consuming 
drying steps, residual solvent issues and possible solvent-mediated drug degradation; b) as the 
materials only encounter shear forces, it allows the processing of brittle materials; c) the 
extensive mixing in the barrel enables the production of final products with a precise, and 
homogeneously dispersed, drug content; d) it is a low-cost operation as it is not a labor-
intensive process and almost no post-production work is required as the product is finished 
upon ejection; e) high production output rates are possible using multi-cavity molds; f) 
product design flexibility by manufacturing molds with various shapes; g) it is a continuous 
process which offers distinct advantages over batch processes in terms of reduced 
development time, reduction of material waste, less product variability and improved product 
quality. During HME, the drug becomes homogeneously dispersed at a molecular level in the 
carrier (often a thermoplastic polymer). This offers several advantages from a formulation 
perspective: increased bioavailability of poorly soluble drugs; enhancement of the dissolution 
rate; inhibition of the recrystallization of an amorphous API; taste masking of API’s; 
possibilities for controlled or targeted drug release. 
 
Limitations of the HME and IM process are mostly related to stability issues. During 
extrusion, all components of the formulation must be thermally stable at the selected 
processing temperature. Due to local friction and shear forces induced by the rotating screws, 
the temperature inside the barrel can become higher than the set temperature, leading to 
possible drug and polymer degradation. The temperature and torque of each barrel segment 
should, therefore, be accurately monitored. The state (crystalline, amorphous) of the drug or 
of other excipients in the formulation form can have a profound impact on the processability 
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and stability of the final product. The API, for instance, can lower the glass transition 
temperature (Tg) of the polymer, thereby decreasing the processing temperature and 
increasing the processability. Or the melting of the API can prevent the hardening of the 
polymer matrix. These changes in physicochemical characteristics are difficult to predict 
upfront and have to be experimentally determined. Moreover, it is for the operator not 
straightforward to change a parameter if product defects are detected. For instance, if 
degradation in the final formulation occurs due to a too high processing temperature, this 
could be resolved by lowering the processing temperature. However, this increases the 
polymer viscosity and the resulting higher shear forces can locally increase the temperature, 
thus enhancing the risk of product degradation. Possible solutions for lowering the processing 
temperature without increasing the shear forces include the lowering of Tg via the addition of 
a plasticizer [7-8], compressed gas [9], CO2 [10-11] or by using API’s with a plasticizing 
effect on the polymer [12-13]. A final limitation of the HME and IM process is the high initial 
equipment investment. 
 
Marketed applications  
Currently, hot melt extrusion and injection molding have been applied for numerous 
applications: dental equipment [14], capsules [15], vaginal rings [16], tissue-engineered 
scaffolds [17], (biodegradable) implants [18], stents [19], taste masking purposes [20], films 
for transdermal or transmucosal delivery [21], solid dispersions [22], etc. In literature, an 
extensive number of reviews have been published representing HME as a robust 
manufacturing method with an enormous potential. It is, therefore, not the aim of this 
introduction to provide a complete literature review about HME/IM and its use as a 
processing technique in research & development (R&D). Examples of commercially available 
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formulations manufactured via HME and/or IM are listed below as these processing 
techniques are the focal point of this research project.  
 
Manufacturing 
The FlexTab
TM
 technology is an interesting example to demonstrate the potential of 
HME/IM. Pharmaceutical companies are continuously looking for ways to improve the 
patient compliance and to create new combination therapies to boost their revenues. To this 
end, new capsule designs are needed to meet their increasing demands (e.g. delivering of two 
liquids in one dose, multicompartimented capsules to incorporate a drug in powder form and 
in a liquid form, etc.). The traditional capsule manufacturing technique (dip-molding) is 
currently not capable of meeting those demands. The FlexTab
TM
 technology, on the other 
hand, allows the manufacturing of new complex and multicompartimented capsules as IM as 
processing technique offers the dimensional precision needed in the design of these new 
capsules.  
The Egalet
®
system [15] was developed to create a sustained release formulation. As 
erosion and dissolution of the polymer matrix increases the formulation’s surface area, 
thereby hampering the sustained release characteristics, the Egalet
®
 system is based on the 
development of a product with a constant surface area. It consists of a two-step IM process. 
The first step involves the molding of a non-degradable polymer into an open-ended tube in 
which, in a second step, the formulation is injected (Figure 2). As the formulation is 
surrounded by a non-degradable polymer, the drug is released via erosion from the open ends 
(i.e. constant surface area), thereby controlling the drug release. Covering both open ends with 
polymeric plugs resulted in a delayed release system (the Egalet
®
 Chrono technology). Before 
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drug is released from the core of the tablet, the end-plugs, containing polymeric carriers with 
pre-determined dissolution rates, must dissolve. 
 
 
Figure 2. The Egalet
®
 release technology (A) and the Egalet chrono delayed release system (B); Obtained from 
ref [15] 
The Intac
®
 technology is a tamper-resistant formulation technology (TRF) developed 
by Grünenthal. Using this technology should prevent the misuse and abuse of medication, 
which is a raising concern of public health. Abusers seek to achieve a “high” from 
prescription medication, by crushing the pills, followed by snorting, smoking or injecting the 
new altered formulation (e.g. sustained release formulation with opioids) [23]. The 
combination of HME as processing technique and (very) high molecular weight polyethylene 
oxide as matrix polymers, allow them to create TRF-formulations, thereby preventing the 
abuse. Nucynta
®
 (Janssen), for example, was developed as an opioid, sustained release, and 
tamper resistant formulation [24]. 
Intravaginal rings 
Several intravaginal rings (IVR) such as FemRing
®
/Estring
® 
and Progering
®
/Fertiring
®
 
for hormone replacement therapy and contraception, respectively, were manufactured via 
HME and/or IM. They are commonly made of silicone (poly(dimethylsiloxane)) due to its 
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low toxicity, high thermal stability and physiological inertness. As the production process 
involves the curing of the silicones in the mold at high temperatures (around 150°C) and often 
a post-curing (at 200°C), several other raw materials such as thermoplastic polyurethanes 
(TPUR) [25] and polyethylene vinylacetate (EVA) [26-27] are evaluated as alternatives. 
NuvaRing
®
 [26, 28], for example, is a novel contraceptive vaginal ring, manufactured with 2 
different EVA-polymers via HME. The ring consists of a core of EVA-polymer (with 28% 
vinylacetate content) containing both contraceptive APIs (ethinyl estradiol and etonorgestrel) 
surrounded by a coat of drug-free EVA-polymer (with a 9% vinylacetate content). The 
polymer with the lower vinylacetate content in the coat is responsible for the sustained release 
profiles over a period of 3 weeks as the drug first must diffuse through this low permeable 
EVA coat [29]. (Figure 3).  
 
 
Figure 3. Commercially available IVRs for hormone replacement therapy (Femring
®
 and Estring
®
) or 
contraception (Nuvaring
®
). Obtained from ref. [26] 
 
Ocular, dental and subcutaneous implants 
Lacrisert
®
 was the first hot melt-extruded pharmaceutical product, launched by Merck 
(now MSD) in 1981. It is a drug-free, translucent, rod-shaped, water soluble ophthalmic insert 
made of hydroxypropyl cellulose (HPC). The polymer lubricates and protects the eye from 
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dryness by stabilizing the precorneal tear film and prolonging the tear film breakup time [30]. 
HME was chosen as a processing technique as it allows the formation of rods with a specific 
shape (to fit into the eye) in a continuous manner at low cost.  
 
Ozurdex
®
 is a sterile, single-use system intended to deliver a biodegradable implant 
containing dexamethasone to treat macular oedema [31]. The formulation was initially 
developed as a solid, tablet-shaped implant that was surgically inserted in the posterior 
segment of the eye. Manufacturing via HME allowed the production of a precisely controlled 
filament, which could be inserted in the eye using a thin needle-shaped applicator. A 
combination of poly D,L-lactic-co-glycolic acid (PLGA) polymers was selected to deliver 
dexamethasone in a sustained manner, while ensuring a mechanical strength suitable for use 
in the applicator [31]. Upon production, the implant was sterilized via gamma irradiation, in 
compliance with the European Pharmacopeia requirements.  
 
Zoladex
®
 is a small implant designed to be subcutaneously injected to release 
goserelin acetate (a decapeptide analogue of lutinizing hormone releasing hormone) over 1 or 
3 months, depending on the drug loading [32]. During processing, peptide and PLGA are co-
dissolved in acetic anhydride as a solvent and subsequently freeze-dried to remove the 
solvent. Afterwards, the mixture is hot-melt extruded into an implant, sterilized and packaged. 
These marketed PLGA-products are only partially made via extrusion as it is used as a tool to 
shape the product into its final form, not as a process to mix and homogenize the raw 
materials.  
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Progestasert
®
 is a T-shaped intrauterine device (IUD) developed to release a hormone 
directly into the uterus to prevent pregnancy over a 1 year period. In order to compensate for a 
too fast release, the hormone was suspended in a hydrophilic liquid in which the active 
ingredient is insoluble, mixed with a poly dimethylsiloxane matrix and upon cross-linking 
extruded in the specific T-shaped form [33-34].  
Implanon
®
 is a single rod implant, similar to a matchstick, containing sufficient 
etonorgestrel (ENG) to inhibit ovulation for up to 3 years [35]. It is inserted under the skin of 
a woman’s upper arm, releasing its ENG content in a sustained manner. Comparable to 
Nuvaring
®
, it consists of a drug-loaded EVA-core (with a 28% vinylacetate content) 
surrounded by a low permeable EVA coat (with a 15% vinylacetate content). Implanon
®
 and 
Nuvaring
®
 highlight the capability of EVA polymers to control drug release and their 
essential characteristics (ease of manufacturing, flexibility, non-toxic) for HME/IM 
applications [36-37]. However, a currently unresolved issue with EVA polymers is a 
commercial source of medical grade approved materials (e.g. Celanese polymers). Litigation 
issues and related costs are negatively influencing the new supply agreements with a lack of 
medical-approved raw materials which hinder further developments [26]. The research of 
incorporating microbicides in IVRs composed of EVA polymers, for instance, has a huge 
potential but is hindered due to these regulatory constraints.  
 
Oral delivery applications 
In terms of drug delivery, oral drug administration still remains the route of choice for 
the majority of applications due to its high patient compliance. To manufacture oral dosage 
forms HME/IM has received considerable attention to incorporate drugs in polymer matrices. 
Basically, the drug is homogeneously mixed with the molten polymer during thermal 
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processing, which upon cooling results in a formulation with distinct characteristics: (a) the 
drug can be released in a sustained manner as the polymer acts as a release retardant; (b) the 
drug is protected from external influences (e.g. alcohol, enzymes); (c) taste masking of the 
drug; (d) higher drug solubility/bioavailability. Especially the latter has received considerable 
attention  
as a means to manufacture solid dispersions via HME/IM in order to improve the dissolution 
of new chemical entities when poor solubility is the rate limiting step for its in vivo 
application.  
 
The classification of solid dispersions, first introduced by Chiou and Riegelman [22], 
include simple eutectic mixtures, amorphous precipitations, glass suspensions and (glassy) 
solid solutions (Table 1). An eutectic mixture is a two-phase system where two components 
cocrystallize at the eutectic temperature, which is lower than the melting temperatures of both 
individual components. Glass suspensions and amorphous precipitations are two-phase 
systems were the crystalline and amorphous API is dispersed in an amorphous and 
crystalline/amorphous carrier, respectively. Miscibility between drug and polymer, on the 
other hand, leads to the formation of solid solutions and glassy solid solutions, i.e. 
homogeneous one-phase systems where the drug is molecularly dispersed in a crystalline and 
amorphous matrix, respectively. To obtain a homogeneous one-phase system, a certain degree 
of drug/carrier miscibility and kinetic stabilization is required [38]. The latter referring to the 
immobilization of an amorphous drug in a highly viscous matrix (i.e. when the difference 
between storage temperature and glass transition temperature (Tg) of the formulation is higher 
than 50°C). The idea behind the creation of the different types of solid dispersions is derived 
from the Noyes-Whitney equation [39]: 
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hV
CCsDA
dt
dC )( 
  
which defines the rate of dissolution (dC/dt) as a function of diffusion coefficient (D), surface 
area (A), the maximum concentration of the compound in the dissolution medium (saturated 
solution, Cs), the concentration of the compound in the dissolution medium (C), the volume 
of the medium (V) and the diffusion layer height (h). Dispersing crystalline API in a 
crystalline or amorphous matrix increases the surface area which positively influences the 
dissolution rate. Transferring the drug into its amorphous state maximizes the surface area, 
but also excludes the breakage of the crystal lattice of the drug which is often a dissolution 
rate limiting step.  
Table 1. Types of solid dispersions. Obtained from [40-42] 
 Eutectic 
mixture 
Glass 
Suspension 
Amorphous 
precipitation 
Glassy solid 
solution 
Solid solution 
PHASES 2 2 2 2 1 1 
DRUG crystalline crystalline amorphous amorphous molecularly 
dispersed 
molecularly 
dispersed 
CARRIER crystalline amorphous crystalline amorphous amorphous crystalline 
 
The first directly shaped HME solid dispersion on the market was Verapamil
®
 SR-E, 
created by Abbott Laboratories as an alcohol-resistant dosage form [43-44]. As a controlled-
release formulation contains a significantly higher amount of API relative to its immediate 
release counterpart, failure of the controlled release system could lead to critical, and even 
life-threatening, situations due to the sudden exposure to high drug concentrations (dose 
dumping effect). Therefore, in order to improve the safety profile of a sustained release 
formulation, resistance to the dose dumping effect caused by alcohol is advised. Processing a 
verapamil.HCl formulation via HME allowed to disperse the API in a HPMC/HPC polymer 
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melt, thereby protecting the formulation from the concomitant intake of alcohol (shielding 
effect). To this end, Roth et. al. [43] compared the influence of ethanol on the in vitro release 
rate of Verapamil
®
 SR-E with three commercially available Verapamil SR formulations 
processed via direct compression. The results indicated that the melt extrusion formulation 
was resistant to the solubilizing effects of ethanol in a medium containing up to 40% ethanol.  
The development of Kaletra
®
 illustrates the potential of HME as processing technique 
to increase the solubility and bioavailability of an API. Abbott Laboratories was facing 
difficulties to achieve adequate plasma concentrations when lopinavir and ritonavir were 
processed via conventional processing techniques (direct compression into tablets or filling 
into capsules). Although soft gelatin capsules, wherein both API’s were dissolved, improved 
bioavailability of these drugs, patient compliance for this formulation was low as it required 
storage at low temperature and the intake of up to 6 capsules/day, concomitant with food. 
HME, on the other hand, enabled the production of a solid solution as both API’s completely 
dissolved in a polyvinylpyrrolidone/polyvinylacetate (PVP/PVA) matrix during processing. 
HME allowed the production of a formulation, which was stable at room temperature, with a 
reduction of the daily tablet intake, less influenced by the patient’s food intake and with 
higher plasma levels. A similar approach was used for the development of Norvir
®
, designing 
a solid dispersion of ritonavir in a PVP/PVA matrix which can be stored at room temperature.  
 
Abbott Laboratories also developed a fast-onset ibuprofen (IBP) formulation via HME 
[45], where IBP was formulated in a readily soluble dosage form. Thermal processing of IBP 
in combination with PVP induced molecular interactions between both substances, which 
solubilized (i.e. molecularly dispersed) IBP in the PVP matrix. As a result IBP release 
depended on the disintegration time of the formulation and the dissolution of the polymer, 
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which provided a fast onset of drug release and a pH-independent release profile [44-45]. 
Upon extrusion, the extrudate was conveyed to a calendering device, shaped into granules, 
milled, mixed with other ingredients and finally compressed into a tablet.  
Rezulin
®
 was also successfully melt extruded into a solid dispersion containing 
troglitazone as an antidiabetic drug, but this formulations was withdrawn from the market 
because of safety concerns of the drug (liver toxicity) [46]. 
 Table 2. Overview of commercially available formulations that are manufactured via hot-melt extrusion. 
Product Company API Indication Polymer Application Reason for 
HME/IM? 
 
Femring
® 
 
 
Warner 
Chilcott 
 
Estradiol  
acetate 
 
Hormone 
replacement 
 
Silicone 
 
Vaginal 
 
Specific shape + 
SR 
 
Estring
®
 Pfizer Estradiol  
acetate 
Hormone 
replacement 
Silicone Vaginal Specific shape + 
SR 
 
Progering
® 
Fertiring
®
 
Silesia 
Laboratories 
 
Progesteron Contraception 
 
Silicone Vaginal Specific shape + 
SR 
 
Nuvaring
®
 MSD Estradiol 
Etonorgestrel 
Contraception 
 
EVA (28%) 
EVA (9%) 
Vaginal Specific shape + 
SR 
 
Implanon
®
 MSD Etonorgestrel Contraception 
 
EVA (28%) 
EVA (15%) 
Subdermal Specific shape + 
SR 
 
Progestasert
®
 Alza 
Corporation 
Progesteron Contraception Silicone 
EVA 
Intra Uterine 
Device 
Specific shape + 
SR 
 
Lacrisert
®
 MSD / Dry eye HPC Ophthalmic 
insert 
Specific shape + 
SR 
 
Orzurdex
®
 Allergan Dexametha-
sone 
Macular edema PLGA Biodegr. 
implant 
Specific shape + 
SR 
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Zoladex
®
 AstraZeneca Goserelin 
acetate 
Prostate cancer PLGA Biodegr. 
implant 
Specific shape + 
SR 
 
Norvir
®
 Abbott 
Laboratories 
Ritonavir HIV PVP/PVA Oral increase in 
bioavailability 
       
Kaletra
®
 Abbott 
Laboratories 
Lopinavir 
Ritonavir 
HIV PVP/PVA Oral increase in 
bioavailability 
 
 
      
Isoptin
®
 
SR-E 
Abbott 
Laboratories  
Verapamil Hypertension HPMC 
HPC 
Oral resistant to dose 
dumping 
 
Ibuprofen 
meltlets 
®
 
Abbott 
Laboratories 
Ibuprofen Pain PVP Oral fast onset 
 
 
Rezulin
®
 Withdrawn Troglitazone Diabetic PVP Oral increase in 
bioavailability 
       
EVA: ethylene vinyl acetate (% vinyl acetate content); HP(M)C: hydroxyl propyl (methyl) cellulose; PLGA: poly D,L-
lactide-co-glycolide acid; PVP(VA): polyvinyl pyrrolidone (vinyl acetate); SR: sustained release 
 
The commercially available pharmaceutical dosage forms which are (partially) 
manufactured via HME/IM are listed in table 2. Despite the benefits of HME/IM as 
processing technique, the large number of research papers and several high quality reviews [1, 
41, 47-49], only a limited number of HME/IM-processed products have reached the 
commercial market. Especially, the manufacturing of oral drug formulations has been limited. 
And even if HME/IM is included in the manufacturing process it is often combined with other 
techniques to finalize the dosage form (e.g. via direct compression). 
 
A variety of problems have been limiting the commercial applications of solid 
dispersions, the low availability of manufacturing equipment being a first reason. 
Pharmaceutical companies are currently not convinced that it is worthwhile making the 
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significant investments required to install HME/IM equipment in their facilities as solid 
dispersions can also be manufactured via other techniques which are widely available (e.g. 
spray-drying) . A possibility to limit these high investment costs is to omit IM in the early 
stages of development. Analyzing the performance of a solid dispersion does not require the 
transformation into its final specific shape, the characterization can be done on the hot melt 
extrudates. A second limiting factor for the low number of commercially available HME/IM 
products has been the formulation’s stability [49]. A molecularly dispersed drug can be 
subjected to drug diffusion (drug mobility) leading to non-homogeneous distribution 
(amorphous drug clusters). This thermodynamically unstable amorphous drug can nucleate to 
(partially) crystalline drug particles. Several underlying forces are influencing this 
crystallization process. To this moment, there is still a lack of fundamental understanding with 
respect to the chemistry behind these underlying forces [50]. Stability issues can also occur 
upon dissolution. Some excipients (e.g. PEG) or polymers have been able of stabilizing the 
supersaturated drug state, while others fail. The underlying reasons are, again, not fully 
understood. Third, the process of HME still remains a ‘black box’. A physical mixture 
API/polymer is fed to the extruder, where thermal energy and shear forces (rotational screws) 
transform the material into a homogeneous extrudate. But how the polymer/API mixture is 
interacting or behaving inside the polymer barrel is largely unknown; characterization mainly 
depends on off-line instruments. Recent process analytical tools (e.g. near infrared and raman 
spectroscopy) are currently addressing this issue, also providing a quality built into the 
products rather than testing it off-line [51-52]. To this end, there has been a narrow range to 
select the proper parameters from a formulation point of view. Processing at, for instance, 
100°C could lead to the formation of a glassy solid solution, where the drug is molecularly 
dispersed in the amorphous carrier, while processing at 90°C could yield an amorphous 
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precipitation, a 2-phase system where the amorphous drug is dispersed in the amorphous 
carrier. Similar, a rotational screw speed of 100rpm instead of 60rpm can have significant 
consequences on the type of solid dispersion formed. Only a small shift in processing 
parameters can have major consequences on the batch quality. Moreover, these small 
molecular changes (glassy solid solution or amorphous precipitation) are difficult to distingue 
during characterization [53]. A final limiting factor for the low number of commercially 
available HME/IM products has been the formulation’s drug load. Elevated drug loads are 
difficult to achieve. Most drug-carrier systems are only partially miscible, resulting in phase 
separation and the formation of unstable amorphous drug clusters at elevated drug loads [54-
55]. It is, therefore, important to choose an ideal polymer/API combination. A tool to estimate 
the solubility of the API in the polymer is proposed by the Hansen solubility parameters [56]. 
Small differences in solubility parameters are, most likely, equal to high miscibility between 
API and polymer. Similar, the sustained release (SR) formulations have been limited in drug 
load, either linked to processing issues during the HME process, or due to a significant burst 
release when less polymeric matrix former is incorporated in the formulation. Quinten et. al. 
[57], for instance, described that drug load in an acrylic polymer matrix was limited to 30% 
when processed via HME/IM, drug release from these matrices occurred in a first order 
manner via a combination of swelling and diffusion 
 
Polymers 
To date, a variety of polymers have been evaluated as excipient for the production of 
immediate or sustained release formulations via HME. Examples of polymers used for this 
purpose are listed with their respective chemical structure in table 3 and 4. The polymers need 
to fulfil several criteria in order to allow processing via HME: thermoplastic, thermostable, 
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chemically stable, pharmacologically inactive and non-toxic. Thermoplastic polymers are a 
class of polymers which exhibit softening and elasticity at a temperature above its glass 
transition temperature (Tg). Upon cooling, the polymer returns to its original hardened state, 
regaining its structural strength with a smooth surface finish as a result. Generally, a 
thermoplastic polymer consists of non-crosslinked polymer chains, often with high molecular 
weights. During processing, it is advisable to use low viscosity grade thermoplastic polymers 
[58] as the combination of a high processing temperature and the mechanical shear stress 
during HME/IM could damage the polymer. Especially during the injection step into the 
mold, the materials are exposed to more stress. The choice of the type of thermoplastic 
polymer is critical as its properties determine the processing conditions, the release 
mechanism, the type of solid dispersion, etc.  
Controlled release formulations can be developed with a variety of polymers: 
ethylcellulose (EC) [59-61], hydroxypropyl (methyl) cellulose (HP(M)C) [62], ethylene vinyl 
acetate (EVA) [29, 63], polyvinyl acetate (PVA) [64], poly lactic (co-glycolic) acid (PL(G)A) 
[65-66], silicone [67], polycaprolactone (PCL) [68-69], polyoxazolines [70], polyanhydrides 
[71], methacrylate copolymers (Eudragit
®
 RS/RL) [72-73], and even several lipid materials 
[74-76]. Using one of these polymers results in matrix or reservoir systems [77-78]. In matrix 
systems, the drug is homogeneously distributed in a polymer matrix. Drug release occurs via 
diffusion through pores, swelling of the matrix and/or polymer erosion. The cumulative 
release of an API from a matrix formulation is generally first order (i.e. release rate is in 
function of the drug concentration available at that time) [27]. As drug fraction at the surface 
of the system is released faster than the drug in the inner core, due to the smaller diffusion 
distance, an initial burst release is likely to occur. Two types of matrix devices exist, 
depending on the concentration of the API in the polymer matrix. The API has a maximum 
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solubility in the polymer matrix (saturated concentration). If the formulation contains less API 
than the saturated concentration, the formulation is classified as a monolithic solution device. 
If an amount of API is not able to dissolve in the polymer matrix (API concentration > 
saturated concentration), the formulation is classified as a monolithic dispersion system. In 
reservoir systems, the drug is encapsulated in a core matrix, which is completely surrounded 
by a release-controlling polymer membrane. An initial burst release cannot occur as the drug 
release rate is controlled by the polymer membrane. However, reservoir systems are less 
reliable than matrix systems as rupture or damaging of this membrane causes dose dumping 
[79]. Generally, zero order release kinetics (i.e. a constant rate independent of the initial or 
existing concentration) are pursued from reservoir systems.  
 
A wide range of mechanisms can control the drug release rate from a dosage form: 
delayed dissolution, diffusion controlled and solvent flow controlled. Polymers synthesized to 
delay the drug dissolution aim to protect the drug from the aqueous environment using a 
reservoir or matrix system where a polymer coating or a polymer matrix dissolves, degrades 
or erodes at a slower rate than the respective drug. In diffusion-controlled mechanisms, the 
polymer acts as an insoluble polymer matrix through which the drug molecules must diffuse. 
The percolation theory states that a minimal drug load is needed to generate sufficient pores 
and diffusional channels throughout the insoluble matrix to allow dissolution and release of 
the entire drug content (percolation threshold). Polymers that form a hydrogel upon contact 
with the dissolution medium (e.g. xanthan gum or polyethyleneoxide, PEO) are also able of 
controlling the drug release [80]. The viscous gel hinders the API’s mobility and diffusion via 
its entangled polymer structure. The solvent flow mechanism utilizes the osmotic potential 
gradient across a semi-permeable membrane to release the drug from the delivery device. The 
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flow rate of the dissolved drug from the dosage form is determined by the pore diameter of 
the semi-permeable membrane or by the osmotic gradient (which depends on the drug load). 
Polymers used in controlled release applications can also be classified as either biodegradable 
or non-biodegradable. Biodegradable matrices (e.g. thermoplastic starch, polylactic acid) are 
able to degrade in an aqueous environment via hydrolytic- or enzymatic-induced polymer 
chain scission. They often are synthesized as a combination of two or more polymers 
(copolymer) which allows the formulation scientist to alter the degradation rate by varying the 
distinct polymer ratios [81]. Wu et. al., for instance, determined a higher biodegradation rate  
for PLGA containing a higher glycolic acid moiety. Ester bond hydrolysis was considered as 
responsible for its biodegradability.  
Immediate release systems can be developed via a variation of polymers: low 
molecular weight polyethylene oxide (PEO) [82-83], starch [84], hydroxypropyl (methyl) 
cellulose (HP(M)C, Klucel
®
) [85], polyvinylpyrrolidone (PVP, Kollidon
®
) [86], 
vinylpyrrolidone/vinylacetate copolymer (Kollidon
®
 VA) [87-88], methacrylate polymer 
(Eudragit
®
 E) [53, 89], and a copolymer of PEG6000/vinylcaprolactam/vinyl acetate 
(Soluplus
®
) [58, 90]. An important factor determining the release rate is the state of the drug 
in the polymer matrix, which can be crystalline, amorphous or dissolved. As breaking of the 
crystal lattice during dissolution is often a rate-limiting step, drug particles in the amorphous 
or dissolved state are preferred for immediate release formulations. Critical with these 
formulations is their stability. Due to the substantial energy uptake during the HME/IM 
process, followed by a fast cooling of the melt, the amorphous drug is kinetically trapped 
resulting in a blend far from its thermodynamic equilibrium. Several methods have been 
proposed to decrease the rate of the recrystallization and, hence, increase the stability. One of 
them is the use of a polymer with a high glass transition temperature (Tg) providing lower 
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molecular mobility to the drug in the viscous polymer matrix, resulting in an increased 
physical and kinetic stability [38]. This approach, however, is not always successful as recent 
studies evidenced the existence of β-mobility, besides the known α-mobility. The latter 
referring to slow movement on a large length scale, similar to those involved in viscous flow, 
while β-mobility is related to fast motions on the length scale of local molecular motions such 
as rotations of side chains. A high β-mobility can cause API recrystallization, even at 
temperatures below the polymer glass transition temperature [91]. A second, and far more 
important, issue towards stabilization is the molecular interaction between polymer and API 
(miscibility). Addition of a miscible polymer may reduce the tendency of the drug to 
recrystallize by increasing the energy barrier since prior to recrystallization the drug must 
break its interaction with the polymer. If the drug load is lower than the saturated solubility, 
the solid dispersion is unsaturated with no thermodynamic driving force to recrystallize (i.e. 
drug is solubilized). An API solubilized in the polymer matrix becomes an intrinsical part of 
the matrix, thus influencing its wettability, viscoelastic properties and release characteristics. 
A thermodynamically unstable formulation occurs when the drug load is exceeding the 
saturated solubility. Therefore, drug-polymer miscibility is an important aspect of the 
formulation design. However, drug solubility in the polymer matrix is usually low [92], often 
resulting in solid dispersions that do not meet the dose requirements. Many studies indicate 
that strong drug-polymer interactions may even help to minimize thermal degradation of heat 
sensitive drugs, and also to prevent drug precipitation during dissolution by maintaining the 
supersaturation state of the drug [93-94].  
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Table 3. Overview of important polymers used to process sustained release formulations via HME 
Polymer Chemical 
name 
Chemical structure Comment Ref. 
PLGA 
 
Copolymer of 
poly lactic and 
poly glycolic 
acid 
 
 Biodegradable polymer 
 Used in implants 
 Tg, crystallinity and biodegradation 
can be varied by altering the lactic 
and glycolic acid molar ratio 
 
[66, 
95] 
Silicone 
polydimethyl 
Polydimethyl-
siloxaan 
(pDMS) 
 
 Used for production of vaginal 
rings 
 Very flexible, often used in 
cosmetics and food industry (anti-
foaming agent) 
[27, 
96] 
Kollidon
®
 SR 
 
Spray dried 
mixture of  
PVP and poly 
vinyl acetate 
(PVA) 
 
 Molar ratio PVP/PVA 20/80  
 The soluble part, PVP, can dissolve 
and leach out, resulting in porous 
PVA matrices 
 Requires high extrusion 
temperatures (140-180°C) 
[51, 
97] 
Soluplus
®
 Copolymer of 
PEG, vinyl-
caprolactam and 
vinylacetate 
 
 Can solubilize a wide range API’s  
 Amphiphilic structure: micelle 
formation with APIs 
 Amorphous polymer, low Tg 
 Broad temperature range for 
extrusion (120-200°C) 
[58, 
90] 
Kollicoat
®
 MAE Copolymer of 
methacrylic acid 
and 
ethylacrylate 
 
 Molar ratio 50/50 
 Anionic: intended to be used as an 
enteric matrix, drug mainly 
released in the intestine  
 Targetting duodenum 
[98-
99] 
EC: 
Ethylcelulose 
Polysaccharide 
 
 Good rheological properties, 
cohesiveness  
 Needs a plasticizer for extrusion 
 Often used as coating agent 
 Specific properties possible 
depending on the degree of ethoxyl 
substitution 
[100-
101] 
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MCC: 
Microcrystalline 
cellulose 
Polysaccharide 
 
 Good rheological properties, 
cohesiveness  
 Often used in extrusion-
spheronization 
[102-
103] 
Klucel
®
 Hydroxypropyl 
cellulose (HPC) 
Similar to MCC, with H 
partially substituted by 
CH2CH(OH)CH3 
 Thickening and swelling upon 
contact with water (depends on 
degree of substitution) 
 Flexible without the need of 
plasticizer 
[85] 
Hypromellose
®
 Hydroxypropyl 
methyl cellulose 
(HPMC) 
Similar to MCC, with H 
partially substituted by CH3 or 
CH2CH(OH)CH3 
 Thickening and swelling upon 
contact with water (depends on 
degree of substitution) 
 Flexible without the need of 
plasticizer 
 Acidic groups can be added to 
create enteric coating formulations 
(e.g. succinic and acetic acid for 
HPMC-AS) 
[104-
106] 
EVA 
 
Poly ethylene 
vinylacetate 
 
 Drug permeability can be tailored 
by varying the ratio of vinyl acetate 
 Non-conventional polymer for oral 
drug release 
 Used in vaginal ring formulation 
(Nuvaring
®
) 
[63, 
107] 
Eudragit
®
 L  
100-55 
Copolymer of 
methacrylic acid 
and ethyl 
acrylate 
 
 Soluble above pH>5.5 
 Requires plasticizer for extrusion 
 Anionic: used as enteric coating, 
can be used to form polycomplex 
matrices 
 Targetting duodenum 
[108-
109] 
Eudragit 
®
 L Copolymer of 
methacrylic acid 
and methyl 
methacrylic acid 
 
 Soluble above pH> 6 
 Anionic: used as enteric coating, 
can be used to form polycomplex 
matrices. Targetting jejunum 
[110-
112] 
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Eudragit
®
 S 
 
Copolymer of 
methacrylic acid 
and methyl 
methacrylate 
 
 Soluble above pH> 7 
 Anionic: used as enteric coating, 
can be used to form polycomplex 
matrices 
 Targetting ileum and colon 
[112-
114] 
Eudragit
®
 FS Eudragit S + 
methyl acrylate 
 
 Similar characteristics as  
Eudragit S 
 More flexible (lower glass 
transition temperature) 
[115] 
Eudragit 
®
 RS 
Eudragit 
®
 RL 
Copolymer of 
ethyl acrylate, 
methyl metha-
crylate, 
dimethyl-
aminoethyl 
methacrylate 
 
 Sustained release characteristics 
dependent on the number of 
cationic groups 
 Dimethylaminoethyl methacrylate 
with quaternary ammonium groups 
to induce hydrophilicity/porosity in 
the polymer structure  
[72-
73, 
116-
118] 
Eudragit 
®
 NE 
 
Copolymer of 
ethyl acrylate 
and methyl 
methacrylate 
 
 Insoluble 
 Neutral polymer: swells 
independent of pH 
[119-
120] 
Polyurethanes 
based on 
polyesters or 
polyethers 
Polyesters or 
polyethers 
linked together 
via a urethane 
(NCO) group: 
 
Note: Other variants of soft 
segments and hard segments 
are also possible. 
 Superior physical strength 
 High flexural endurance 
 Ease of processability 
 Allow high drug loading 
 
[121-
122] 
Polycaprolactone Polyester  
 
 Biodegradable 
 Very broad temperature range for 
extrusion, highly flexible 
 Often used for bone tissue 
engineering 
 
[123-
125] 
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Table 4. Overview of polymers used to process immediate release formulations via HME 
Polymer Chemical 
name 
Chemical structure Comment Ref. 
PVOH Poly-vinylalcohol 
 
 Formed by hydrolyzing poly 
vinylacetate 
 Requires high extrusion 
temperatures 
 Drug release can be tailored 
depending on the amount of 
hydroxyl groups 
[126-
127] 
Carbopol Polyacrylic acid 
 
 Various types available 
dependent on the degree of 
crosslinking 
 Becomes tacky upon wetting 
[128-
129] 
Eudragit
®
 E Copolymer of 
methyl-, dimethyl-
aminoethyl-, and n-
butyl methacrylate 
 
 Soluble above pH> 1 
 Targetting stomach: becomes 
protonated at low pH values 
 Ammoniumgroup of the 
polymer is important for 
molecular interaction 
[53, 
89, 
130] 
Kollicoat
®
 IR Copolymer of PEG 
and PVA 
 
 Semi-crystalline 
 Excellent water solubility: can 
be used as pore-forming agent 
 Difficult to extrude (Tg 45°C, 
Tm 208°C) 
 Emulsion stabilizer 
[131-
132] 
Kollidon
®
 
(Povidone) 
Polyvinyl 
pyrrolidone 
(PVP) 
 
 Range of Mw available 
 Very hygroscopic, amorphous 
 Used in coatings, binding agent 
 Often used to stabilize the 
supersaturated state of API’s 
[86, 
133] 
Kollidon
®
 VA 64 
(Copovidone) 
 
Copolymer of 
PVP and 
Polyvinylacetate 
(PVA) 
 
 Molar ratio PVP/PVA 60/40  
 Less hydroscopic as PVP 
 Broad temperature range for 
extrusion 
 
[88, 
134] 
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PEO Polyethyleneoxide 
 
 Available in variety of Mw 
 Often used as pore-forming 
agent 
 Often used to stabilize the 
supersaturated state of API’s 
 Easily extrudable at low 
temperatures 
[135-
136] 
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Conclusion  
HME and IM have been identified as promising manufacturing techniques for the 
production of formulations as they offer distinct advantages over standard pharmaceutical 
processing technologies: it is a solvent-free process, allows the processing of brittle and dusty 
materials, a reduction in labor forces during processing, high production rates are possible, 
enables the manufacturing of products with a high three-dimensional precision and it is a 
continuous process. Moreover, several types of solid dispersions can be manufactured, 
offering a solution for poorly water soluble drugs: 40% of all the new molecular entities have 
poor bioavailability due to a low aqueous solubility and this percentage is likely to increase as 
a result of high throughput screening and combinatorial chemistry. Despite these advantages 
and the extensive research that has been published, the number of marketed products 
manufactured via HME and/or IM as processing technique has been disappointing. The 
implementation of HME in the pharmaceutical industry is hindered by a number of barriers 
which are mainly linked to five key areas: 
1) The limited availability of manufacturing equipment as HME/IM is not yet an 
established processing technology within the pharmaceutical industry. 
2) Stability issues. Numerous studies have observed changes to the dissolution rate 
on storage as drug mobility during storage can induce recrystallisation.  
3) Drug load. Stable glassy solid solutions occur when the drug is molecularly 
dispersed in the polymer matrix. As drug solubility in the polymer of choice is 
often low, this hinders the production of formulations with high drug loads, 
limiting their commercial use. Hence, it is important to select an ideal 
polymer/API combination. 
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4) The availability of thermoplastic polymers. The complex intellectual property 
landscape inhibits the development of new thermoplastic polymers for HME and 
IM. The approval of a new polymer as pharmaceutical excipient requires enormous 
investments, which limits the introduction of  novel polymers.  
5) The mechanism of dissolution enhancement. Some excipients (e.g. PEG) or 
polymers are able of stabilizing the supersaturated drug state, while others fail. The 
underlying reasons are not fully understood. 
The key issues listed above are to a large extent related to the type of polymer used in 
the formulation. Although much research has been performed in terms of molecular 
interactions between API and polymer or the use of polymer combinations, little attention has 
been given to the molecular structure of the polymer itself. This is remarkable as the 
availability of novel excipients is important to foster the innovation in (oral) drug delivery. 
The formulation challenges of today cannot be solved with yesterday’s excipients. It is, 
therefore, important that several research groups start to focus on the design and synthesis of 
new polymer excipients. A research collaboration between the polymer chemistry and the 
formulation departments could lead to a more profound understanding of the polymer/API 
interactions and miscibility. This knowledge could then be used to create new polymer 
excipients from a bottom-up approach, instead of the top-down method used today. As 
example: if formulation scientists want to increase the bioavailability of a drug, the current 
protocol is to screen several polymer excipients on the market. Despite the fact that the 
highest drug solubility in available polymers is limited to e.g. 15wt.%, the formulation 
scientist will select the best-performing polymer excipient (top-down method), thus limiting 
the drug load in the formulation and future commercial applications. In contrast, approaching 
this issue from a bottom-up manner could result in a superior formulation in terms of drug 
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load: e.g. an in-depth investigation of the polymer structure indicated that the best-performing 
polymer consist of 2 alternating monomers in a 50/50 ratio. The first monomer being 
responsible for the molecular interaction, while the second monomer is essential for the 
processability (i.e. defining the thermoplastic behavior of the formulation). Synthesizing a 
new polymer with a monomer ratio of e.g. 75/25 increased the polymers’ viscosity (while still 
in the viscosity window that allows processing via HME) and the available functional groups 
to interact with the drug, resulting in a polymer that is now able of solubilizing e.g. 30% drug. 
Hence, approaching the problem from bottom-up could result in custom-made formulations 
with beneficial characteristics for HME/IM applications. An interesting illustration of this 
concept was the launch of Soluplus
®
 by BASF. This thermoplastic copolymer of PEG, 
vinylcaprolactam and vinylacetate was designed to provide solubilization capacity for poorly 
aqueous drugs. The amphiphilic character of the polymer allows the formation of micelles 
making it possible to encapsulate (and solubilize) a low aqueous soluble drugs. Moreover, the 
polymer was designed with a low Tg (70°C), facilitating its use during thermal processing.  
Formulations containing 3 components (API, polymer and other additional excipient) 
have also been extensively described in literature. If the extrudate containing API and 
polymer does not meet the requirements, a third component (plasticizer, drug release 
modifier, etc.) is often added to improve the characteristics of the formulation. Despite the 
fact that the major fraction of the formulation is in most cases the polymer phase (often  
>50%), few research groups would consider modifications of the polymer to modify the 
behavior of the formulation and most will prefer to add an additional excipient to improve the 
formulation’s characteristics.  
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 The availability of novel polymeric excipients also depends on regulatory constraints 
departments. As there is currently no regulatory approval process specifically for excipients, 
novel excipients are not independently evaluated by the regulators. Information about the 
quality and safety of new excipients is only reviewed by the health authorities in the context 
of a new drug application [137]. The absence of such an independent approval process for 
new excipients causes a dilemma for both manufacturers and the users of these excipients. 
Formulation scientists, for instance, prefer to use only the best performing excipients in their 
formulation, yet at the same time they prefer excipients that are regulatory approved in order 
to avoid additional risks in the drug approval process. Manufacturers of novel excipients, on 
the other hand, promote the use of their polymers in new drug products, yet they only disclose 
their sensitive information (e.g. molecular structure, specific additives) in confidentiality. A 
direct communication with the health authorities would be beneficial, rather than 
communicating via the user of the excipient as an intermediate. In the end, a registration 
process of excipients that is independent of the drug product registration would be the best 
option for all parties involved. This could mitigate the risk of a delayed product registration 
when new excipients are used, which should positively affect the HME/IM-based product 
development [138].  
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polymer or the addition of acids –  
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Introduction 
Hot melt extrusion (HME) combined with injection molding (IM) is a versatile 
manufacturing technique which has generated significant interest in the pharmaceutical field 
based on the possibilities offered by this technique. It enables the production of tablets 
independent of the powders compactibility. A homogeneous system can be created via a 
substantial energy input, provided by elevated temperature, high shear force and pressure. 
Different polymers are used as matrix drug delivery systems, wherein the drug is uniformly 
dispersed or dissolved (providing immediate or sustained drug release depending on the 
polymer properties). A well established drug delivery matrix which can be used for HME/IM 
applications is a methacrylate terpolymer based on n-butylmethacrylate (n-BMA), 
dimethylaminoethylmethacrylate (DMAEMA) and methylmethacrylate (MMA) in a 1/2/1.5-
ratio (Eudragit
®
 E PO) [42, 53, 89, 139-141]. It allows the development of stable glassy solid 
solutions, i.e. homogeneous one-phase systems with the drug molecularly dispersed in the 
matrix, ensuring immediate drug release [53, 89]. However, the pH-dependent solubility of 
Eudragit E (i.e. insoluble at high pH, soluble at low pH) could possibly cause bioavailability 
problems when dealing with elderly [142-143], upon food intake [144] or diseases that tend to 
raise the stomach pH [145-146].  
In vitro dissolution studies of nimodipine, for instance, in a medium containing 0.1N 
hydrochloric acid and 0.05% (w/v) sodium dodecyl sulfate (SDS) showed that a solid 
dispersion with EudrE dissolved significantly faster than formulations with 
polyvinylpyrrolidone/vinyl acetate copolymer (PVPVA) and hydroxypropyl methylcellulose 
(HPMC) as polymer excipient. In vivo studies in male beagle dogs, on the other hand, 
revealed the fastest release for the formulation containing PVPVA as polymer excipient, 
followed by EudrE and HPMC [147]. This difference between in vitro and in vivo behavior 
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could be due to the gastro-intestinal (GI) motility of a beagle dog which is among the fastest 
of all laboratory animal (fast stomach clearance), to the limited volume of gastric fluids (± 
400mL) and most importantly to the gastric pH of the dogs which can reach pH 5 [144]. 
EudrE is also used as coating material for pH-controlled drug release in the treatment of 
inflammatory bowel disease [148]. Lag times of drug release for EudrE-coated formulations 
were determined at 10min, 50min and 33h in media with pH values of 2, 5 and 6.8, 
respectively. The pH-dependent release profile of Eudragit E is due to its dimethylaminoethyl 
methacrylate (DMAEMA) moiety which becomes protonated at low pH values. Moreover, as 
shown in previous work [53], the DMAEMA units are crucial with respect to API/polymer 
interaction (which are essential to create glassy solid solutions) and drug release 
characteristics. 
 
This research focuses on the development of a pH-independent Eudragit E-based 
formulation, using 2 approaches to achieve pH-independent ibuprofen release from an 
Eudragit E matrix processed via HME/IM: 1. chemical modification of the Eudragit polymer 
structure by quaternization of the amine function; 2. creation of a low pH micro-environment 
during dissolution via the addition of dicarboxylic acids (succinic, glutaric and adipic acid). 
 
Experimental Section  
Materials 
Ibuprofen 25 (IBP), with a melting endotherm at 76°C and a Tg of -42°C, was 
purchased from Abbott (Ludwigshafen, Germany). Eudragit
®
 E PO (EudrE), a methacrylate 
terpolymer based on n-butylmethacrylate (n-BMA), dimethylaminoethylmethacrylate 
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(DMAEMA) and methylmethacrylate (MMA) in a 1/2/1.5-ratio, was supplied by Evonik 
(Darmstadt, Germany). Diethylether and acetic acid were purchased by Biosolve 
(Valkenswaard, Netherland), hydrochloric acid from VWR International (Leuven, Belgium). 
Iodomethane, silver nitrate and dicarboxylic acids (succinic, glutaric and adipic acid) were 
purchased from Sigma-Aldrich (St-Louis, USA) (Table 1).  
Table 1: Chemical characteristics of dicarboxylic acids. (Characteristics obtained from PubChem) 
Dicarboxylic 
acid 
COOH 
-R- 
COOH 
pKa1 pKa2 Tm 
(°C) 
Solubility 
in H2O 
(g/L) at 25°C 
logP 
Succinic 
Glutaric 
Adipic 
CH2CH2 
 (CH2)3 
(CH2)4 
4.2 
4.3 
4.4 
5.6 
5.4 
5.4 
184 
95 
152 
60 
430 
24 
-0.59 
-0.29 
0.08 
 
Quaternization of Eudragit
®
 E PO 
Eudragit
®
 E PO (20g) was dissolved in 200mL methanol (final concentration: 
100mg/mL), followed by the addition of 0.41, 1.02, 2.03 and 3.05mL iodomethane 
(methylating agent) to synthesize polymethacrylates with a quaternization degree of 10, 25, 
50 and 75%, respectively. The reaction (addition of methylgroup to the polymer structure) 
was allowed to proceed for 2h at room temperature, followed by precipitation of the polymer 
via the addition of diethylether (1/20, v/v). Consequently, the iodide counter ion of the 
quaternary amine was replaced by chloride via dialysis (using a cellulose dialysis membrane 
with a Mw cut-off of 14 kDa, Mw of EudrE ± 18 kDa) for 2 days against a 60g/L aqueous 
sodium chloride solution, which was refreshed multiple times. The removal of iodide ions was 
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verified via the addition of a silver nitrate solution as described in previous research [149]. 
Finally, the quaternized Eudragit
®
 E polymer (EudrE-Q) was isolated as a dry powder by 
lyophilization (average yield: 70%).  
1
H-Nuclear Magnetic Resonance (
1
H-NMR) Spectroscopy 
Polymer composition and degree of quaternization was determined through 
1
H-NMR 
spectroscopy on a Varian Mercury 300 NMR Spectrometer (Vernon Hills, Illinois, USA). 
Samples were dissolved in deuterated methanol. 
1
H-NMR (300 MHz, CD3OD) δ = 4.12 (br, 
COOCH2CH2N(CH3)2), 3.64 (COOCH3), 2.68 (br, COOCH2CH2N(CH3)2), 2.35 (br, 
COOCH2CH2N(CH3)2), 2.21-1.75 (br, CH2 backbone), 1.45 (br, COOC(CH3)3, 1.30-0.8 (br, 
CH3). The degree of quaternization was verified according to Obermeier et al. [149].  
Determination of pKa  
A polymer sample (200mg) was dissolved in 5mL 0.1M HCl solution, followed by the 
addition of 45mL demineralized water. While continuously measuring the pH, small amounts 
of 0.1M NaOH were added to the polymer solution up to pH 12. Consequently, the pKa was 
determined as a minimum of the first derivative of the titration cruve.   
Thermal analysis 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was used 
to investigate the thermal stability of the polymers. The samples were equilibrated at 30°C 
and heated (10°C/min) to 500°C under an N2 atmosphere.  
Tg and melting point (Tm) of pure components, physical mixtures (homogenized using 
mortar and pestle) and injection molded tablets were analyzed by modulated differential 
scanning calorimetry (MDSC Q2000, TA Instruments, Leatherhead, UK) using a heating rate 
of 2°C/min.  The modulation period and amplitude were set at 1min and ±0.318°C, 
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respectively. Dry nitrogen at a flow rate of 50ml/min was used to purge the MDSC cell. A 
heating/cool/heat cycle was run between -70 and 120°C. All results were analyzed using the 
TA Instruments Universal Analysis 2000 software. Samples (± 5mg) were run in Tzero pans 
(TA Instruments, Zellik, Belgium). MDSC heat capacity calibration was done via small 
sapphire disks, placed in a Tzero pan. 
X-ray diffraction (XRD) 
The crystallinity of the samples was determined via X-ray diffraction using a D5000 
Cu Kα diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 kV and 
a current of 40 mA in the angular range of 10° < 2θ < 60° using a step scan mode (step width 
= 0.02°, counting time = 1 s/step). 
Production of injection molded tablets 
Physical mixtures of IBP and polymer (30/70, wt.%) were extruded at 90°C using a 
co-rotating twin-screw extruder at 90rpm (Haake MiniLab II Micro Compounder, Thermo 
Electron, Karslruhe, Germany). Biconvex tablets (mass: 349 ± 2.1mg; diameter: 10mm; 
height: 5mm) were produced via injection molding (Haake MiniJet System, Thermo 
Electron). The injection pressure was 800bar during 10s, in combination with a post-pressure 
of 400bar for 5s. Formulations containing dicarboxylic acids were processed via HME/IM at a 
constant drug load (30%), but varying ratios of Eudragit E to dicarboxylic acid: 60/10, 55/15 
and 50/20 (wt.%). 
In vitro drug release 
Drug release from the injection molded tablets was determined using the paddle 
method on a VK 7010 dissolution system (VanKel Industies, New Jersey, USA) with a paddle 
speed of 100rpm. Hydrochloric acid (pH 1), citric buffer (pH 3 and 5) and phosphate buffer 
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(pH7) were used as dissolution media (900mL) at 37 ± 0.5°C. Samples were withdrawn at 5, 
10, 15, 20, 30, 45 and 60min, and spectrophotometrically analyzed for API concentration at 
221nm.  
Results and Discussion 
Ibuprofen (IBP) is a weak acid with a pKa of 4.4. The carboxylic group in the 
chemical structure is responsible for its pH-dependent solubility. At pH 7, IBP is completely 
dissolved after 15 min, whereas, the release at pH 5, 3 and 1 is limited to 57, 40 and 29%, 
respectively, after 60min of dissolution testing. The tertiairy amine function in the chemical 
structure of Eudragit
®
 E (EudrE) causes its pH-dependent release profiles. In contrast to IBP, 
a higher pH reduces the dissolution rate of EudrE. It was therefore appropriate to combine 
both components (IBP and EudrE) in one formulation. 
The processing of an EudrE mixture containing 30wt.% ibuprofen (IBP) via hot melt 
extrusion (HME), followed by injection molding (IM) yielded a transparent formulation, 
classified as a glassy solid solution. Thermal analysis revealed a single Tg, located between 
the Tg values of the individual components, indicating complete miscibility and compatibility 
between drug and polymer. Spectroscopic analysis indicated that electrostatic interactions 
between the ammonium group of the polymer and the carboxyl group of IBP (i.e. salt 
formulation) were responsible for the solubilization of IBP [cf. chapter 2] [53]. EudrE is a fast 
dissolving polymer in acidic media (pH 1 and 3) due to the hydratation of the dimethylamino 
groups that are fully protonated at this lower pH range, yet it is insoluble in media with a pH 
above 5. Chemical modification of the tertiary ammonium group of the polymer to its 
quaternized form should allow to determine the minimum amount of positive charges needed 
to eliminate this pH-dependent effect, quaternisation of 10, 25, 50 and 75% were tested.  
A pH-independent immediate release polymethacrylate formulation Ι Chapter 1 
 
 53 
 
All polymer samples were analyzed via 
1
H-nuclear magnetic resonance spectroscopy 
to verify the degree of quaternization. Figure 1 illustrates that the decrease of the signal of the 
tertiary ammonium group R-N(CH3)2 at ~2.7 ppm is correlated with larger signals of the 
quaternary ammonium group R-N
+
(CH3)3 at ~3.15 ppm. The deviation between the 
theoretical calculated and experimental degree of quaternization was 5, 7, 5 and 8% (higher 
experimental value) for EudrE-Q10, -Q25, -Q50 and -Q75, respectively. As the objective was 
to determine the relative influence of the degree of quaternization on drug release, these 
differences were regarded as negligible. 
 
 
Figure 1. 
1
H-NMR (300 MHz, CD3OD) of EudrE-Quaternized (EudrE-Q) to verify the degree of quaternization 
via integration of the signals a and b, representing the signals of the quaternary and tertiary ammonium groups, 
respectively.  
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Second, it was determined whether quaternized Eudragit
®
 E (q-EudrE) samples were 
suitable as polymers to solubilize ibuprofen (IBP) upon processing via hot melt extrusion 
(HME) and injection molding (IM). As the quaternization of EudrE did not significantly alter 
the polymers’ glass transition temperature (maximum deviation of 3°C) and a similar drug 
load (30wt.%) was used, the processing conditions were chosen similar to the EudrE/IBP 
70/30 mixture [53]. All processed formulations with quaternized EudrE (EudrE-Q) as carrier 
were transparent with smooth surfaces. Figure 2 illustrates their dissolution behavior in 
function of pH. At pH 1, all formulations had similar release characteristics. At pH 3, the 
protonation rate of the tertiary ammonium group of EudrE is reduced, resulting in a slower 
hydratation of  the polymer and a lower IBP release rate compared to pH 1. In contrast, all 
quaternized EudrE (EudrE-Q) formulations were not affected by this lower acidic character of 
the dissolution medium. As a positive charge is intrinsically present in the chemically 
modified polymers, the lag phase for polymer protonation and hydratation is avoided, yielding 
faster release profiles for EudrE-Q formulations. At pH 5, no IBP was released from the 
EudrE formulation, while the EudrE-Q10 formulation resulted in a release of 40% after 1h. At 
pH 5, not all ammonium groups of the polymer are protonated by the solvent based on their 
pKa value of 6.1, resulting in insufficient or no release from the EudrE-Q10- and EudrE-
formulations, respectively. Eudr-Q25, -Q50 and -Q75 formulations, on the other hand, still 
resulted in fast IBP release profiles as they already carried sufficient positive charges (due to 
the high degree of quaternization) and do not rely on protonation by the solvent to obtain fast 
drug release. At pH 7, release from all formulations (EudrE as well as EudrE-Q grades) was 
slow, indicating that at this pH even a high degree of quaternisation could not ensure fast 
hydration of the chemically modified polymethacrylate. Possibly, the formation of a complex 
between the positively charged polymer and the negatively charged IBP also contributed to 
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the incomplete release under these conditions [150-151]. Overall, in vitro dissolution 
experiments revealed that a minimum of 25% of quaternization was sufficient to partially (up 
to pH 5) eliminate the pH-dependent effect of the EudrE/IBP formulation.  
 
Figure 2. Release characteristics at different pH-values (1, 3, 5 and 7) of formulations containing 30wt.% 
ibuprofen and different polymethacrylate carriers: EudrE (no symbol), EudrE-Q10 (●), EudrE-Q25 (■), EudrE-
Q50 (▲), EudrE-Q75 (▼). 
As glassy solid solutions are inherently thermodynamically metastable, 
recrystallization is inevitable. However, a previous study indicated that the tertiary 
ammonium group of the polymer is of high importance as an interaction with the 
carboxylgroup of IBP (i.e. salt formation) stabilizes the glassy solid solution for at least 6 
months of storage at 25°C and 60% relative humidity [53]. Performing a stability study in 
similar conditions revealed the recrystallization of IBP in all formulations containing 
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quaternized EudrE polymers (EudrE-Q) upon 3 months of storage, irrespective of the amount 
of quaternization. The transparent formulations became opaque, an IBP melting endotherm 
was observed via thermal analysis and XRD-spectra evidenced clear signs of crystallinity 
(data not shown). Hence, quaternization of EudrE, even at a low percentage (i.e. 10%), limits 
the interactions between drug and polymers, and reduces the stability of IBP solid solutions 
upon storage. Possibly the positive charges of EudrE-Q polymers are obstructing the ability of 
IBP to release its hydrogen atom, limiting the possibility for electrostatic interaction with the 
polymer which is essential for the stabilization of molecularly dispersed ibuprofen in an 
Eudragit E matrix. It is also possible that EudrE-Q polymers, obtained after quaternization in 
methanol, precipitation in diethylether, dialysis and lyophilization, still contained some 
residual solvents. These can alter the molecular mobility of IBP and increase its tendency to 
recrystallize.  
As protonation of EudrE is responsible for the fast hydratation/dissolution of the 
polymer and as this protonation is evidently reduced at higher pH values, a second approach 
to achieve pH-independent release was to create a low pH micro-environment around the 
tablet during dissolution via the addition of acids to the HME/IM processed formulations. 
High concentrations of acids in the diffusion layer during dissolution could lower the pH, 
leading to accelerate protonation of EudrE and enhance the drug release rate. To this end, 
several dicarboxylic acids (succinic, glutaric and adipic acid) were added to the formulation  
(Table 1). 
The addition of dicarboxylic acids to the IBP/EudrE 30/70 mixture did not influence 
the formulation’s ability to form transparent tablets. Dissolution experiments illustrated that 
the addition of dicarboyxlic acids did not alter IBP release in a pH 1 and 3 medium (data not 
shown), as the dimethyl amino groups of EudrE are already fully protonated. Moreover, the 
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ability of dicarboxylic acids to release hydrogen atoms is lower at this pH given pKa values of 
succinic, glutaric and adipic acid of 4.2, 4.3 and 4.4, respectively. At pH 5, IBP release was 
significantly improved (Figure 3) upon the addition of dicarboxylic acids, as the low pH 
environment in the diffusion layer around the tablet enhances IBP release rate. This 
improvement was concentration driven as higher concentrations of dicarboxylic acids induced 
faster drug release. IBP release depended also on the type of dicarboxylic acid: the fastest 
release was observed in combination with succinic acid, while adipic acid had less impact. 
This could be related to the polarity of the dicarboxylic acids, as succinic acid was the most 
polar compound (log P -0.59, vs. -0.29 and 0.08 for glutaric and adipic acid, respectively) 
(Table 1).  
 
Figure 3. Release profiles of IBP/EudrE 30/70 mixtures (no symbol) at pH 5 with the addition of 10, 15 and 
20% of adipic (♦), glutaric (■) and succinic acid (●), respectively. 
The importance of low pH in the diffusion layer was illustrated by the addition of 20% 
disodium succinate to the formulation: IBP release was limited to 10% after 60 min, vs. 92% 
in combination with 20% succinic acid (cf: a solution containing 0.1N of succinic acid and 
disodium succinate has a pH value of 2.7 and 7, respectively). 
  
A pH-independent immediate release polymethacrylate formulation Ι Chapter 1 
 
 58 
 
Figure 4 illustrates the formulation’s stability at room temperature. The glassy solid 
solution tablets containing dicarboxylic acids were mechanical unstable (unable to maintain 
their structure). Two underlying reasons were identified: 1. The plasticizing effect of IBP on 
EudrE [53]. Increasing the dicarboxylic acid concentration also increased the IBP/EudrE ratio 
thereby inducing more molecular mobility; and 2. The molecular mobility of the dicarboxylic 
acids. Figure 4 and Table 2 illustrates that the formulation’s mechanical stability was 
dependent on the length of the dicarboxylic acid (stability of formulation with succinic > 
glutaric > adipic). It is known from previous research [53] that the change of a t-butyl group 
in the polymer structure to a n-butyl group increases the molecular mobility of the polymer as 
a result of an increase in free volume and a less denser polymer structure. As adipic acid had 
the highest amount of carbons between its 2 carboxylic groups, the polymer’s free volume and 
its molecular mobility were increased to a higher extent compared to succinic and glutaric 
acid containing formulations, resulting in a lower mechanical stability (Table 2).  
 
Table 2. Tablet diameter upon 1 month of storage at 25°C, 60% relative humidity of EudrE/IBP 70/30 with the 
addition of 10, 15 and 20% of dicarboxylic acid, respectively. 
Dicarboxylic 
acid 
 
 
IBP/EudrE/Acid 
30/70/0 
 
30/60/10 
 
30/55/15 
 
30/50/20 
Succinic  10.0mm 10.2mm 10.4mm 11.9mm 
Glutaric  10.0mm 10.4mm 11.1mm 13.8mm 
Adipic  10.0mm 10.4mm 11.4 14.2mm 
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Figure 4. Tablet diameter upon 1 month of storage at 25°C, 60% relative humidity of EudrE/IBP 70/30 (upper 
left) with the addition of 20% succinic acid (upper right), glutaric acid (lower left) and adipic acid (lower right), 
respectively. 
Conclusion 
A pH-independent immediate release polymethacrylate formulation was created via a 
chemical modification of the polymer (i.e. quaternisation of amine function) and via the 
addition of dicarboxylic acids (succinic, glutaric and adipic acid). The presence of a positively 
charged polymer and the low pH micro-environment during dissolution allowed the release of 
IBP independent of the solvent pH (up to pH 5). However, the quaternization of the polymer 
induced stability issues (recrystallization of API) and the formulations containing 
dicarboxylic acids were classified as mechanically unstable. Hence, further research is needed 
to obtain a pH-independent immediate release formulation containing EudrE and IBP.  
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Introduction 
Hot melt extrusion (HME) has attracted increasing attention as novel drug formulation 
strategy to produce solid solutions with enhanced oral bioavailability of dissolution-limited 
drugs [1, 41, 47-48, 152-154]. Moreover, the combination with injection molding (IM) 
enables the processing of materials with high dimensional precision [155-156]. This technique 
relies on obtaining a homogeneous system via a substantial energy input, provided by 
elevated temperature, high shear force and pressure during HME and IM. The development of 
glassy solid solutions, i.e. homogeneous one-phase systems with the drug molecularly 
dispersed in the matrix, is challenging in particular, as such formulations are inherently 
metastable [157-160]. Due to the substantial energy uptake during the HME/IM-process, 
followed by a fast cooling of the melt, the obtained glassy solid solution is kinetically trapped 
resulting in a blend far from its thermodynamic equilibrium. 
Several methods have been proposed to decrease the rate of recrystallization and, 
hence, increase the stability of solid solutions. These methods are often based on molecular 
interactions between the active pharmaceutical ingredient (API) and the polymer. For 
instance, Eudragit E PO (EudrE; an n-butyl-, dimethylaminoethyl-, methylmethacrylate-
terpolymer) was used as antinucleant agent in ibuprofen containing transdermal 
polydimethylsiloxane patches [161]. Interactions on a molecular level inhibited drug mobility 
inside the matrix and reduced recrystallization. An antiplasticizing effect by combining two 
polymers is also proposed as a stabilizing factor by several authors [162-164]. The use of a 
polymer with a high glass transition temperature (Tg) provides lower molecular mobility of 
the drug in a polymer/drug system at room temperature, maintaining the drug in its metastable 
amorphous state. Sufficient miscibility of the drug in the polymer matrix [165] and the 
absence of clusters are crucial conditions for this approach. Six et al.[162], for instance, 
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combined Eudragit E PO with PVP-VA64 in order to increase the physico-chemical drug 
stability in a hot melt extruded polymer matrix. Although much research has been performed 
in terms of molecular interactions between API and polymer or the use of polymer 
combinations, little attention has been given to the molecular structure of the polymer itself.  
In this paper, we report the synthesis of several novel polymethacrylate analogues of 
Eudragit E PO, with the aim to increase the Tg of the polymers, allowing better processing of 
drugs into glassy solid solutions, based on increased mechanical stability, via HME and IM. 
Ibuprofen (IBP, a non-traditional plasticizer) was selected as model drug since it challenges 
the polymethacrylates to a higher extent [13, 117, 166-167]. The second API used in this 
study was celecoxib (CEL). Eudragit E PO (EudrE) was chosen as carrier to produce glassy 
solid solutions.  
Experimental Section  
Materials 
Ibuprofen 25 (IBP; figure 1, left), with a melting endotherm at 76°C and a Tg of -
42°C, was purchased from Abbott (Ludwigshafen, Germany). Celecoxib (CEL; figure 1, 
right), with a melting endotherm of 162°C and a Tg of 58°C, was purchased from Utag 
(Amsterdam, The Netherlands). Eudragit
®
 E PO, a methacrylate terpolymer based on n-
butylmethacrylate (n-BMA), dimethylaminoethylmethacrylate (DMAEMA) and 
methylmethacrylate (MMA) in a 1/2/1.5-ratio, was supplied by Evonik (Darmstadt, 
Germany). 
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Figure 1. Chemical structure of ibuprofen (left) and celecoxib (right) with a pKa of 4.5 and 9.7, respectively. 
 
Polymer synthesis 
The different monomers tert-butylmethacrylate (t-BMA), DMAEMA, MMA, and 
isobornylmethacrylate (iso-BMA; Sigma Aldrich, St-Louis, USA) were purified to remove 
the inhibitor via filtration over aluminium oxide (Acros Organics, New Jersey, USA) and 
subsequently degassed via N2 bubbling. Free radical polymerization of these monomers in 
varying ratios (Table 1) was carried out in toluene (Biosolve, Valkenswaard, the Netherlands) 
under a nitrogen atmosphere at 70°C for 24h using azoisobutyronitrile (AIBN, Sigma Aldrich, 
St-Louis, USA) as initiator. The resulting polymethacrylates were subsequently precipitated 
(3 times) from toluene in hexane (Biosolve, Valkenswaard, the Netherlands), dried for 48h at 
40°C and vacuum dried at 55°C for 48h. 
Size exclusion chromatography (SEC) 
SEC measurements were performed in an Agilent 1260-series equipped with a 1260 
ISO-pump, a 1260 Diode Array Detector (DAD), a 1260 Refractive Index Detector (RID), 
and a PSS Gram30 column in series with a PSS Gram1000 column inside a 1260 
Thermostated Column Compartment at 50°C. The used solvent was DMA containing 50mM 
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of LiCl (flow rate of 1 mL min
-1
). The molar masses were calculated against polymethyl 
methacrylate standards. 
1
H-Nuclear Magnetic Resonance (
1
H-NMR) Spectroscopy 
Polymer composition was determined through 
1
H-NMR spectroscopy on a Varian 
Mercury 300 NMR Spectrometer (Vernon Hills, Illinois, USA). Samples were dissolved in 
deuterated methanol. 
1
H-NMR (300 MHz, CD3OD) δ = 4.12 (br, COOCH2CH2N(CH3)2), 3.64 
(COOCH3), 2.68 (br, COOCH2CH2N(CH3)2), 2.35 (br, COOCH2CH2N(CH3)2), 2.21-1.75 (br, 
CH2 backbone), 1.45 (br, COOC(CH3)3, 1.30-0.8 (br, CH3). More apolar samples were 
dissolved in deuterated chloroform. 
1
H-NMR (300 MHz, CDCl3) δ=4.34 (br, COOCHC9H16), 
δ=4.08 (br, COOCH2CH2N(CH3)2), δ=3.60 (COOCH3), δ=2.59 (br, COOCH2CH2N(CH3)2), 
δ=2.31 (br, COOCH2CH2N(CH3)2), 2.11-1.65 (br, CH2 backbone),  δ=1.41 (br, 
COOC(CH3)3), 1.30-0.7 (br, CH3). 
Thermal analysis 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was used 
to investigate the thermal stability of the polymers. The samples were equilibrated at 30°C 
and heated (10°C/min) to 500°C under an N2 atmosphere.  
The Tg and melting point (Tm) of pure components, physical mixtures (homogenized 
using mortar and pestle) and injection molded tablets were analyzed by modulated differential 
scanning calorimetry (MDSC Q2000, TA Instruments, Leatherhead, UK) using a heating rate 
of 2°C/min.  The modulation period and amplitude were set at 1min and ±0.318°C, 
respectively. Dry nitrogen at a flow rate of 50ml/min was used to purge the MDSC cell. A 
heating/cool/heat cycle was run between -70°C and 120°C. All results were analyzed using 
the TA Instruments Universal Analysis 2000 software. Samples (± 5mg) were run in Tzero 
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pans (TA Instruments, Zellik, Belgium). MDSC heat capacity calibration was done via small 
sapphire disks, placed in a Tzero pan. The thermoanalytical investigations in terms of 
interaction were surveyed in the first heating cycle by analyzing the melting enthalpy, Tmelt-
max (i.e. inflection point of melting endotherm) and Tmelt-onset (i.e. start of melting 
endotherm).  
Hot stage microscopy (HSM) 
 Polarized light microscopy images were recorded on a Leica DM2500P microscope 
equipped with a 10x objective and a DFC 425 CCD camera. Polymer samples were subjected 
to controlled heating using a Linkham THHS 600 heating stage. 
X-ray diffraction (XRD) 
The crystallinity of the samples was determined via X-ray diffraction using a D5000 
Cu Kα diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 kV and 
current of 40 mA in the angular range of 10° < 2θ < 60° using a step scan mode (step width = 
0.02°, counting time = 1 s/step). 
Fourier-transform infrared (FTIR) spectroscopy  
Attenuated total reflectance (ATR) FTIR spectroscopy was used to evaluate the solid-
state of the injection molded tablets. Spectra were collected from the pure amorphous 
components (after melting and quenching in liquid nitrogen), the physical mixtures and the 
injected molded tablets. The ATR-FTIR spectra were collected with a Bruker Vertex 70 FT-
IR spectrometer, equipped with a DTGS detector and a PIKE accessory, equipped with a 
diamond ATR crystal (4 cm
-1
 resolution, 32 scans). 
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Production of injection molded tablets 
Physical mixtures, homogenized using mortar and pestle, of drug (IBP, CEL) and 
polymer (with a drug content varying from 30 to 50 wt.%) were extruded at 100-120°C using 
a co-rotating twin-screw extruder at 100rpm (Haake MiniLab II Micro Compounder, Thermo 
Electron, Karslruhe, Germany). Biconvex tablets (diameter: 10mm/height: 5mm) were 
produced via injection molding (Haake MiniJet System, Thermo Electron). The injection 
pressure was 800bar during 10s, in combination with a post-pressure of 400bar for 5s. 
In vitro drug release 
Drug release from the injection molded tablets was determined using the paddle 
method on a VK 7010 dissolution system (VanKel Industies, New Jersey, USA) with a paddle 
speed of 100rpm. Hydrochloric acid (pH 1) and citric/phosphate buffers (pH 3 and pH 5) were 
used as dissolution media (900mL) at 37 ± 0.5°C. Samples were withdrawn at 5, 10, 15, 20, 
30, 45 and 60min and spectrophotometrically analyzed for API concentration at 221 and  
250nm for IBP and CEL, respectively. 
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Results and Discussion 
 
Polymer synthesis and characterization 
The synthesis of novel polymethacrylates for the manufacturing of immediate release 
tablets via hot melt extrusion (HME) and injection molding (IM) was performed aiming to 
ensure good mechanical and physical stability of these dosage forms via high Tg 
polymethacrylates. The starting point for this study was the commercially available Eudragit 
E PO, a n-BMA/DMAEMA/MMA terpolymer with monomer molar percentages of 22/45/33 
as determined by 
1
H-NMR spectroscopy. Based on this monomer composition we synthesized 
novel polymethacrylate analogues via free radical polymerization, the yield of all synthesis 
procedures was about 70%. Compared to the commercial Eudragit E PO we first replaced the 
n-BMA group by t-butylmethacrylate (t-BMA, Figure 2). Substituting the flexible n-butyl 
side chains with the more compact t-butyl side chains should result in a reduced free volume 
and a denser polymer structure, promoting interpolymer interactions as is evident from the 
higher Tg of poly(t-BMA) (Tg = 107 
o
C) in comparison to poly(n-BMA) (Tg = 20 
o
C). 
MDSC indeed demonstrated that changing the n-BMA groups to t-BMA yielded a Tg increase 
of 14.8°C to a value of 64,7 
o
C (Table 1; thermograms in supporting information). In a next 
step, we investigated the influence of the cationic DMAEMA repeating unit on the thermal 
behavior of the polymethacrylates and on the drug release properties of injected molded 
tablets. Lowering the DMAEMA content yielded polymers with a higher Tg, i.e Tg increased 
from 64.7±2.8°C to 80.8±2.2°C upon decreasing the DMAEMA content from 45 to 17% 
(Table 1; thermograms in supporting information), which is due to the low Tg of 
poly(DMAEMA) (Tg = 20 
o
C). Further decreasing the DMAEMA content was not an option 
as the DMAEMA group appeared to be critical for the polymer’s dissolution behavior and its 
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interaction with API (see section Interactions and in vitro drug release). A third modification 
of the polymer structure was the incorporation of an isobornyl-group to the polymer structure, 
creating a quarterpolymer (i.e. consisting of 4 different monomers). Incorporation of isoBMA 
increased the rigidity of the polymer (Tg of poly(isoBMA) is 197 
o
C) as indicated by a Tg 
increase from 62.7 to 103.0°C for polymers with 5 and 50% iso-BMA, respectively (Table 1). 
These modifications identified two strategies to increase the Tg of polymethacrylates [168]. 
First, by decreasing the length of side groups (replacing n-butyl by t-butyl and lowering the 
DMAEMA-content), the free volume was reduced, increasing the probability of interpolymer 
interactions and yielding a higher Tg of the obtained polymers. Secondly, by incorporating a 
bulky side group (via the incorporation of an isobornyl repeating unit), the mobility of the 
polymer chain is reduced as steric hinderance reduces the rotation of the polymer backbone. 
This latter effect also plays a role when replacing the n-butyl side chains with t-butyl groups. 
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Table 1. Characteristics of the synthesized polymethacrylates: polymer composition (theoretical molar 
percentages vs. composition determined via 
1
H-NMR spectroscopy), molecular weight (determined via SEC), 
and glass transition temperature (Tg, determined via MDSC). 
 
Polymer  
t-BMA/DMAEMA/MMA(%)
(1)
  
Mn
(2)
 
(x 10
4
) 
 
Mw
(3)
 
(x 10
4
) 
 
PDI
(4)
 
 
Tg ± SD 
(°C) 
Theoretical  determined by NMR 
A1 Eudragit E PO
(5) 
22/45/33
(5) 
1.75 4.48 2.56 49.9±0.6 
A2 22/45/33 24/44/32 1.32 3.65 2.77 64.7±2.8 
B1 36/36/27 39/34/36 1.45 3.86 2.66 70.5±2.0 
B2 29/28/43 31/28/41 1.27 3.64 2.87 78.5±3.7 
B3 33/17/50 36/15/49 1.24 3.60 2.90 80.8±2.2 
 t-BMA/DMAEMA/MMA/isoBMA(%)
(1)
     
C0 25/50/25/0 22.6/48.5/28.9/0 1.32 3.65 2.77 62.7±1.2 
C1 22.5/50/22.5/5 21.1/50.3/26.2/2.4 1.83 4.13 2.26 67.1±1.8 
C2 17.5/50/17.5/15 18.6/53/18.1/10.3 2.13 4.78 2.24 75.3±1.5 
C3 15/50/15/20 14.8/48.2/20.2/16.8 2.35 4.89 2.08 77.5±1.9 
C4 12.5/50/12.5/25 12.5/51.5/16.1/19.9 2.36 5.09 2.16 84.7±1.7 
C5 10/50/10/30 12.5/51.9/9.4/26.1 2.28 5.76 2.52 88.1±2.4  
C6 5/50/5/40 5.4/55.3/5.5/34 2.43 6.42 2.64 91.1±1.3 
C7 2.5/50/2.5/45 4.9/52.3/5.2/38 2.86 6.95 2.43 98.2±2.5 
C8 0/50/0/50 0/53.9/0/46.1 3.21 6.27 1.95 103 ±2.2 
(1) Molar percentages of tertbutylmethacrylate (t-BMA), dimethylaminoethylmethacrylate 
(DMAEMA), methylmethacryalte (MMA) and isobornylmethacrylate (isoBMA) 
(2) Number average molecular weight 
(3) Weight average molecular weight 
(4) Polydispersity-index (Mw/Mn) 
(5) This polymer contains n-butylmethacylate (n-BMA) instead of t-BMA 
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Figure 2. Overview of the different chemical modifications to the polymer structure: (A) replacement of n-BMA 
to t-BMA in n-BMA/DMAEMA/MMA terpolymers, (B) reducing the DMAEMA content (highlighted 
monomer) of t-BMA/DMAEMA/MMA and (C) incorporation of an isoBMA monomer. 
 
The synthesized polymers were further characterized by 
1
H-NMR spectroscopy and 
size exclusion chromatography (SEC, Table 1). The good correlation between the theoretical 
and experimental compositions of the different polymers indicated a robust polymer synthesis 
process. Small differences between experimental and theoretical values for the isobornyl 
group repeating units were attributed to the technical grade of the monomer solution. As the 
objective was to determine the relative influence of the isobornyl group on the drug release 
characteristics and thermal behavior, these small difference were regarded as negligible. 
Furthermore, the molecular weight and the polydispersity index (PDI) of the synthesized 
polymers were analyzed by SEC. Replacing the n-butyl groups with t-butyl groups and 
reducing the DMAEMA content (Figure 2, polymer A and B) did not affect the polymer Mw 
or Mn compared to Eudragit E PO. Incorporation of isobornyl repeating units (Figure 2, 
polymer C) increased the Mw from 1.32 to 3.21 and the Mn from 3.65 to 6.27 for the 
polymers with an isoBMA content of 0 and 50%, respectively. The molecular weight 
distributions of all the polymers investigated were comparable, as indicated by their similar 
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PDI values. It should be noted, however, that based on these characterization data it is not 
possible to exclude variations in microstructure (average block lengths) and the 
stereoregularity (tacticity) between different polymer chains that might result from differences 
in monomer reactivity. 
Interactions between ibuprofen and the polymers 
In a next series of experiments we evaluated the interactions between the different 
polymers and ibuprofen (IBP) using three different methods: thermal analysis via MDSC, hot 
stage microscopy (in combination with visual evaluation of injection molded tablets) and 
ATR- FTIR. 
Thermal analysis provides four parameters to identify possible drug/polymer 
interactions: API melting enthalpy (% crystallinity), Tmelt-max and Tmelt-onset during the 
first heating cycle, and the presence of a single Tg during the second heating cycle [38, 169]. 
The melting enthalpy of IBP was found to be inversely correlated with the polymer’s 
DMAEMA content (Figure 3, left). The percentage of crystallinity dropped from 40 to 11% 
for physical mixtures, homogenized using mortar and pestle, of IBP and polymer (in a 50/50 
wt% ratio) with 17 and 50% DMAEMA, respectively. The lower crystallinity (observed 
during the first heating cycle) indicated that part of the API dissolved in the polymeric carrier 
during heating, whereby the DMAEMA group in the polymer structure is essential for 
interaction with the API. This was confirmed by Tmelt-onset (Figure 3, right) and Tmelt-max 
(data not shown) as the more intense interaction between API and carrier at higher DMAEMA 
content shifted these signals to a lower temperature. As more interactions occurred smaller 
IBP crystals are formed, being intrinsically less stable, which resulted in a broadened melting 
peak with a lower Tmelt-max and Tmelt-onset. It should be noted that these thermal 
investigations only provide a rough estimate of drug/polymer interactions as only directly 
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adjacent molecules are able to interact in the MDSC-cup (limited mobility). Figure 4 
illustrates the importance of DMAEMA with respect to drug/polymer interactions by 
analyzing the difference between the theoretical (predicted via the Gordon-Taylor equation, 
supporting information for calculations) and experimental Tg. The experimental Tg values of 
polymers with a DMAEMA-content of 36 and 28% (B1 and B2) exhibited a positive 
deviation (of ca. 20°C for formulations with 50wt.% IBP) compared to the theoretical Tg 
values, which is indicative for molecular interactions between IBP and the polymer. However, 
at a DMAEMA-content of 17% (B3), there were insufficient DMAEMA units available to 
allow complete interaction with IBP, leading to similar experimental and theoretical Tg 
values. In this formulation, phase separation is likely to occur which increases the likelihood 
of recrystallization of this less-stabilized phase during storage. The positive deviation between 
experimental and theoretical Tg values was also detected for isoBMA-containing polymers 
(Figure 4, C1-3), indicating that the bulky isobornyl group is not hindering the ability of IBP 
to interact with DMAEMA. 
 
Figure 3. Percentage crystallinity (left) and Tmelt-onset (right) of physical mixtures of IBP in combination with 
polymethacrylates having a varying DMAEMA content. The IBP/polymer ratio in all formulation was 50/50 
(wt.%). Thermal properties were measured during the first heating cycle. 
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Figure 4. Comparison of the experimental (red ●) and theoretical (calculated using the Gordon-Taylor equation) 
Tg values (dotted blue line -) of formulations containing IBP and different polymethacrylate carriers: (A1) 
Eudragit E, (A2) polymethacrylate with n-butyl replaced by t-butyl, (B1-3) polymethacrylates with DMAEMA 
contents varying from 36% to 17%, (C1, C3, C8) polymethacrylates with isobornyl contents of 10, 20 and 50%, 
respectively. The IBP content in the formulations was varied from 0 to 50%. 
 
The analysis of the second heating cycle revealed a single Tg, located between the Tg 
values of the individual components, which indicated complete miscibility and compatibility 
between drug and polymer. This was also confirmed by the presence of a single Tg when 
analyzing the first heating cycle of the injection molded tablets. The formation of transparent 
tablets after injection molding and visualization by hot stage microscopy (HSM) under 
polarized light (Figure 5) confirmed good miscibility between IBP and the polymethacrylates. 
On the left side of figure 5, the melting process of pure IBP is presented. IBP in combination 
with Eudragit E, polymer B1 (36% DMAEMA) and polymer B2 (28% DMAEMA) showed a 
similar melting behavior as compared to pure IBP. However, after cooling no recrystallization 
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of API was observed in drug/polymer mixtures (note that pure IBP crystallized immediately 
upon cooling, whereas the pictures of the polymer/drug formulations were taken after 2 days 
storage at ambient conditions).  
 
 
Figure 5. Hot stage microscopy under polarized light of IBP (left) and physical mixtures (PM) of IBP in 
combination with (A1) EudragitE, (B1) 36% DMAEMA polymer, (B2) 28% DMAEMA polymer. The 
IBP/polymer ratio in all formulation was 70/30 (wt.%). 
 Whereas thermal analysis and visual evaluation revealed attractive interactions and 
good miscibility between API and polymers, in this section we aimed to further identify the 
type of interactions occurring between IBP and the polymethacrylates via spectroscopic 
analysis. FTIR spectra of the injection molded tablets (IM-spectrum) were different from 
those of the physical mixture (PM-spectrum; which can be considered as the sum of the 
Structural Modifications of Polymethacrylates Ι Chapter 2 
 
 77 
 
spectra of the individual components) and the pure amorphous components (Figure 6). First, 
peak broadening occurred in the IM-spectrum, indicating interactions between the 
components and the presence of amorphous segments in the formulation. Second, a peak at 
1565-1579 cm
-1
 was observed in the IM-spectrum which was absent in the PM-spectrum. This 
specific peak is characteristic for carboxylate groups, indicating that electrostatic interactions 
between the tertiary ammonium group of the polymer and the carboxyl group of IBP are 
occurring (i.e. salt formation) when a physical mixture of these components is processed by 
HME and injection molding. The 2770-2980cm
-1
 region, in which the symmetrial and 
asymmetrical C-H stretch vibrations of the tertiary ammonium group (methyl and methylene) 
appear, was not suitable for interpretation due to overlap with the C-H stretch vibrations of 
the aliphatic carbons of IBP (2850-2980cm
-1
). Third, in formulations where the entire IBP 
load can interact with the polymer (i.e. when combined with polymethacrylates with a 
sufficient DMAEMA content), the fingerprint region (500-1430cm
-1
) is completely dominated 
by the polymer. In contrast, the spectrum of formulation IBP-B3 (with 17% DMAEMA and a 
drug load of 50wt.% IBP, Figure 6) produced a fingerprint region which was the sum of the 
two spectra of the individual components. In addition, a broad peak (2500-3300cm
-1
) is 
present in the IM-spectra, indicating intermolecular, H-bond based, IBP interactions (i.e. 
partial phase-separation of IBP, allowing dimerization and crystallization). Interestingly, these 
intermolecular IBP interactions are absent in formulation IBP-B2 (using a polymer with 28% 
DMAEMA content) for 30 and 50wt.% drug load (data not shown) and in formulation IBP-B3 
(using a polymer with 17% DMAEMA) at a drug load of 30wt.% (Figure 6). This again 
confirmed that complete IBP-polymer interactions and the creation of a glassy solid solution 
is possible when a sufficient amount of DMAEMA is present in the formulation. The 
minimum amount of DMAEMA needed in the polymer to interact with 50wt.% IBP is 
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between 17 and 28% DMAEMA, which corresponds to a DMAEMA/IBP molar ratio between 
0.25 and 0.45. The substitution of n-butyl by t-butyl groups and the incorporation of isobornyl 
repeating units does not influence these interactions. 
Figure 6. FTIR-spectra of (left) IBP and polymer B3 (with 17% DMAEMA content), and of (right) physical 
mixtures (PM) and injection molded tablets (IM) of IBP and polymer B3, at drug loads of 30 and 50wt.%.  
 
Processability via extrusion and injection molding: mechanical stability 
Formulations composed of EudrE/IBP in a 70/30 (wt.%) ratio were easily extruded 
and injection molded. However, at higher IBP concentration (50wt.%) solid non-sticking 
extrudates could not be obtained due to the plasticizing effect of IBP. As a consequence, 
tablets containing EudrE/IBP in a 50/50 (wt.%) ratio exhibited a high plasticity and were, due 
to a too low Tg, not sufficiently solid to maintain their structure. Figure 7 displays a stable 
and an unstable formulation after 1 week storage at room temperature. The mechanical stable 
tablet has a height and width of 5 and 10mm, respectively, while deformation of the highly 
plastic tablet after 1 week storage at room temperature resulted in a height and width of 3.5 
and 12.5mm, respectively. Injection molding of the commercial EudrE grade was therefore 
considered impossible in combination with 50wt.% IBP. The extrusion of the other 
formulations (using the modified polymers A, B1-2, C) with 50wt.% IBP yielded non-sticking 
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extrudates which could be injection molded. These tablets retained their structure after 
processing as their Tg was sufficient to provide a solid mechanically stable matrix. These 
experiments indicated that by increasing the polymer’s Tg, the processability improved as the 
novel polymethacrylates enabled the incorporation of 50wt.% IBP in the formulation.  
However, the processability also depended on the DMAEMA content as formulations 
containing polymer with 17% DMAEMA were mechanically unstable. DSC data indicated 
that the plasticizing effect of IBP on the 17% DMAEMA polymer (Figure 4, B3) was higher 
compared to the other polymethacrylates (Figure 4, B1-2), which can be ascribed to 
incomplete salt formation.  
 
Figure 7. Cross section of injection molded tablets containing 50wt.% ibuprofen in combination with polymer 
B1 (top, 36% DMAEMA) and  polymer B3 (bottom, 17% DMAEMA) as matrix. 
 
In vitro drug release  
The commercially available Eudragit E is a fast dissolving polymer up to a pH of 5 
due to the hydratation of the dimethylamino groups that are fully protonated at this pH value. 
Although lowering the DMAEMA content decreased the amount of tertiary amines, it did not 
affect the erosion based release profiles at low pH (pH 1 and 3) for matrices formulated via 
polymers with DMAEMA contents varying from 45 to 28% (Figure 8). Interestingly, 
formulations containing 17% DMAEMA did not release IBP, indicating that the DMAEMA 
content is a crucial parameter with respect to immediate drug release and that a minimal 
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DMAEMA content is required to have sufficient charge density of the polymer to ensure 
sufficient hydrophilicity for fast dissolution at low pH values. This again highlights the 
importance of the DMAEMA repeating unit as it is not only essential to stabilize the solid 
solution via interaction with IBP, but also determines the release rate of the drug.  
The addition of an isobornyl group to the polymer did not influence the release profile 
at pH 1 up to an isobornylmethacrylate content of 40% and at pH 3 up to 30% isobornyl-
methacrylate content (Figure 8).   
 
Figure 8. Release curves of IBP at pH 1 (top) and pH 3 (bottom) from formulations containing IBP (30%) and 
different polymethacrylate carriers: Eudragit E, (A) n-butyl replaced by t-butyl, (B) variable DMAEMA-content 
and (C) variable isobornyl content. 
The release profiles of formulations with 30 and 50wt.% drug load were similar (data not 
shown) confirming the carrier-mediated release of glassy solid solutions. This observation 
leads to the assumption that, besides phase transformation of the drug from crystalline to 
amorphous, sufficient interactions are needed between drug and carrier in order to improve 
the drug release properties.  
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Stability 
As glassy solid solutions are inherently thermodynamically metastable, 
recrystallization is inevitable. Previous studies revealed that a strategy for dealing with 
amorphous pharmaceutical formulations, in order to obtain a physically stable formulation, is 
storage at 50°C below the glass transition temperature of the formulation [9]. At this 
temperature, API mobility is negligible and API recrystallization is delayed. Therefore, the 
effect of IBP content on the thermal behavior of the formulations was analyzed. Figure 4 
indicates the plasticizing effect of IBP on the polymethacrylates with varying DMAEMA 
content. It is obvious that the Tg increase in the chemically modified polymers was 
counteracted by the plasticizing effect of IBP, and that producing stable formulations (i.e. 
with a Tg 50°C above room temperature) was therefore not possible. However, no 
recrystallization was observed in the XRD patterns after 6 months storage of injection molded 
tablets with a 30wt.% IBP load at 25°C and 60% relative humidity (Figure 9). At a 50% drug 
load crystallinity was detected for the mixtures formulated with the polymer containing 17% 
DMAEMA, whereas the other formulations showed no signs of crystallinity. This again 
illustrated the importance of drug/polymer interactions for the stabilization of the injection-
molded IBP/polymethacrylate mixtures, i.e. the IBP salt form does not readily diffuse through 
the glassy hydrophobic polymer matrix.   
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Figure 9. XRD-patterns of pure IBP powder (top), a physical mixture of IBP and EudrE (ratio: 30/70 wt.%) 
(blue) and an injection molded tablet (red) containing 30wt.% IBP with polymer B1 (36% DMAEMA) as matrix 
(red) after 6 months storage at 25°C and 60% relative humidity.  
Evaluation of celecoxib as non-plasticizing API 
 In addition to IBP, celecoxib (CEL) was also combined with the polymethacrylates. 
This non-steroidal anti-inflammatory drug was chosen for several reasons.  Similar to IBP, it 
is able to form a glassy solid solution with the polymethacrylates [89] and it has a low 
solubility in acidic media. In contrast to IBP (pKa 4.5 and Tg -42°C), CEL has a weak acidic 
character (pKa 9.7) and a higher Tg (58°C). Therefore, it was interesting to evaluate the 
possible differences with respect to thermal behavior, interactions and drug release properties.  
When combined with the polymethacrylates a lower melting enthalpy, Tmelt-max and 
Tmelt-onset of CEL was detected in the first heating cycle, in combination with a single Tg, 
situated between the Tg values of the individual components, in the second heating cycle 
(data not shown). Similar to IBP/polymer mixtures, this was indicative for molecular 
interactions between CEL and polymethacrylate. The free electron pair of the DMAEMA 
moiety enables interaction with the hydrogen atom in the sulfonamide group of CEL. The 
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difference between the Tg’s of the pure components is too low (Tg CEL=58°C, Tg 
EudrE=50°C) and taking the precision of DSC-data into account (± 5%), a significant 
interaction between CEL and the polymethacrylates cannot be identified via a deviation of Tg. 
Using IBP (Tg= - 42°C) as API this deviation was significant to identify the interaction. The 
formation of transparent tablets confirmed the miscibility between CEL and the 
polymethacrylates.  
FTIR spectra of the injection molded tablets also evidenced molecular interactions 
between CEL and polymethacrylates (Figure 10). In comparison to spectra of physical 
mixtures and individual amorphous components, peak broadening was observed for the 
injection molded tablets, an indication of molecular interactions and the presence of 
amorphous CEL in the formulation. Second, the broad peak around 3100-3600 cm
-1
 (as 
compared to the two sharp N-H stretch vibration absorptions of theCEL amino group around 
3333 and 3327cm
-1
 for the physical mixtures and the small peak in the amorph component) is 
indicative of intermolecular hydrogen bonds in the formulation, most likely between the 
tertiary ammonium group of the polymer and the sulfonamide of CEL. The asymmetrical C-H 
stretch vibration of the tertiary ammonium group present at 2950cm
-1
 in the physical mixture 
is shifted to 2974cm
-1
in the formulation (highlighted in Figure 10). Last, as the fingerprint 
region (500-1430cm
-1
) of the physical mixtures (PM) and injection molded tablets (IM) show 
multiple differences in wavenumber as well as in intensity (not shown on Figure 10), it can be 
decided that CEL is completely dissolved in the polymer. FTIR analysis of the formulations 
containing IBP and CEL revealed the importance of the API’s pKa towards the type of 
molecular interactions in the thermally processed formulations. Whereas electrostatic 
interactions (salt formation) were identified between the polymethacrylates and IBP (pKa 
4.5), salt formation in combination with CEL was not possible due to its lower acidity (pKa 
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9.7) and molecular interactions were limited to the formation of hydrogen bonds. 
 
Figure 10. FTIR-spectra of CEL, Eudragit E, physical mixtures (PM) and injection molded tablets (IM) of CEL 
and Eudragit E, at a drug load of 50wt.%.  
Stability studies were performed on formulations with 30 and 50% drug loads with 
EudrE as carrier. MDSC-results indicated partial recrystallization (about 10%) of celecoxib in 
a formulation with a 50% drug load. No recrystallization was observed in the 30% drug load 
formulation. The instability detected with the 50% formulation was assigned to the strength of 
interaction between API and polymer. The H-bond interaction detected between CEL and 
EudrE (Figure 10) is known to be weaker than the electrostatic interactions detected between 
IBP and EudrE. Furthermore, this difference in strength was also confirmed by the difference 
in API affinity for EudrE, estimated from the API melting enthalpy in the first MDSC heating 
cyclus of physical mixtures (API/polymer, 50/50): the percentage crystallinity (compared with 
their pure crystalline form) after processing in the EudrE matrix was about 38% and 72% for 
IBP and CEL, respectively 
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All formulations containing 30 and 50wt.% CEL drug loads were easily extruded and 
injection molded. Even at higher CEL concentrations solid non-sticking extrudates were 
obtained, due to the higher Tg of CEL. The formulations with EudrE and polymer B2 
(28%DMAEMA) combined with 50wt.% CEL resulted in glassy solid solutions with a Tg of 
62°C and 76°C, respectively. The release profiles of formulations with CEL and IBP as API 
were similar (data not shown). At pH 1 and 3, API release was 80% after 10 and 30min, 
respectively. This again confirmed the carrier-mediated release of glassy solid solutions. 
Conclusion 
The structural modification of polymethacrylates revealed that it is possible to alter the 
polymer Tg (thermal behavior) without changing the drug release characteristics and glassy 
solid solution forming properties. However, in order to produce mechanical and physical 
stable formulations, the API still has a large influence on the formulation’s Tg. Nonetheless, 
careful attention should be given to a more rational design of new extrusion (and injection 
molding) polymers for specific drug formulations.  
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Supporting information 
Gordon-Taylor Equation: the experimental values of the glass transition temperature can be compared 
with the calculated theoretical values to evaluate the miscibility of drug and excipients following the 
Gordon-Taylor equation. This relationship states that if drug and polymer are miscible, the mixture 
will show a single Tg that ranges between the Tg of pure components and depends on the relative 
portion of each component: 
21
2211
wKw
wTgKwTg
Tg


  
 
For which Tg1 and Tg2 are the glass transition temperature of the ibuprofen and the polymer, 
respectively, w1 and w2 are the weight fractions of the ibuprofen and the polymer, and K is a constant 
that can be calculated using the Simha-Boyer rule: 
22
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With ρ1 and ρ2 the true densities of the respective ibuprofen and polymer as determined by means of 
helium pycnometry (AccuPyc 1330, Micromeritics Instruments, Norcross, USA). Since the Gordon-
Taylor addresses the densities of amorphous components, the density of amorphous ibuprofen was 
estimated from the true density of teir respective crystalline counterpart, reduced by 5%. 
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MDSC-thermograms 
 
Figure S1. MDSC-thermograms (reversed heat flow) of injection molded tablets with EudrE/IBP at various 
ratios (wt.%)  indicating the plasticizing effect of IBP on EudrE. 
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Figure S2. MDSC thermograms (reversed heat flow) demonstrating that changing the n-BMA groups to t-BMA 
(EudrE vs polymer A2) and lowering the DMAEMA content (polymer B1-3) yielded polymers with a higher Tg.  
 
Figure S3. FTIR-spectra comparing both API’s in crystalline (left) and amorphous form (right). 
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Introduction 
 Hot melt extrusion (HME) and injection molding (IM) are emerging as 
pharmaceutical processes for the formulation of drugs in polymeric matrices for 
controlled drug release.  [170] In these processes heat and shear forces are applied to 
convert thermoplastic polymers mixed with drug into matrix tablets that can contain 
the drug in a dispersed (i.e. solid dispersion) or solubilised (i.e. solid solution) state. 
Both solid solutions and solid dispersions can offer enhanced drug dissolution, which 
is highly desired for poorly water-soluble drugs. On the other hand, by using 
polymers with different properties one can design either immediate release 
formulations or sustained drug formulations. Immediate release formulation produced 
via HME usually contain the amorphous drug dispersed in a hydrophilic carrier 
matrix of one or more polymers, such as polyethylene oxide (PEO), hydroxypropyl 
(methyl) cellulose (HP(M)C), vinylpyrrolidone/vinyl acetate copolymer (Kollidon® 
VA), polymethacrylates (Eudragit® E) and PEG6000/vinylcaprolactam/vinylacetate 
copolymer (Soluplus®). In case of a solid solution where the drug is molecularly 
dissolved in the matrix polymer, drug dissolution will be governed by the dissolution 
of the hydrophilic matrix polymer. Sustained release formulations aim to release drug 
over an extended period or at a specific time during treatment. This is in particular 
beneficial for drugs with short half-lifes and/or fast excretions. Controlled drug 
release is obtained by slow diffusion of the drug through a hydrophobic polymer 
matrix or by a slowly eroding polymer matrix, or by a combination of both. Typical 
polymers used for HME of sustained release formulations are ethylcellulose (EC), 
ethylene vinyl acetate (EVA), polyvinyl acetate (PVA), poly lactic (co-glycolic) acid 
(PL(G)A), polycaprolactone (PCL) and the methacrylate copolymers (Eudragit® 
RS/RL). 
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 Despite the usefulness of these polymers there is still a need for generic 
polymeric excipients that allow formulation of a wide variety of drug molecules with 
different physicochemical behaviour, to produce immediate as well as sustained 
release formulations. Poly(2-alkyl-2-oxazoline)s are an interesting class of polymers 
for the preparation of tailored made polymers with well-defined structure. [171] A 
wide range of functionalities can easily be incorporated in the poly(2-alkyl-2-
oxazoline) structure by both side chain and end group functionalization. Dissolution 
properties of these polymers can be altered by changing the chain length of the side 
groups. Poly(2-alkyl-2-oxazoline) with methyl and ethyl side-chains, as example, are 
fully water-soluble at ambient body temperature with a lower critical solution 
temperature (LCST) of 60°C for poly(2-ethyl-2-oxazoline) (PEtOx). Poly(2-alkyl-2-
oxazoline) with propyl side chains, on the contrary, exhibits a LCST below 
physiological temperature (i.e. 37 °C). Moreover, the physicochemical properties of 
poly(2-alkyl-2-oxazoline)s can be widely tailored from amorphous materials with 
branched aliphatic side chains to semi-crystalline polymers with linear aliphatic side 
chains.  
Previously we and others have reported on the biocompatibility of PEtOx, 
paving the road for their use as component in drug delivery systems. [172-174] So far 
polyoxazoline-based materials have been evaluated as protein-conjugates, [175] block 
copolymer micelles for encapsulation of low molecular weight hydrophobic drugs, 
[176] as well as for surface functionalization of materials intended for biomedical use. 
[177] However, up to our knowledge, polyoxazolines have not yet been used as 
excipient to formulate drugs into solid dosage forms for oral intake. An important 
issue in this regard, is the stability of PEtOx in the gastro-intestinal tract. PEtOx are 
prone to hydrolysis in acidic medium, resulting in the formation of ethylene imine 
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units that hold potential toxicity risks. [178] Recently we addressed this issue and 
revealed that 24 h at 0.1 M HCl (the acidic environment in the stomach) and 37 °C, 
results in negligible, i.e. less than 1 %, hydrolysis. [174] Moreover, we also assessed 
the influence of the extent of hydrolysis on cell viability and mucosal irritation. We 
observed that PEtOX with up to 25 % ethylene imine units did not significantly affect 
cell viability and did not induce mucosal irritation. These findings encouraged us to 
further explore the potential of PEtOx for drug delivery applications. 
In this paper we evaluate PEtOx as pharmaceutical excipient to produce oral 
solid dosage forms for drug molecules with different water solubility. For this 
purpose, commercially available PEtOx with molecular weights of respectively 50, 
200 and 500 kDa were formulated with metoprolol tartrate (MPT) and fenofibrate 
(FBT) as good and poorly water-soluble drugs, respectively. Hot melt extrusion 
(HME) coupled with injection molding (IM) was used as technique to produce these 
tablet formulations. [179] 
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Experimental section 
Materials 
  Poly(2-ethyl-2-oxazoline) (PEtOx) with a molecular weight of respectively 50, 
200 and 500 kDa was purchased from Sigma-Aldrich. Note that this material is not of 
pharmaceutical grade, however high purity grade PEtOx has become commercially 
available very recently under the tradename Aquazol HP from PCI, Inc. To reduce the 
particle size, the PEtOx was mechanically milled using a hammer mill, Figure S1 
(supporting information) shows scanning electron microscopy images of the 
polymeric material before and after milling. Figure 1A shows the molecular structure 
of PEtOx. MPT (Figure 1D) was purchased from Esteve Quimica. FBT (Figure 1E) 
was purchased from Roig Farma.  
 
Figure 1. (A) Molecular structure of PEtOx. (B) Photograph of a HME/IM tablet after opening of the 
biconvex mold. The tablet is indicated with a white arrow. (C) Cumulative release curves showing the 
dissolution of pure PEtOx tablets, produced via HME/IM of PEtOx of different molecular weight. (D) 
Molecular structure of metoprolol tartrate. (E) Molecular structure of fenofibrate. 
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Hot melt extrusion and injection molding 
 Active pharmaceutical ingredient (API) and polymer were mixed with a 
mortar and pestle, and fed to a co-rotating twin-screw extruder at 100 rpm (Haake 
MiniLab II Micro Compounder, Thermo Electron). Table 1 lists the respective 
process temperatures. These optimal extrusion settings were empirically selected in 
order to achieve an optimal torque value, melt flow and retention time. The 
homogeneous extruded blends are consequently collected in a reservoir and injection 
molded (Haake MiniJet System, Thermo Electron) with high dimensional precision to 
produce biconvex tablets (height = 5 mm/ diameter = 10 mm). Figure 1B shows a 
photograph of a PEtOx tablet in an opened mold. The injection pressure was 880 bar 
during 10 s, in combination with a post-pressure of 400 bar for 5 s. The temperature 
of the mold was set at 20 °C. 
Scanning electron microscopy (SEM) 
 Samples were first sputtered with gold followed by imaging with a Quante 
FEG FEI scanning electron microscope operating at an acceleration voltage of 5 kV. 
Hot stage microscopy 
Optical microscopy images were recorded on a Leica DM2500P microscope 
equipped with a 10x objective, a 360FX CCD camera and a Linkham THMS600 
heating stage. 
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X-ray diffraction (XRD 
X-Ray diffraction was performed on a D5000 diffractometer (Siemens). 
Diffractograms were ontained with Cu Kα radiation (45 kV x 40 mA; λ = 1.54 Å) at a 
scanning speed of 25 °(2)/min and step size of 0.03 °(2). 
Thermal analysis 
The glass transition temperature (Tg) and melting point (Tm) of pure 
components, physical mixtures and injection molded tablets were analyzed by 
differential scanning calorimetry. (DSC Q2000, TA Instruments, Leatherhead, UK)  
Dry nitrogen at a flow rate of 50 ml/min was used to purge the DSC cell. Temperature 
heating/cool/heat cycle was run between -70 °C and 140 °C applying 10 °C/min 
heating and cooling ramps. All results (first cycle) were analyzed using the TA 
Instruments Universal Analysis 2000 software. 
In vitro dissolution testing 
The release characteristics of the injection molded tablets were evaluated 
using the paddle method on a VK 7010 dissolution system (VanKel Industies, New 
Jersey, USA) with a paddle speed of 100rpm. Hydrochloric acid (pH 1) and phosphate 
buffer (pH 7) were used as dissolution media (900 mL) at 37 ± 0.5 °C. For in vitro 
dissolution testing of the poorly water-soluble FBT, sodium lauryl sulfate (0.5 %) was 
added to the medium to simulate sink conditions. Samples were withdrawn at regular 
time intervals and spectrophotometrically analyzed for API concentration at their 
specific wavelength of maximum absorbance. For FBT, MPT and PEtOx this 
wavelength was respectively 289, 274 and 203 nm. 
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Results and Discussion 
First we assessed whether PEtOx is suitable as matrix polymer to produce 
tablets via hot melt extrusion (HME) followed by injection molding (IM). Therefore, 
an essential step is to  mechanically mill the commercial PEtOx to reduce the particle 
size. This is required to allow, in a further part of this research, producing tablets with 
the drug homogeneously distributed within the polymer matrix and to avoid large 
discrepancies between inter-tablet drug loads. Figure S1 (Supporting Information), 
shows scanning electron microscopy images of the POX before and after milling, 
clearly indicating a substantial size reduction below 1 mm of the polymeric material, 
needed to obtain a homogeneous drug:polymer mixture. Next we assessed the process 
conditions required for HME/IM of PEtOx. PEtOx has a Tg varying between 43 °C 
and 57 °C, dependent on its molecular weight. [180] We observed that applying a 
process temperature of 160 °C, which is sufficiently below the decomposition 
temperature of PEtOx (>300 °C; thus avoiding degradation), allowed obtaining 
transparent tablets with a smooth surface. Subsequently we assessed the dissolution 
behaviour of these tablets under conditions that are used to monitor in vitro 
dissolution of oral drug formulations. This means adding the PEtOx tablets to 
dissolution vessels containing 900 mL of 0.1 M HCl (to simulate the acidic conditions 
in the stomach) and set at 37 °C. Subsequently, liquid samples were withdrawn at 
regular time points and as PEtOx exhibits UV activity in the 200 nm region, PEtOx 
concentration could be determined by measuring the UV-VIS absorbance. Figure 1B 
shows the dissolution behaviour of the PEtOx tablets, indicating the dissolution time 
of the tablets is affected by the molecular weight of the PEtOx as might be expected 
from the increased chain entanglement density with longer chains. Furthermore, 
although PEtOx has high water-solubility it takes a considerable amount of time to 
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dissolve, i.e. 30 min, 60 min and 120 min for 50 % dissolution, for PEtOx with a 
molecular weight of respectively 50, 200 and 500 kDa. The reason for this slow 
dissolution is likely the high pressure applied during the HME/IM process, which 
results in a dense entangled polymer matrix with very low porosity. Note that lower 
pressures would lead to incomplete filling of the mold with the molten polymer/drug. 
These observations open the avenue to control drug release by varying the molecular 
weight of the PEtOx as well as the concentration of PEtOx in a PEtOx/drug 
formulation. 
Next we investigated whether solid solutions could be formed between PEtOx 
and the two model APIs (i.e. MPT as good water-soluble API and FBT as poor water-
soluble API). A solid solution is a molecular dispersion of the API in a polymer 
matrix, obtained by dissolving the API in a molten polymer phase, followed by 
cooling of the system to a solid state. Crucial in such process is the solubility of the 
drug molecules in the molten polymer phase required to suppress phase separation 
and drug crystallization. To assess this for our two model APIs we performed hot 
stage microscopy experiments. Figure 2 shows the corresponding microscopy 
images. All rows start with an image recorded at a temperature of 70 °C where no 
melting of either drug or PEtOx is observed. The subsequent series of images start 
from the temperature at which melting or flowing occurs. Figures 2A-B indicate that 
MPT and FBT melt at respectively 125 °C and 85 °C while PEtOx started to flow at 
125 °C. Although PEtOx is an amorphous polymer it is likely that plastic deformation 
can be induced during the extrusion process at considerably lower temperatures. 
When mixtures of PEtOx and respectively 25 wt% MPT (used in this study as good 
water-soluble model drug; Figure 2D) and 20 wt% FBT (used in this study as poorly 
water-soluble model drug; Figure 2E) are heated, it was observed that both 
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components were miscible. Moreover, upon cooling of the molten phase to a solid 
phase no recrystallization of either of the model drugs was observed.  
 
Figure 2. Optical microscopy images recorded on a hot stage set-up. Panels (A) and (B) represent 
respectively (A) metoprolol tartrate and (B) fenofibrate. These crystalline drugs readily melt when their 
melting point is reached. Panel (C) represents PEtOx (as representative example PEtOx was chosen 
with a molecular weight of 200 kDa). This polymer started to flow at a temperature of 125 °C. Panels 
(D) and (E) represents mixtures of PEtOx and respectively (D) metoprolol tartrate (25 wt%) and (E) 
fenofibrate (20 wt%). These mixtures form a solution with PEtOx upon heating above the melting point 
of the respective drug molecules. 
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Taken into account the above-described encouraging results, we prepared 
powder mixtures containing PEtOx with different molecular weight and respectively 
MPT and FBT that were fed to a twin screw extruder. The applied extrusion 
temperatures are listed in Table 1. We observed that a transparent molten phase was 
produced, indicating that elevated temperature combined with high shear forces 
during the extrusion process enables the production of homogenous molecularly 
dispersed polymer/API blends. This blend is consequently collected in a reservoir and 
injection molded with high dimensional precision to produce biconvex tablets. 
Table 1. Process temperatures [°C] used to extrude the drug/PEtOx formulations. MPT refers to 
metoprolol tartrate while FBT refers to fenofibrate.  
 
 PEtOx 50 kDa 
[°C] 
PEtOx 200 kDa 
[°C] 
PEtOx 500 kDa 
[°C] 
25 wt.% MPT 120  120 140 
50 wt.% MPT 120 130 145 
20 wt.% FBT 115 115 120 
 
In a first series of drug formulation experiments we used MPT as good water-
soluble model API. MPT is a β1 blocker used in the treatment of hypertension and is 
on the market formulated as tablets. Drug payloads of 25 and 50 wt% were chosen 
and the obtained tablets were subjected to differential scanning calorimetry (DSC) 
(Figure 3A) analysis. The thermograms of the tablets clearly indicate the formation of 
a solid solution in which the MPT is molecularly dissolved within the polymer matrix. 
This is evidenced by the absence of a melting peak for metoprolol tartrate in the 
thermogram and the absence of the crystalline peaks in the diffractogram, whereas 
crystallinity is clearly observed for physical mixtures of the two components that 
were recorded as a control. In addition, one single Tg, situated between the Tg’s of 
Polyoxazolines Ι Chapter 3 
 
 103 
 
both components separately, indicates good miscibility and the absence of 
pronounced phase separation. Figure 3A shows thermograms for crude metoprolol 
tartrate, PEtOx, the physical mixture and HME/IM tablets. These data correspond to 
PEtOX with an molecular weight of 200kDa, however identical observations were 
done for the other molecular weights. Furthermore, all tablets were fully transparent 
and no birefingance is observed by polarized light microscopy. However, after several 
weeks of storage, the tablets bearing 50 wt% MPT became opaque. X ray diffraction 
(XRD) analysis (Figure 3B) indicated recrystallisation of the drug molecules. By 
contrast the tablets containing 25 wt% MPT remained stable for several months and 
no recrystallisation could be observed. Again, identical observations were done, 
irrespective of the molecular weight of the PEtOx. Figure 3B shows the X-ray 
diffractograms of the tablets containing respectively 25 wt% and 50 wt% MPT after 4 
weeks of storage. 
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Figure 3. (A) Differential scanning calorimetry profiles recorded of metoprolol tartrate,  PEtOx (200 
kDa was chosen as representative example), a physical mixture of both drug and polymer and HME/IM 
tablets. Panels (A1) and (A2) represent respectively a 25 wt% and 50 wt% MPT:PEtOx ratio. (B) X-ray 
diffractograms recorded from physical mixtures and HME/IM tablets of PEtOx and metoprolol tartrate 
with a metroprolol content of respectively (B1) 25 wt% and (B2) 50 wt%. The tablets were stored for 4 
weeks at ambient conditions prior to XRD analysis. (C) Cumulative release curves showing the 
dissolution of metoprolol tartrate from HME/IM PEtOx tablets using PEtOx of different molecular 
weight. In (C1) the drug load was 25 wt% while in (C2) the drug load was 50 wt%. 
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Subsequently the tablets were assessed for their in vitro release properties by 
putting them in dissolution vessels, at pH 1 and 37 °C to simulate the conditions in 
the stomach. Figure S2 (Supporting Information) shows the UV-VIS spectra of 
respectively PEtOx and MPT, showing that there is no interference from PEtOx when 
measuring at the secondary absorption maximum of MPT (i.e. 274 nm). The drug 
dissolution profiles are shown in Figure 3C along with the dissolution profile of pure 
MPT. These graphs show that whereas the pure drug immediately dissolves, sustained 
release is observed for metoprolol tartrate formulated in PEtOX HME/IM tablets. The 
fastest dissolution rate was observed for tablets containing 50 wt% metoprolol tartrate 
followed by the 25 % tablets. When looking at Figure 1C, pure PEtOx tablets exhibit 
an even slowed dissolution. This clearly demonstrates that higher loads of  
hydrophilic drug increases the dissolution rate. Additionally, in accordance to the 
dissolution profiles of the pure PEtOx tablets, a decrease in dissolution rate was 
observed with increasing molecular weight of the PEtOx. For many applications, a 
sustained release of up to 24h is desired, which is not achieved in the present study as 
complete release of MPT is reached after 3 hours. However, we anticipate that the 
release kinetics of good water-soluble drugs could further delayed by increasing the 
length of the alkyl-side chain of the oxazoline monomer. In previous studies the 
introduction of longer side chains >3 carbons atoms clearly indicated  a more 
hydrophobic behaviour of the resulting polymer, [180] which could be beneficial for 
the production of sustained release formulations. Furthermore, longer monomer alkyl 
side result in a lower Tg of the polymer, which might facilitate processing via 
HME/IM.  
In a next series of experiments we used FBT as poorly water-soluble model 
drug. Fenofibrate is used in the treatment of elevated cholesterol levels and is on the 
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market formulated as gelatin capsules filled with fenofibrate micro- or nanocrystals. 
Due to its poor water solubility we lowered the API content and produced HME/IM 
tablets containing 20 wt% FBT. DSC (Figure 4A) and XRD (Figure 4B) analysis on 
these tablets revealed the absence of crystallinity and thus the formation of a solid 
solution. Figure 4 shows the representative data for 200 kDa PEtOx tablets 
containing 20 wt% FBT. These data are representative for all studied molecular 
weights of PEtOx. Moreover, storage over prolonged times did not alter the 
crystallographic state of the drug. 
 
Figure 4. (A) Differential scanning calorimetry profiles recorded of fenofibrate, PEtOx (200 kDa was 
chosen as representative example), a physical mixture of both fenofibrate and PEtOx (20 wt% 
fenofibrate) and HME/IM tablets. (B) X-ray diffractogram of HME/IM PEtOx tablets containing 20 
wt% fenofibrate. The molecular weight of the PEtOx was 200 kDa. (C) Cumulative release curves 
showing the dissolution of fenofibrate from HME/IM PEtOx tablets containing 20 wt% fenofibrate 
using PEtOx of different molecular weight.  
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 For the dissolution experiments, sodium lauryl sulfate (SLS) was added as 
surfactant in order to enhance the dissolution of FBT according to the instructions of 
the European Pharmacopoeia. [181] Note that there is a physiological relevance for 
the addition of surfactant to the dissolution medium as the bile salts in the gastro 
intestinal tract also possess surface-active properties that will enhance the dissolution 
of poorly water-soluble drugs in vivo. Again, as shown in  Figure S2 (Supporting 
Information), interference from PEtOx is avoided when measuring at 289 nm. 
Figure 4C shows the dissolutions profiles of the tablets as well as pure FBT. Whereas 
pure FBT exhibits only slow and incomplete dissolution, formulation into PEtOX 
tablets via HME/IM greatly enhances the dissolution rate as well as the total 
availability. Most likely this is attributed to the formation of solid solutions of 
fenofibrate in a PEtOx matrix, which was evidenced by XRD and DSC, i.e. 
dissolution from a solid solution does not compete with crystal formation as is the 
case for pure FBT. Furthermore, also FBT formulated in PEtOx HME/IM tablets 
revealed a dissolution rate that was dependent on the molecular weight of the PEtOx.  
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Conclusions 
In conclusion, we have demonstrated in this paper that PEtOx is a potentially 
interesting class of polymers to serve as matrix for controlled released formulations produced 
by hot melt extrusion followed by injection molding. We found that both good water-soluble 
as well as poorly water-soluble drug molecules could be solubilized within the polymeric 
matrix upon hot melt extrusion. Whereas formulation of a good water-soluble drug led to a 
slower dissolution and drug release profile, due to a slower dissolution rate of the polymeric 
matrix compared to the pure drug, a dramatic increase in dissolution rate was observed when 
a poorly water-soluble drug was formulated. Furthermore we also showed that the release rate 
could be tailored by varying the molecular weight of the PEtOx.  
Despite that we showed the great promise of PEtOx for controlled release applications 
by HME/IM, there is still a long way to go before the first commercial tablets will enter the 
market. In depth studies have to be performed on toxicity of PEtOx, the influence of longer 
alkyl side chains or higher PEtOx MW on the release properties, elaborate stability studies 
and pharmaceutical grade PEtOx has to be developed on the way to FDA approval, which is 
currently only granted for usage as indirect food additive.   
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Supporting Information  
 
 
Figure S1. Scanning electron microscopy images of PEtOx of different molecular weight before (upper row) and 
after (lower row) milling. 
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Figure S2. UV-VIS spectra recorded at the maximum concentration of the respective components in the 
dissolution vessel. The wavelengths that were chosen to calculate the concentration of the respective components 
are annotated with an arrow. 
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Thermoplastic Polyurethanes for the Manufacturing of 
Highly Dosed Oral Sustained Release Matrices via Hot 
Melt Extrusion and Injection Molding 
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Introduction 
 
Sustaining drug release from a dosage form after oral administration offers distinct 
advantages to chronic and poly-medicated patients: maintaining drug levels in the therapeutic 
range, lower dosing frequency, less side effects; resulting in a better patient compliance. 
While sustained drug release can be achieved based on the design of the dosage form 
(reservoir systems vs. matrices) and/or the physicochemical properties of the polymeric 
materials incorporated in the formulation (diffusion controlled vs. delayed polymer 
dissolution), hot melt extrusion (HME) (possibly in combination with injection molding) has 
been evaluated to manufacture sustained-release matrices using various polymers: 
ethylcellulose (EC) [59-61], hydroxypropyl (methyl) cellulose (HP(M)C) [62], ethylene vinyl 
acetate (EVA) [29, 63], polyvinyl acetate (PVA) [64], poly lactic (co-glycolic) acid (PL(G)A) 
[65-66], silicone [67], polycaprolactone (PCL) [68-69], polyoxazolines [70], polyanhydrides 
[71], methacrylate copolymers (Eudragit
®
 RS/RL) [72-73], and several lipid materials [74-
76]. While sustained-release dosage forms have been successfully developed via HME using 
these polymers, a common drawback is that the drug load in these formulations is often low, 
either linked to processing issues during HME of formulations with a high drug load, or due 
to a significant burst release when less polymeric matrix former is incorporated in the 
formulation. Quinten et. al. [57], for instance, described that drug load in an acrylic 
polymermatrix was limited to 30% when processed via HME/IM, drug release from these 
matrices occurred in a first order manner via a combination of swelling and diffusion. Reitz et 
al. managed [182] to produce extrudates with 65wt.% diprophylline via solid lipid extrusion 
(with glycerol trimyristate as carrier) and identified the importance of drug particle size: 
although a larger drug particle size reduced the release rate and minimized the burst release, 
sustained release from these high dosed lipid matrices was limited (70% drug release after 1 
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and 3 h for small and large drug particle sizes, respectively). Another study [183] 
incorporated 30wt.% Dyph in Eudragit
®
 S100 and Eudragit
®
 L matrices, processed via HME 
at 160°C, and due to the complete dissolution of dyphylline in the matrix poor sustained 
release properties (>50% released within 2h in 1N HCl) were registered. It is well 
documented that a higher drug load enhanced the release rate from the matrix since more 
pores are created in the micro-capillary network of the insoluble matrix upon drug release, 
often combined with a burst release. To this end, the design of novel sustained release dosage 
forms using innovative polymeric materials with improved characteristics for controlled drug 
release is continuously under investigation. 
Thermoplastic polyurethanes (TPUR) are inert, non-ionic, water-insoluble polymers 
that have been successfully used for many years as drug release controlling polymers in 
vaginal rings [16, 25, 184], stents [185], coatings [186] and implants [187]. Another important 
application of TPUR is in medical tubing as its superior mechanical properties (compared to 
polyvinyl chloride) allow the use of thinner walled tubes, even without a plasticizer [122]. 
The chemical structure of TPUR consists of alternating hard segments (HS) in a continuous 
phase of soft segments (SS) (Figure 1). Typically the SS phase is composed of a relatively 
long, flexible polyester or polyethers with a molecular weight of 1000-10.000g/mol. The HS 
can be composed of linear 4,4’-methylene diphenyl diisocyanate (MDI) or its hydrogenated 
form (HMDI), possibly linked to one another via a chain extender (often short chain diols). 
Thermodynamic incompatibility of both segments results to a certain degree of insolubility 
between HS and SS, yielding a microphase-separated (segmented) polymer. This generates a 
polymer with unique physicochemical characteristics: an elastomeric material with superior 
tensile strength, abrasion resistance, crack resistance, inherent lubricity and biocompatibility 
[188]. To this end, the HS contributes to the polymers’ strength due to the formation of 
intermolecular hydrogen bonds between the urethane structures (NH-(C=O)-O) in each HS, 
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while the SS fraction with a low glass transition temperature (Tg) provides the polymers’ 
elasticity [189]. TPUR are available in various molecular weights, different types (polyester, 
polyether) of SS, different SS lengths, and variable SS/HS ratios which makes them attractive 
candidates to alter drug release performances based on polymer composition.  
 
Figure 1. Schematic structure of thermoplastic polyurethanes 
In this study, we evaluated thermoplastic polyurethanes (TPUR) as matrix excipients 
for oral sustained release purposes. The formulations were produced via hot-melt extrusion 
followed by injection molding and were consequently (physicochemically) characterized. 
Metoprolol tartrate (MPT), theophylline (Th) and diprophylline (Dyph) were embedded as 
model drugs in the TPUR matrices. 
 
Experimental Section  
Materials 
Various grades of TPUR (Table 1) with varying composition of the hard and soft 
segments and with variable SS/HS ratio (Table 1) were obtained from Merquinsa (a Lubrizol 
company, Ohio, USA): the Pearlbond polyurethanes (P520, P522, P523, P539) were non-
medical grades, while the Tecoflex types (T85A, T100A, T72D) were medical grades (Figure 
2). Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain), theophylline (Th) and 
diprophylline (Dyph, 7-(2,3-dihydroxypropyl)-theophylline) (Sigma Aldrich, Bornem, 
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Belgium) are embedded as model drugs in the TPUR matrices. Polyethylene glycol 4000 and 
Tween 80 were obtained from Fagron (Waregem, Belgium). 
Figure 2. Chemical structure of the aromatic Pearlbond TPUR (top) and the aliphatic Tecoflex TPUR (bottom) 
 
Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) was performed on a Waters instrument, 
equipped with 3 serial Polymer Standards Services columns (1 x GRAM Analytical 30 Å and 
2 x GRAM Analytical 1000 Å, 10 µm particle size) at 35°C. Poly(methylmethacrylate) 
(PMMA) standards were used for calibration and dimethylacetamide (DMA), containing LiBr 
(0.42 g/mL) to increase polymer solubility, was used as solvent at a flow rate of 1 mL/min. 
100 µL of a 10 mg/mL TPUR solution was injected onto the column. TPUR in the eluent was 
detected using a Waters 2414 refractive index detector. Molecular weights were determined 
using the Empower software (Waters, Zellik, Belgium). 
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Nuclear magnetic resonance (NMR) 
NMR spectra were recorded on a Bruker AVANCE 300 spectrometer, using 
deuterated dimethylformamide (DMF) as solvent, to determine the polymer structure and 
SS/HS ratio. The spectra were analyzed with the ACD/Spec Manager software from 
ACD/Labs. 
1
H-NMR (300 MHz, DMF-d7) of Pearlbond polymers: δ (ppm) = 1.37 (m, CH2-
CH2-CH2-O), 1.61 (m, CH2-CH2-CH2-O), 2.33 (t, CH2-CH2-CH2-(CO)), 3.86 (s, Ph-CH2-Ph), 
4.05 (t, CH2-CH2-CH2-O), 7.17 (d, aromatic), 7.48 (d, aromatic), 9.45 (s, O(CO)NH). 
1
H-
NMR (300 MHz, DMF-d7) of Tecoflex polymers: δ (ppm) = 0.86 – 1.88 (br, CH2 cyclic and 
CH2-CH2-O(CO)NH), 1.57 (br, CH2 backbone pTHF), 3.39 (br, CH2-O), 3.62 (br, O(CO)NH-
CH), 3.98 (br, CH2-CH2-O(CO)NH), 6.71-7.03 (br, O(CO)NH). 
Fourier-transform infrared spectroscopy 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 
performed on the polymers before and after the SHIME-experiment in order to identify 
molecular changes. Spectra were recorded using a Nicolet iS5 ATR FT-IR spectrometer 
(Thermo Fisher Scientific). A diamond ATR crystal was pressed against the samples. Each 
spectrum was collected in the 4000 - 550 cm
-1
 range with a resolution of 2 cm
-1
 and averaged 
over 32 scans. 
Thermal analysis 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was used 
to investigate the thermal stability of the polymers. The samples were equilibrated at 30°C 
and heated (10°C/min) to 500°C under an N2 atmosphere.  
The glass transition temperature (Tg) and melting point (Tm) of pure components, 
physical mixtures and injection molded tablets were analyzed in Tzero pans (TA instruments, 
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Zellik, Belgium) by modulated differential scanning calorimetry (MDSC Q2000, TA 
Instruments, Leatherhead, UK) using a heating rate of 2°C/min. The modulation period and 
amplitude were set at 1min and 0.318°C, respectively (heat-iso method). Dry nitrogen at a 
flow rate of 50mL/min was used to purge the MDSC cell. All results were analyzed using the 
TA Instruments Universal Analysis 2000 software. Samples (± 5mg) were run in Tzero pans 
(TA Instruments, Zellik, Belgium). MDSC heat capacity calibration was done via small 
sapphire disks, placed in a Tzero pan. Analysis of the thermal characteristics (Tm and Tg) was 
done via a heating/cool/heat run between -70°C and 75°C and between -70°C and 140°C for 
the physical mixtures with Pearlbond and Tecoflex polymers, respectively. The melting 
enthalpy (in the total heat flow signal), Tmelt-max (i.e. inflection point of melting endotherm) 
and Tmelt-onset (i.e. start of melting endotherm) were analyzed in the first heating cycle. 
Analysis of the glass transition temperature was done in the first and second heating cycle for 
injection molded tablets and physical mixtures, respectively. All results were analyzed using 
the TA Instruments Universal Analysis 2000 software. 
Production of injection molded tablets 
Physical mixtures, homogenized using mortar and pestle, of drug/polymer at a ratio of 
50/50, 65/35 and 75/25 were extruded at 70°C for MPT-containing formulations, and at 
140°C for Th- and Dyph-containing formulations using a lab-scale co-rotating twin-screw 
extruder at 100rpm (Haake MiniLab II Micro Compounder, Thermo Electron, Karlsruhe, 
Germany). The mixtures were manually fed into the extruder in order to avoid segregation 
due to differences in particle size between API (µm range) and TPUR (mm range). 
Immediately after HME, the thermoplastic melt was processed into biconvex tablets 
(diameter: 10mm/height: 5mm) via injection molding (Haake MiniJet System, Thermo 
Electron). The injection pressure was 800bar during 10s, in combination with a post-pressure 
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of 400bar for 5s. The temperature during injection molding was the same as during HME: 70 
and 140°C for MPT-containing and Th- and Dyph-containing formulations, respectively. 
Raman mapping 
The homogeneity of the distribution of MPT in the tablets was evaluated by Raman 
microscopic mapping using a Raman Rxn1 Microprobe (Kaiser Optical Systems, Ann Arbor, 
MI, USA) equipped with an air-cooled CCD detector. The laser wavelength employed was a 
785 nm from a Invictus NIR diode laser. The tablet surface was scanned by a 10x long 
working distance objective lens (spot size 50 μm) in area mapping mode using an exposure 
time of 4s and a step size of 50 μm in both the x (18 points) and y (13 points) direction (=234 
spectra or 850 x 600µm per mapping segment). Six areas were analyzed in total. Data 
collection and data transfer were automated using HoloGRAMS™ data collection software 
(version 2.3.5, Kaiser Optical Systems), the HoloMAP™ data analysis software (version 
2.3.5, Kaiser Optical Systems) and Matlab
®
 software (version 7.1, The MathWorks, Natick, 
MA, USA). All spectra were reduced to 800-1500cm
-1
, a spectral range which contains the 
fingerprint region of both components. The spectra were preprocessed using Pearson’s 
method to perform a baseline correction and normalized. 
 
The 234 Raman spectra collected per monitored area were each introduced into a data 
matrix (D), resulting in a Raman data matrix per area. Each D was analyzed using 
multivariate curve resolution (MCR). MCR aims to obtain a clear description of the 
contribution of each pure component in the area from the overall measured variation in D. 
Hence, all collected spectra in the area are considered as the result of the additive contribution 
of all pure components involved in the area. Therefore, MCR decomposes D into the 
contributions linked to each of the pure components in the system: 
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D = CS + E 
where C and S represent the concentration profiles and spectra, respectively. E is the error 
matrix, which is the residual variation of the dataset that is not related to any chemical 
contribution. Next, the working procedure of the resolution method started with the initial 
estimation of C and S and continued by optimizing iteratively the concentration and response 
profiles using the available information about the system. The introduction of this information 
was carried out through the implementation of constraints. Constraints are mathematical or 
chemical properties systematically fulfilled by the whole system or by some of its pure 
contributions. The constraint used for this study was the default assumption of non-negativity; 
that is, the data were decomposed as non-negative concentration times non-negative spectra 
[190]. 
Melt rheology 
 Melt rheology of TPUR was determined using an Anton Paar MCR301 (Oregon, 
USA) rheometer. The gap between plate spindle (diameter 25 mm) and plate was 1 mm. The 
strain amplitude and the angular frequency used were 1% and 10 rad/s, respectively. The 
Pearlbond and Tecoflex viscosities were measured at a temperature of 70 and 140°C, 
respectively.  
Scanning electronic microscopy 
IM tablets were sputtered with platinum using the JEOL JFC 1300 Auto Fine Coater 
(Jeol, Zaventem, Belgium). The samples were examined with a JEOL JSM 5600 LV scanning 
electron microscope (Jeol) at a magnification of 1000x.  
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He pycnometry 
The tablet porosity was calculated based on the difference between the bulk and 
skeletal volume of the injection molded tablets. The skeletal volume of the tablets was 
measured (at different time points during dissolution experiments: 2, 4, 6, 8 and 24 h) via He 
pycnometry (AccuPyc 1330, Micromeritics, Norcross, USA). Prior to He pycnometry the 
tablets were dried for 2 days at 30°C. As no shrinkage or swelling of the injection molded 
tablets was observed immediately after injection molding nor after 24 h dissolution testing 
(verified by measuring tablet diameter and height using a digital slide caliper), the bulk 
volume of the tablets was determined from the dimensions of the mold. The tablet porosity (ɛ) 
was calculated based on the following equation: 
ɛ = [ (bulk volume – skeletal volume)/bulk volume ] x 100 
In vitro drug release 
Drug release from the injection molded tablets was determined using the paddle 
method on a VK 7010 dissolution system (VanKel Industries, New Jersey, USA) with a 
paddle speed of 100rpm. Distilled water was used as dissolution medium (900mL) at 37 ± 
0.5°C. Samples were withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and 
spectrophotometrically analyzed for API concentration at 272nm for Th and 274nm for MPT 
and Dyph, respectively. 
In vivo evaluation  
All procedures were performed in accordance with the guidelines and after approval 
by the Ethics Committee of the Faculty of Veterinary Medicine (Ghent University). To study 
the influence of MPT concentration, 2 formulations were administrated to 6 dogs: (a) 
formulation F1:  IM tablets containing 65 % MPT and 35 % Pearlbond 539 (equivalent to 
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239mg MPT), (b) formulation F2 (reference): Slow-Lopresor® 200 Divitabs® (Sankyo, 
Louvain-la-Neuve, Belgium), a commercial sustained release formulation consisting of matrix 
tablets containing 200 mg MPT. 
 
All formulations were administrated to 6 male mixed-breed dogs (10 – 13 kg) in a 
cross-over study with a wash-out period of at least 8 days. Since the size of the molded tablets 
was fixed, different MPT doses (239 and 200 mg for F1 and F2, respectively) were 
administered. The pharmacokinetic profiles were normalized as linear pharmacokinetics have 
been reported for MPT in a dose range between 50 and 400 mg [191]. The dogs were fasted 
12 h prior to administration and 12 h after administration, although water was available ad 
libitum. Before administration, an intravenous cannula was placed in the lateral saphenous 
and a blank blood sample was collected. The formulations were administrated with 20 mL 
water, and blood samples were collected in dry heparinized tubes at 0.5, 1, 2, 4, 6, 8, 12, 16, 
20 and 24 h after administration. The obtained blood samples were centrifuged at 1500g 
during 5 min. A validated HPLC method [192] with fluorescence detection was used for the 
determination of MPT in dog plasma. The peak plasma concentration (Cmax) and the time 
needed to reach the highest plasma concentration (tmax) were determined. The controlled 
release characteristics of the formulations were evaluated by means of the HVDt50%Cmax 
defined by the period during which the plasma concentration exceeds 50 % of Cmax [193-194]. 
The intact tablets, collected in the faeces of the dogs, were analyzed for their remaining MPT 
concentration. These tablets were crushed using mortar and pestle, suspended in 100mL demi 
water for 24 h and the MPT concentration in the supernatant was spectrophotometrically 
analyzed at 274nm. 
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Simulator of the Human Intestinal Microbial Ecosystem (SHIME)  
The stability of TPUR grades T85A and P523 upon oral ingestion was evaluated in the 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME), developed by the 
Laboratory of Microbial Ecology and Technology, Ghent University, as described earlier 
[195]. In brief, both polymers (2 g/l) were added to a standardized nutritional medium and 
incubated under simulated stomach conditions for 90 min (37°C, aerophilic conditions). Next, 
an appropriate amount of bile salts and digestive enzymes was added to simulate small 
intestinal conditions, and the samples were further incubated for 150 min (37°C, 
microaerophilic conditions). Finally, a complex microbial community was taken from the 
ascending colon compartment of the SHIME and added to the setup. The samples were further 
incubated for a period of 48 h (37°C, anaerobic conditions). All experiments were performed 
in triplicate. As a control, the same experiment was performed in parallel, without addition of 
TPUR. Both polymers were isolated from the stomach, small intestinal and colon incubation 
medium, and the polymer’s integrity and structure was analyzed by means of MDSC and 
FTIR. The potential breakdown of the polymer by the intestinal microflora was indirectly 
assessed. Changes in composition or activity of the microbial community in the test with 
TPUR as compared to the control were used as marker for interaction between TPUR and the 
intestinal microbiota. Changes in composition were assessed by selective plate counting for 
different bacterial groups, as described by Possemiers et al. [196]. Effects on microbial 
activity were evaluated by pH measurements and by quantification of the concentrations of 
shortchain fatty acids (SCFA) in the samples at the beginning and end of the colonic 
incubations, as described earlier [196]. 
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Results and Discussion 
Processability via extrusion and injection molding 
Initially, the maximum drug load of the formulations that allowed processing via HME 
and IM was determined. Using Pearlbond and Tecoflex polymers as matrix formers, two 
distinct factors were negatively influencing the production of high drug load matrices: 
processing temperature and powder fraction in the formulation. If the processing temperature 
exceeded the API’s melting point (Tm), HME processing became impossible at high drug 
loads as the matrix former was not able to absorb the large amount of molten API, resulting in 
a too liquid phase without the plasticity required for the HME process. In addition, a large 
powder fraction in a formulation also compromised HME processing below the API’s Tm as 
the high percentage of crystalline API resulted in a too high torque during HME. Therefore, 
the TPUR fraction in the formulation must be sufficient to provide sufficient plasticity during 
thermal processing. 
Thermal processing of Pearlbond polymers was possible at a temperature of 70°C. 
Polycaprolactone (PCL, (C6H10O2)n), the semi-crystalline polyester soft segment (SS) in 
Pearlbond, has a Tg of around -60°C and melts at 55°C [197]. The combination of hard 
segments (HS), intermolecular connected via H-bonds, and the molten SS provides the 
polymer with sufficient plasticity needed for the extrusion process. This low processing 
temperature enabled the production of high drug loaded formulations with all three API’s: 
MPT, Dyph and Th (Tm of 120, 160 and 270°C, respectively). The maximum drug load was 
65wt.% API using P523 and P539 as matrix formers, while only 50wt.% API could be 
combined with P520 and P522. This difference in processability was correlated with the lower 
SS/HS ratios of P520 and P522 (Table 1). A higher fraction of hard segment (HS), methylene 
diphenyl diisocyanate (MDI) in Pearlbond, hampers the movement of SS, which makes the 
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polymer more rigid and, hence, more difficult to process. Thermal analysis confirmed this 
increase in rigidity as the change in heat capacity (∆Cp) at the Tg of P539, P523 and P520 
was inversely correlated to the SS/HS ratio (Figure 3): a higher fraction of HS in TPUR 
increased the energy needed to transform the polymer from its glass state to a rubbery phase, 
reducing the processability of P520. These findings were also confirmed by melt rheology 
experiments of the polymers, as higher melt viscosities were measured at 70°C for P520 and 
P522, respectively (Table 1). The polymer melt viscosity could be correlated with their 
extrusion processability as the API did not dissolve in the polymer melt during HME/IM 
processing: no loss of API crystallinity was detected in the IM tablets based on the melting 
enthalpy of an MPT/P539 formulation containing 50 and 65% drug, corresponding to 99 and 
100% MPT crystallinity, respectively. Similar results were obtained when the other 
Pearlbond/drug combinations were processed (data not shown). 
The formulations based on the medical grade polyether TPUR (Tecoflex) could only 
be processed via extrusion and injection molding at a temperature of 140°C. This higher 
energy input, required for the Tecoflex polymers to provide sufficient plasticity to the 
formulation, is most likely linked to their chemical structure consisting of hydrogenated MDI 
(HMDI) as HS with a shorter and thus more rigid poly-tetrahydrofuran (pTHF, (C4H8O)n) as 
SS [198]. They also contain a chain extender, most likely a butanediol, which increases the 
HS length, a significantly lower SS/HS ratio (Table 1) and a higher polymer melt viscosity. 
The higher processing temperature, however, excluded MPT from Tecoflex-based 
formulations as its melting point (Tm: 120°C) was below the process temperature, yielding a 
liquid mixture without the (thermo)plasticity required for HME. Using T85A and T100A as 
matrix former, formulations were produced up to an API content of 65wt.%, while even a 
drug load of 75wt.% was possible in combination with T72D. Processing of Dyph/Tecoflex 
mixtures at high drug load via HME and IM was facilitated by the partial loss of Dyph 
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crystallinity during HME: at a drug load of 65 wt%. in T72D and T100A matrices 63 and 
70%, respectively, of crystalline Dyph was recovered in the IM tablets.  
An additional advantage of TPUR is its inherent lubricity [188]. Previous studies 
considering the injection molding technique used a silicon-based anti-sticking spray to 
facilitate the release of the solidified tablets from the mold [60, 199] or had problems with the 
brittleness of their formulations [53, 70]. Using TPUR as matrix former, no sticking to the 
mold was observed, nor brittleness of the matrix after cooling.  
Table 1. Physico-chemical characteristics of poly-ester (Pearlbond) and poly-ether (Tecoflex) thermoplastic 
polyurethanes (TPUR). 
 
TPUR 
grade 
HS SS SS/HS
(1)
 
 
Mw 
(g/mol) 
Tm 
(°C) 
Tg  
(°C) 
Melt ŋ 
(Pa.s)
(2) 
Max. drug load 
allowing HME 
(wt.%)  
P522 MDI
(3)
 PCL
(5)
 100 72 000 55 -60 12 000 50 
P520 MDI
(3)
 PCL
(5)
 100 72 000 55 -62 8 000 50 
P523 MDI
(3)
 PCL
(5)
 140 78 150 55 -60 1 500 65 
P539 MDI
(3)
 PCL
(5)
 150 67 500 56 -60 700 65 
T85A HMDI
(4)
 pTHF
(6)
 15 82 000 77 -26 7 000 65 
T100A HMDI
(4)
 pTHF
(6)
 5 89 000 64 10 12 100 65 
T72D HMDI
(4)
 pTHF
(6)
 3.5 59 000 53 / 20 000 75 
(1)
 determined via 
1
H-NMR; 
(2)
 determined at 70 and 140°C for Pearlbond and Tecoflex grades, respectively; 
(3)
 
methylene diphenyl diisocyanate; 
(4)
 Hydrogenated  methylene diphenyl diisocyanate; 
(5)
 polycaprolactone; 
(6)
 
polytetrahydrofuran  
  
Thermoplastic polyurethanes Ι Chapter 4 
 
 129 
 
 
 
Figure 3. Thermal analysis: (A) MDSC thermograms of Pearlbond TPUR grades with different SS/HS ratios ; 
(B) detailed MDSC thermograms identifying Tg and ∆Cp. 
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In-vitro drug release 
 
Figure 4. Mean dissolution profiles (± S.D.) of Pearlbond matrices in function of (A) drug load: 50% (■), 60% 
(●) and 65% MPT (x); (B) drug solubility: 65wt.% TH (∆), Dyph ( ) and MPT (x); pore former (C) PEG 4000 
or (D) Tween 80: Dyph/Pearlbond 65/35 (■) with 2 (▲), 5 (▼) and 10% (♦) of pore former, respectively.  
The influence of drug load on the release is illustrated in Figure 4A. By incorporating 
50, 60 and 65wt.% MPT in the TPUR matrix, the release after 24h is 33, 66 and 100%, 
respectively. These findings can be correlated to the percolation theory [200-201] as a 
minimum amount of MPT (percolation threshold) is needed to generate sufficient pores in the 
inert TPUR matrix in order to ensure sufficient diffusional channels throughout the entire 
matrix allowing dissolution and release of the entire drug content. The release mechanism 
from the TPUR matrices is entirely diffusion controlled as no changes in tablet dimensions 
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(diameter/height) and tablet geometry (biconvex tablets) were observed for any of the 
formulations: no swelling or erosion occurred upon wetting of the TPUR matrices. At 
constant drug load, the drug release profiles were independent of the TPUR grade 
incorporated in the formulation (data not shown). Figure 4B illustrates the effect of drug 
solubility on the release profiles (at a 65wt.% drug load). While the highly soluble MPT 
(aqueous solubility >1000 mg/mL) ensures a complete release after 24h, the release of Th 
(10mg/mL) and Dyph (333mg/mL) was, due to their lower aqueous solubility, limited to 20 
and 50%, respectively. The addition of a pore former was required to ensure complete release 
of these drugs: Figure 4C and 4D represent the effect of PEG 4000 (hydrophilic substance) 
and Tween 80 (surfactant) on the release of Dyph. A gradual increase in drug release is 
observed in function of the amount of pore-former. The addition of PEG 4000 and Tween 80 
to the formulation not only facilitated drug release from the TPUR matrices by generating 
extra diffusional channels for the API, it also enabled the production of matrices with a higher 
drug load (>65wt.%) as the melting of PEG 4000 and the liquid Tween 80 phase acted as a 
lubricant during HME/IM processing. A P539 formulation with a 70% MPT load and 10%  
PEG 4000 could be processed into high quality tablets; obviously this higher drug load 
compromised the sustained release capacities of the formulation (complete release already 
after 12h, data not shown). In addition to the lubricating effect of the pore formers, the 
addition of 5 and 10% Tween 80 to the formulation (Dyph/P539 65/35) reduced Dyph 
crystallinity to 76% and 67%, respectively, thus lowering the rotational friction during 
HMEand improving processability. Similar results were obtained when PEG 4000 was used 
as pore-former (data not shown). Figure 5 illustrates the correlation between tablet porosity 
and in vitro drug release of a MPT/P539 65/35 formulation: the dissolution of interconnecting 
drug clusters creates additional pores through which the remaining drug can dissolve, creating 
an empty porous TPUR matrix after 24 h. The formation of additional pores during 
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dissolution and the creation of an empty porous TPUR matrix was confirmed via AFM and 
SEM experiments (Figure 6). Prior to dissolution, needle-like MPT crystals were detected at 
the surface of the tablet, whereas after dissolution pores of approximately 10µm were 
observed.  
 
Figure 5. Mean dissolution profile (± S.D.) of MPT/Pearlbond 65/35 in correlation with the tablet porosity.  
 
Figure 6. Tablet characterization before and after dissolution: porosity (He pycnometry), AFM and SEM 
images. 
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Raman mapping  
To evaluate the distribution homogeneity of the crystalline API, Raman microscopic 
mapping was performed on the tablets. Six areas were mapped and each area was analyzed 
using MCR analysis to determine the true underlying factors contributing to the spectral 
variation. The spectral range studied (800-1500cm
-1
) contained the fingerprint region of both 
components of the formulation. No spectral difference was observed in any of the six 
evaluated area: crystalline API was homogeneously distributed at the surface of the tablet 
(mapping in supporting information). 
Oral toxicity: Simulator human intestinal microbial ecosystem (SHIME) 
Toxicological reports of TPUR have been widely described for their use in (breast) 
implants, intravaginal rings, stents, coating, etc. [16, 25, 184-185, 187, 202-204]. However, 
no data about the toxicity of TPUR are available upon oral intake. While the SHIME study 
does not provide an entire toxicological report, it can give a first impression about the impact 
of the gastro-intestinal fluids on the integrity of TPUR and the effect of TPUR on the 
microbial flora. Upon oral intake, the formulation passes the intestinal environment where 
chemical and/or enzymatic reactions can affect the polymer structure. Also, the human colon, 
which is colonized by a complex microbial community, can modify the polymer structure and 
may in turn be influenced by exposure to the polymer. To this end, P523 and T85A (2g/l) 
were added to the SHIME system to determine its intestinal stability and its possible impact 
on microbial metabolism indicators (pH, short chain fatty acids [205] and bacteria). No 
significant differences were observed in bacterial count (Figure 7), short chain fatty acids and 
pH (data not shown). The polymer structure of T85A was not altered during gastro-intestinal 
transit as MDSC and FTIR showed similar thermal behavior and spectra, respectively. The 
structure of P523, on the other hand, was affected as the peaks at 1100, 1275 and 1325cm
-1
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disappeared after exposure to the SHIME media. The first peak was linked to symmetrical 
ester stretch vibration [206], whereas the other two were assigned to chemical changes in the 
amorphous SS region of TPUR [206]. Previous research [207-208] already described that 
polyether-based polyurethanes are more resistant to biodegradation than polyester-based 
polyurethanes. This first toxicity screening of T85A revealed no evidence of chemical and/or 
enzymatic reaction after exposure to the intestinal environment, whereas P523 showed signs 
of ester linkage degradation/hydrolysis. This first indication, regarding TPUR toxicity upon 
oral administration, was considered positive as the activity or composition of the GI bacterial 
community, the pH values and the presence of short chain fatty acids were not altered after 
exposure to both polymers.  
 
 
Figure 7. Boxplot curves of bacterial counts of the SHIME experiment after exposure of (A) P539, (B) T85A 
and (C) control. The polymer concentration was 2g/l in both treatment groups; no polymer was used in the 
control group. 
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In vivo evaluation 
Figure 8 illustrates the in vitro dissolution profiles and the mean plasma concentration-
time profiles after oral administration to beagle dogs of MPT tablets (polyurethane matrix, 
drug load 65wt.%) and the reference formulation (Slow-Lopresor® 200 Divitabs®, drug load 
47wt.%). In vitro dissolution yielded a complete release of MPT after 12 and 24 h for the 
reference and the polyurethane matrix, respectively. The reference formulation is subjected to 
surface erosion of its matrix allowing MPT to escape faster due to the increased surface area, 
while the tablet geometry of the polyurethane matrix remained unchanged after 24 h 
dissolution experiments. These differences between in vitro drug release patterns were also 
reflected in their in vivo behavior. Oral administration of the polyurethane formulation 
resulted in a lower Cmax and a more sustained release of MPT (up to 16 h) compared to the 
reference formulation (up to 12 h). These differences in MPT plasma concentration, however, 
were not statistically significant. Moreover, intact TPUR tablets, which still contained 13% of 
their initial MPT content, were collected from the faeces of the dogs. No remnants of the 
reference formulation were found. This is probably attributed to the fast gastro-intestinal (GI) 
transit time in dogs in combination with a limited amount of fluids in the dog [144], thereby 
limiting MPT dissolution from the polyurethane matrix. The reference formulation is, 
compared to the polyurethane matrix, less susceptible to the GI transit time and the limited 
fluids as surface erosion altered the surface area of the formulation. Other pharmacokinetic 
parameters (AUC, tmax and HVDt50%Cmax) did not differ significantly (p>0.05).  
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Figure 8. In vitro dissolution experiments and mean MPT plasma concentration (± S.D.) after oral 
administration of 200mg MPT (normalized dose) to dogs (n=6) as tablets containing MPT/Pearlbond 65/35 (■)  
and as Slow-Lopresor 200 Divitabs® (●) 
Conclusion 
This study demonstrated that TPUR polymers are promising matrix formers to 
produce oral controlled release formulations. Sustained release (in vitro and in vivo) of MPT, 
a highly water-soluble drug, was achieved, while diprophylline required a drug release 
modifier (Tween 80 or PEG 4000). The high drug load in combination with controlled release 
capacities is noteworthy in the field of formulations produced via HME/IM. 
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Supporting information 
Raman Mapping: the spectral range studied (800-1500cm
-1
) contains the fingerprint region of 
both components. For each mapped area, two MCR analysis were done. Firstly, as the tablet is 
composed by two elements, a 2 factors MCR was performed. Two identical spectra were 
systematically obtained (SF1), the MCR analysis wasn’t able to separate the two contributions 
in the spectra signifying the homogeneity of the spectra within the monitored area. 
 
Figure S1. Spectra 1 and 2 obtained after a 2 factors MCR analysis. 
 
The homogeneity of the tablet can also be visualized with 2D plots of a 2 factors MCR 
analysis (SF2). 
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Figure S2. Raman mapping of an area of the surface of an IM-tablet containing 65% MPT and 35% 
TPUR: red and blue color corresponding to spectral differences 
 
Secondly, an auto MCR was performed and always resulted in only one spectra, a 
supplemental indication of the homogeneity of the spectra within the monitored areas. 
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Introduction 
 
Hot melt extrusion (HME) combined with injection molding (IM) as downstream 
processing step is a suitable technique to manufacture solid dosage forms with high 
dimensional precision [53, 70, 155, 209]. The use of polyurethanes as carrier for the 
production of sustained release formulations is favorable due to their highly elastomeric 
character, superior tensile strength, crack resistance and inherent lubricity. They have been 
successfully used for many years as drug release controlling polymers in vaginal rings [16, 
25, 184], stents [185], coatings [186], implants [187], and medical tubings [122]. The inert, 
non-ionic and water-insoluble nature of polyurethanes enables them to release the 
incorporated API in a sustained manner, even at high drug loadings (>50wt.%) [121].  
However, depending on the properties of the drug the addition of a third component is 
required in the formulation to ensure complete drug release. The development of a 
polyurethane-based biomaterial, for instance, required the use of a pore former to alter the 
release characteristics of an antibacterial agent (cefadroxil) to prevent bacterial adhesion and 
growth on its surface. The highest release rate was observed when bovine serum albumin 
(BSA) was incorporated in the TPUR matrix, compared with polyethylene glycol (PEG 1450) 
and mannitol, possibly due to the different aqueous solubility of the pore formers although 
further investigation was necessary [210]. In the development of an antifungal catheter, PEG 
2000 and BSA were added to control the release of fluconazole in a water-swellable 
polyurethane matrix. The addition of PEG resulted in faster release profiles, whereas BSA 
was able to control the release over a longer period, which was attributed to its higher 
molecular weight (69 000 and 2000 g/mol for BSA and PEG, respectively) [211]. An oral 
TPUR application, containing mixtures of TPUR and diprophylline required the incorporation 
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(2, 5 and 10%) of a pore former (PEG 4000) or a surfactant (Tween 80) to ensure complete 
drug release over a 24 h period [121]. 
This paper evaluates the effect of dicarboxylic acids on the release characteristics of 
diprophylline from polyurethane matrices processed via hot-melt extrusion and injection 
molding. Malonic, succinic, maleic and glutaric acid were selected as dicarboxylic acids as 
their differences in aqueous solubility, melting point, pKa, polarity and chemical structure 
allows to identify the critical parameters towards the release enhancing effect from the 
polyurethane matrix.   
Experimental Section  
Materials 
Diprophylline (Dyph, 7-(2,3-dihydroxypropyl)-theophylline) was embedded as drug in 
the thermoplastic polyurethane (TPUR) matrix. Tecoflex 72D (T72D, a medical-grade 
polyurethane) was obtained from Merquinsa (a Lubrizol company, Ohio, USA). Malonic, 
succinic, maleic and glutaric acid were purchased from Sigma (St-Louis, USA). The chemical 
structures of all materials are detailed in Figure 1, while the chemical properties of the 
dicarboxylic acids are listed in Table 1. Distances between various atoms were determined via 
Chem 3D Pro (PerkinElmer, Massachusetts, USA). 
Table 1: Chemical characteristics of dicarboxylic acids 
Dicarboxylic 
acid 
COOH 
-R- 
COOH 
pKa1 Tm 
(°C) 
Solubility 
in H2O 
(g/L) 
logP 
Malonic 
Succinic 
Maleic 
Glutaric 
CH2 
CH2CH2 
CH=CH 
(CH2)3 
2.8 
4.2 
1.9* 
4.3 
135 
184 
135 
95 
1400 
60 
790 
430 
-0.81 
-0.59 
-0.5 
-0.29 
   * Low pKa due to intramolecular H-bonding 
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Figure 1. Chemical structure of (A) diprophylline, (B) dicarboxylic acids and (C) Tecoflex 72D thermoplastic 
polyurethane. 
Thermal analysis 
The glass transition temperature (Tg) and melting point (Tm) of pure components, 
physical mixtures and injection molded tablets were analyzed in Tzero pans (TA instruments, 
Zellik, Belgium) by modulated differential scanning calorimetry (MDSC Q2000, TA 
Instruments, Leatherhead, UK) using a heating rate of 2°C/min. The modulation period and 
amplitude were set at 1min and 0.318°C, respectively (heat-iso method). Dry nitrogen at a 
flow rate of 50mL/min was used to purge the MDSC cell. All results were analyzed using the 
TA Instruments Universal Analysis 2000 software. Samples (± 5mg) were run in Tzero pans 
(TA Instruments, Zellik, Belgium). MDSC heat capacity calibration was done via small 
sapphire disks, placed in a Tzero pan. Analysis of the thermal characteristics (Tm and Tg) was 
done via a heating/cool/heat run between -70 and 140°C. The melting enthalpy (in the total 
heat flow signal), Tmelt-max (i.e. inflection point of melting endotherm) and Tmelt-onset (i.e. start 
of melting endotherm) were analyzed in the first heating cycle. Analysis of the glass transition 
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temperature was done in the first and second heating cycle for the injection molded tablets 
and the physical mixtures, respectively. All results were analyzed using the TA Instruments 
Universal Analysis 2000 software. 
X-ray diffraction (XRD) 
The crystallinity of the samples was determined via X-ray diffraction using a D5000 
Cu Kα diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 kV and 
current of 40 mA in the angular range of 10° < 2θ < 60° using a step scan mode (step width = 
0.02°, counting time = 1 s/step). 
Karl Fischer 
The water content of all dicarboxylic acids was determined by volumetric Karl Fischer 
titration using a V30 volumetric KF titrator (Mettler Toledo, USA). Methanol (Hydranal, 
Sigma Aldrich, Germany) was used as solvent. Before titration, 1g was dissolved in methanol 
during 1000 s. All measurements were performed in triplicate. 
Fourier Transform Infrared Spectroscopy 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 
performed on pure substances, physical mixtures and heated physical mixtures in order to 
identify molecular changes upon heating. Physical mixtures of Dyph and dicarboxylic acid 
(PM acid) at a molar ratio of 1/1 were compared with their respective PM after heating 
(2°C/min up to 140°C) and recooling to room temperature (heat-treated PM). 
Spectra (i.e. 10 samples per physical mixture, 1 spectrum per sample, 40 spectra for 
PM acid and 40 spectra for PM acid heated) were recorded using a Nicolet iS5 ATR FT-IR 
spectrometer (Thermo Fisher Scientific). A diamond ATR crystal was pressed against the 
samples. Each spectrum was collected in the 4000 - 550 cm
-1
 range with a resolution of 2 cm
-1
 
and averaged over 32 scans. FTIR spectral data analysis was done using SIMCA P+ v.12.0.1 
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(Umetrics, Umeå, Sweden). The spectral ranges of 1000-1120cm
-1
 and 880-780cm
-1 
were 
evaluated via principal component analysis. All collected FTIR spectra were preprocessed 
using standard normal variation (SNV)  
 
Production of injection molded tablets 
Physical mixtures of drug and polymer were extruded at 140°C using a co-rotating 
twin-screw extruder at 100rpm (Haake MiniLab II Micro Compounder, Thermo Electron, 
Karslruhe, Germany). The API/TPUR ratios (wt.%) used in this study were 75/25, 65/35 and 
50/50 with a processing temperature of 140°C. Biconvex tablets (diameter: 10mm/height: 
5mm) were produced via injection molding (Haake MiniJet System, Thermo Electron). The 
injection pressure was 800bar during 10s, in combination with a post-pressure of 400bar for 
5s. 
In vitro drug release 
Drug release from the injection molded tablets was determined using the paddle 
method on a VK 7010 dissolution system (VanKel Industies, New Jersey, USA) with a paddle 
speed of 100rpm. Distilled water was used as dissolution medium (900mL) at 37 ± 0.5°C. 
Samples were withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and spectrophotometrically 
analyzed for Dyph concentration at 274nm. 
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Results and Discussion 
The standard formulation: processability, release and solid state characterization 
Processing of TPUR/Dyph mixtures via HME and IM at 140°C required a minimum 
of 25% of thermoplastic polymer to provide sufficient plasticity to the formulations, as Dyph 
remained mainly crystalline during thermal processing. Mixtures with higher drug loads 
(>75wt.%) could not be processed as the powder fraction was too high to ensure an adequate 
flow in the extruder (i.e. too high screw torque). Dyph release (Figure 2A) from the standard 
formulation was incomplete: 9, 41 and 55% Dyph was released after 24h from TPUR matrices 
with drug loads of 50, 65 and 75%, respectively. This indicated that - despite the high drug 
load - a continuous interconnecting network was not achieved in the TPUR matrix and that a 
release modifier is required to enhance Dyph release. Although 2 polymorphs of Dyph with 
distinct melting temperatures, melting enthalpies and crystallographic spectra (Figure 2B and 
2C) have been described, after thermal processing only Form I (Tm 162°C, 175J/g, a 
thermodynamically stable form) was detected in the DSC signal of TPUR/Dyph matrices. 
This observation was confirmed via XRD (Figure 2C). The formation of the kinetically stable 
Form II (Tm 150°C, 135J/g) has been described after recrystallization from solvents/melts 
[212].  
Figure 2. (A) Mean dissolution profiles (± S.D.) of the standard formulation Dyph/TPUR at different ratios 
(wt.%): (▲) 50/50, (□) 65/35 and (●)75/25; (B) thermal analysis via MDSC and (C) XRD-diffractograms 
confirming the presence of Dyph form I in the standard formulation. 
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Addition of dicarboxylic acids as drug release modifiers  
 
Figure 3. Mean dissolution profiles (± S.D.) of the standard formulation Dyph/TPUR (75/25) (●) with 
dicarboxylic acids as drug release modifiers: (A) maleic acid, (B) malonic acid, (C) glutaric acid and (D) 
succinic acid: 2.5% (○) and 5% (□); (Summary) comparison of the profiles Dyph/TPUR (75/25) with the 
addition of 2.5% dicarboxylic acids. 
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Figure 3 evidences that the release of Dyph was improved via the addition of 
dicarboxylic acids. This improvement was concentration driven, as higher concentrations of 
dicarboxylic acids induced faster drug release. However, figure 3E shows that the solubility of 
the dicarboxylic acids is not the main contributing factor for the enhanced release rate. 
Malonic acid (Fig 3B), having the highest water solubility (1400g/L), was the least successful 
drug release modifier. No correlation was found between the drug release modifying capacity 
and logP, pKa or Tm of the dicarboxylic acids. Succinic and maleic acid yielded the highest 
release modifying effect, which might indicate that the specific chemical structure of these 
two acids (i.e. two methylene groups between the carboxylgroups) is important for their 
superior drug release altering capacity.  
The effect of dicarboxylic acids on drug release was not linked to changes in 
polymorphic structure of Dyph. XRD profiles of thermally processed Dyph/TPUR matrices in 
combination with maleic acid (Figure 4) only showed signals of the innate crystallographic 
form of Dyph (i.e. Form I) as the specific peaks of Dyph Form II (10.0, 24.1, 25.2 and 28.2°) 
were absent in the formulation. Moreover, there was no correlation found between the water 
content of the dicarboxylic acids and their drug release modifying capacity. Karl Fisher 
experiments indicated that the water content of all dicarboxylic acids was similar and lower 
than 1% (  0.05, n=3, data not shown).  
 
Figure 4. XRD diffractograms of (1) Dyph form I, (2) Dyph form II, (3) standard formulation + 5% maleic acid 
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Interaction between diprophylline and dicarboxylic acids 
The probability of interactions between the different dicarboxylic acids and Dyph were 
evaluated via thermal analysis (MDSC) and spectroscopic analysis (ATR-FTIR combined 
with PCA-analysis). 
MDSC 
The thermal results presented in this section are, for the sake of clarity, limited to a 
comparison between malonic and maleic acid, as both dicarboxylic acids have the same Tm 
(134°C), but their impact on the release characteristics is markedly different (the lowest and 
highest drug release modifying capacity was attributed to malonic and maleic acid, 
respectively).  
The themograms of the physical mixtures revealed an interaction between Dyph and 
both dicarboxylic acids based on the reduction of the thermal parameters (Tmelt-max, Tmelt-onset 
and degree of crystallinity) of Dyph during the first heating cycle. The interaction between a 
crystalline API and an excipient can induce, depending on their respective molar ratio, 
(partial) dissolution of the API, and as the resulting smaller API crystals are intrinsically less 
stable, peak broadening of the melting endotherm is observed. These phenomena were more 
pronounced when Dyph was combined with maleic acid compared to malonic acid (Figure 5, 
left). The second heating cycle of Dyph/dicarboxylic acid mixtures revealed a glass transition 
signal which was constant in combinations with malonic acid, whereas Tg varied when maleic 
acid was used, indicating a change in molecular mobility due to interactions at a molecular 
level (Figure 5, middle). These thermal results of the physical mixtures provide a clear 
indication of stronger interactions between Dyph and maleic acid, compared to Dyph/malonic 
acid mixtures. Thermal investigation of the injection molded tablets (IM) illustrated similar 
effects (Figure 5, right): the addition of 5% malonic and maleic acid reduced Tmelt-max of Dyph 
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from 162 to 159 and 154°C, respectively. Moreover, without the addition of dicarboxylic 
acids, 80% of the Dyph fraction remained crystalline in a TPUR matrix. The degree of 
crystallinity of Dyph in formulations processed with malonic acid was not affected, whereas 
Dyph crystallinity was reduced to 73 and 68%, respectively, when 2.5 and 5% maleic acid 
was used as release modifier. These results confirmed the higher affinity between Dyph and 
maleic acid, compared to malonic acid. 
 
 
Figure 5. Thermograms of physical mixtures (PM) of Dyph and dicarboxylic acids (molar ratio: 9/1, 6/1, 2/1 and 
1/1) during the 1
st
 (left, to analyse Tmelt-max) and 2
nd
 heating cycle (middle, to analyse Tg), and of an HME/IM-
processed Dyph/TPUR mixture (ratio: 75/25) in combination with 2.5 and 5% dicarboxylic acids (right) during 
the 1
st
 heating cycle. Formulations contained malonic acid (top) and maleic acid (bottom). 
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ATR-FTIR  
As thermal analysis indicated the importance of molecular interactions for the release-
enhancing effect of dicarboxylic acid in a TPUR matrix, the affinity between the different 
dicarboxylic acids and Dyph was further explored via FTIR analysis.  
 
Figure 6.  A) PC1 versus PC2 scores plot obtained after PCA of 1000-1120cm
-1
 spectral range of the FTIR 
spectra obtained after heat-treatment (heating rate: 2°C/min to 140°C) of physical mixtures of Dyph and 
dicarboxylic acids. Each point represents one sample and each symbol represents a different physical mixture. B) 
PC1 loadings plot obtained after PCA of the FTIR spectra from the 4 physical mixtures heated. 
Principal component analysis of the FTIR spectra of the heat-treated PM was 
performed using the 1000-1120cm
-1
 spectral range. All preprocessed FTIR spectra were 
decomposed into four principal components (PCs) explaining 98.6% of the total spectral 
variance where PC1 accounted for 65.1%, PC2 24%, PC3 6.1%, and PC4 3.4% of the spectral 
variance, respectively. Figure 6A illustrates the scores clustering according to PC1 and PC2. 
Interestingly, PC1 distinguishes two groups: mixtures with succinic and maleic acid (i.e. 
dicarboxylic acids inducing the highest drug release modifying capacity, Fig. 3) and mixtures 
with malonic and glutaric acid (having the lowest drug release modifying capacity, Fig. 3). 
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Examination of the PC1 loadings plot (Figure 6B) to identify the spectral variability 
responsible for this clustering in group 1 and 2 revealed four important peaks, all attributed to 
the chemical structure of Dyph: 1105 and 1096cm
-1
 of the C-O stretching of the secondary 
alcohol, 1058cm
-1
 of the C-O stretching of the primary alcohol, and 1032cm
-1
 of the C-N 
stretching of the tertiary aliphatic amine [213].  
Figure 7A and 7B illustrate the FTIR spectra of the physical mixtures (full line) and 
the heat-treated samples (dotted lines) over the 1000-1120cm
-1
 spectral range. Before heating, 
the peaks of interest were identical for all PM, independent of the type of dicarboxylic acid. 
Although the intensity of C-O stretching of the primary and secondary alcohol decreased upon 
heating and cooling of all samples, these peaks (1 and 2 on Figure 7) completely disappeared 
in the heat-treated mixtures containing maleic and succinic acid. The peak indicative of C-N 
stretching of tertiary aliphatic amines shifted towards lower wavenumbers (peak 3 on Figure 
7). This shift was larger in combination with maleic and  succinic acid. A new peak was 
formed at 820cm
-1
 and 812cm
-1
 for the heat-treated samples of Dyph/maleic acid and 
Dyph/succinic acid, respectively (peak 4 and 5 on Figure 7). This was attributed to a C-H 
vibration shift due to the interaction between both components [213]. These spectral changes 
clearly confirmed the more extensive interactions between Dyph and maleic/succinic acid 
(compared to malonic/glutaric acid). A structural fit between the primary and secondary 
alcohol of Dyph and both carboxylic groups of the acids is, most likely, at the origin of this 
enhanced interaction (Figure 7E): the distance (i.e. two methyl groups) between the two 
oxygens groups of the carbonyl of maleic (2.7Ǻ) and succinic acid (2.5Ǻ) is similar to the 
distance between the two hydroxyl groups of Dyph (2.8Ǻ). Hence, 2 H-bonds can easily be 
formed, yielding more interactions and the complete disappearing of their respective C-O 
stretch peaks. Malonic acid (i.e. one methyl group) and glutaric acid (i.e. three methyl groups, 
Figure 7E) did not structurally match with Dyph, resulting in a lower degree of molecular 
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interactions (distance between oxygens of the carbonyl group being 3.9 and 4.7Ǻ for malonic 
and glutaric acid, respectively). Hence, the peak of the C-O stretch was still observed in these 
peaks, although its intensity had dropped.  
 
Figure 7. FTIR spectra of physical mixtures (full line) and heat-treated physical mixtures (dotted lines) of Dyph 
and dicarboxylic acid (molar ratio 1/1) over the 880-780cm
-1
 (bottom) and 1000-1120cm
-1
 (top) spectral region: 
(A, C) mixtures with malonic (grey) and glutaric acid (black); (B, D) mixtures with succinic (black) and maleic 
acid (grey); (E) formation of H-bond(s) between Dyph and maleic (top) or glutaric acid (bottom). 
To confirm that stronger interactions between Dyph and maleic/succinic acid are due 
to a structural fit between these components, the interaction between fumaric acid 
(enantiomeric form of maleic acid) and Dyph was monitored. The carboxylic acid groups of 
fumaric acid are in trans-form (both COOH at the opposite side of the backbone), while in 
maleic acid they are in cis-form (similar side of the backbone). FTIR spectra and in vitro 
release data illustrated that fumaric acid did not interact with Dyph to the same extent as 
maleic acid (data not shown): the C-O stretch of both hydroxyl groups and the shift of C-N 
stretch in Dyph were less affected in this combination. Moreover, in vitro Dyph release was 
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lower for fumaric acid in comparison to maleic acid formulations: 39 and 50% after 4 h for 
fumaric and maleic acid, respectively. These observations confirmed that the superior release 
modifying capacity of maleic/succinic acid is attributed to a structural fit between Dyph and 
dicarboxylic acids. 
Ester bond formation between the OH-groups of Dyph and maleic/succinic acid was 
excluded as the addition of a drop of 0.5g/ml LiBr solution to a heat-treated Dyph/maleic acid 
sample neutralized the spectral changes, confirming the reversible nature of the molecular 
interactions between Dyph and maleic acid and the absence of an irreversible ester-bond. The 
addition of a LiBr solution results in a breakdown of the reversible inter- and intra-molecular 
H-bonds, since the bromide anion acts as a strong nucleophilic component, whereas Li
+
 
interacts with the carbonyl group [214].  
Conclusion 
A high dosed sustained release formulation was developed via hot melt extrusion and 
injection molding. Despite the high drug load (75wt.% Dyph), a drug release modifying agent 
was essential to release the entire Dyph fraction in a sustained manner from the TPUR matrix. 
Succinic and maleic acid had a superior release modifying capacity which was attributed to 
more intense molecular interaction with Dyph (H-bonds). A structural fit between the primary 
and secondary alcohol of Dyph and both carboxylic groups of the acids was at the origin of 
this enhanced interaction. 
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GENERAL CONSLUSIONS AND  
FUTURE PERSPECTIVES 
 
 
The objective of this doctoral thesis was to evaluate the use of polymethacrylates, 
quaternized polymethacrylates, modified polymethacrylates, polyoxazolines and 
polyurethanes for the development of immediate and sustained release formulations via hot 
melt extrusion (HME) and injection molding (IM). Modifications were made on 
pharmaceutically approved polymers and two non-conventional polymers were evaluated with 
the goal of expanding the range of polymers currently used for HME/IM. Despite the 
extensive research being conducted today, researchers should face the reality: the number of 
marketed products manufactured via HME and/or IM as processing technique has been 
disappointing.  This work encourages an update of the regulatory framework. Currently, there 
are no regulatory approval processes specifically for novel excipients. Information about the 
quality and safety of new excipients is only reviewed by the health authorities in the context 
of a new drug application causing difficulties for both manufacturers and the users of these 
excipients. This work also encourages formulation researchers to think outside-the-box. There  
really is a need for a more rational design/use of polymer matrix excipients for drug 
formulation via HME and IM. The polymers from yesterday are not satisfactory enough to 
deal with today’s problems. To this end, the use of thermoplastic polyurethanes is especially 
promising. They allow the production of a high drug loaded formulation, thereby diminishing 
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the amount of excipient needed and creating a major advantage for the patient’s compliance 
and the environment. 
Nevertheless, a few topics can be identified for future investigation/are subject for 
improvement: 
 There exist thermoplastic polyurethanes (TPUR) that are hydrophilic and 
water swellable. Evaluating those types of polyurethanes (PU) via HME/IM 
would be interesting.  
 Using other high dosed BCS class I API’s in combination with TPUR. 
 The evaluation of different types of TPUR via HME/IM: TPUR are available 
in various molecular weights, different types (polyester, polyether, 
polycarbonates, etc.) of SS, different SS lengths, and variable SS/HS ratios 
which makes them attractive candidates to alter drug release performances 
based on polymer composition. 
 Thermoplastic polyurethanes (TPUR) are often available in pellet-form. 
Finding processing steps to produce TPUR in powder form would be 
beneficial. 
 An investigation on how to produce the used formulation on a more industrial 
scale (upscaling). 
 Evaluating the use of polyurethanes for vaginal/rectal use would be interesting 
as these routes of administration are subjected to less regulatory obligations. 
 Polyurethanes are in this work evaluated via HME and IM. Processing the PU 
via other manufacturing techniques (melt granulating, direct compression) 
would increase the amount of possible applications. Preliminary tests 
evidenced that melt granulating PU could also lead to high drug load 
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formulation, which upon direct compression can result in very rigid tablets. 
Possible applications can be found in the field of drug abuse (e.g. crushing 
rilatin and taking it sublingual or snorting it to increase its potency). 
 An evaluation of the type of polymers that can be used on a micro-molding 
device. Miniaturized drug delivery systems are especially interesting for 
patients with a daily pill burden. 
 Polymers are widely used for various applications in all types of industry. 
Researchers should reach out and learn from those other domains in order to 
use that knowledge in the field of pharmaceutical technology. The problem is 
often that manufacturers of novel excipients only disclose their sensitive 
information (e.g. molecular structure, specific additives) in confidentiality. 
This makes the formulation research and the physicochemically 
characterization difficult as the researcher is unaware of all the ‘ingredients’ in 
the polymer. A more close collaboration with the industry would be beneficial 
to create trust, recognition and find mutual beneficial projects. To this end, the 
research valorization would increase and it would create more transparency 
resulting possibly in a more positive public opinion about governmental 
sponsored research. 
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SUMMARY 
 
Hot melt extrusion (HME) is an established process that has been used for almost a 
century. The combination with injection molding (IM) enables the processing of materials 
with high dimensional precision. These techniques rely on obtaining a homogeneous system 
via a substantial energy input, provided by elevated temperature, high shear force, and 
pressure. Despite the extensive research being conducted today, the number of marketed 
products manufactured via HME and/or IM as processing technique has been disappointing. 
The objective of this doctoral thesis was, therefore, to evaluate the use of polymethacrylates, 
quaternized polymethacrylates, modified polymethacrylates, polyoxazolines and 
polyurethanes for the development of immediate and sustained release formulations via 
HME/IM. Modifications were made on pharmaceutically approved polymers and two non-
conventional polymers were evaluated with the goal of expanding the range of polymers 
currently used for HME/IM. 
 
Chapter 1 investigated a polymethacrylate polymer, Eudragit

 E PO, as drug delivery 
matrix for immediate release purposes. A formulation IBP/EudrE 30/70 (wt.%) was processed 
via hot melt extrusion and injection molding, and subsequently physicochemically 
characterized. The release profile, however, was pH-dependent (only immediate release in 
acidic environments up to pH 3). The aim was to create a pH-independent release formulation 
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via the quaternization of the polymer (i.e. protonating the polymer’s amine function) or via 
the creation of a low pH microenvironment during dissolution with the aid of dicarboxylic 
acids (succinic, glutaric and adipic acid). Both resulted in a pH-independent (up to pH5)  
immediate release formulation. However, the presence of a positively charged polymer 
induced stability issues (recrystallization of API) and the formulations containing 
dicarboxylic acids were classified as mechanically unstable. Hence, further research is needed 
to obtain a pH-independent immediate release formulation via hot melt extrusion and 
injection molding. 
 
In chapter 2 several Eudragit E PO (n-butyl-, dimethylaminoethyl-, methyl-
methacrylate-terpolymer) analogues were synthesized via free radical polymerization. These 
polymers were processed via hot melt extrusion and injection molding, and evaluated as 
carriers to produce immediate release solid solution tablets. Three chemical modifications 
increased the glass transition temperature of the polymer: (a) substitution of n-butyl by t-butyl 
groups, (b) reduction of the dimethylaminoethyl methacrylate (DMAEMA) content and (c) 
incorporation of a bulky isobornyl repeating unit. These structural modifications revealed the 
possibility to increase the mechanical stability of the tablets via altering the polymer’s Tg 
without influencing the drug release characteristics and glassy solid solution forming 
properties. The presence of DMAEMA units proved to be crucial with respect to API/polymer 
interaction (essential in creating glassy solid solutions) and drug release characteristics. 
Moreover, these chemical modifications accentuate the need for a more rational design of 
(methacrylate) polymer matrix excipients for drug formulation via hot melt extrusion and 
injection molding. 
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Chapter 3 evaluated poly(2-ethyl-2-oxazoline)s (PEtOx) as matrix excipient for the 
production of oral solid dosage forms via hot melt extrusion (HME) followed by injection 
molding (IM). Using metoprolol tartrate as good water-soluble model drug, it was 
demonstrated that the drug release can be delayed via HME/IM, with the release rate 
controlled by the molecular weight of the PEtOx.  Using fenofibrate as lipophilic model drug, 
the drug dissolution rate was strongly enhanced. Hence, PEtOx polymers are a potentially 
interesting class of polymers to serve as matrix for controlled released formulations. Future 
research should, therefore, focus on the toxicity analysis of PEtOx, improving the release 
characteristics of the formulation (e.g. by investigating the influence of longer alkyl side 
chains or higher PEtOx MW), elaborating stability studies and the development of 
pharmaceutical grade PEtOx. 
 
Chapter 4 evaluated thermoplastic polyurethanes (TPUR) as matrix excipients for the 
production of oral solid dosage forms via hot melt extrusion (HME) in combination with 
injection molding (IM). It was demonstrated that TPURs enabled the production of solid 
dispersions – crystalline API in a crystalline carrier – at an extrusion temperature below the 
drug melting temperature (Tm) with a drug content up to 65% (wt.%). The release of 
metoprolol tartrate (MPT) was controlled over 24h, whereas a complete release of 
diprophylline (Dyph) was only possible in combination with a drug release modifier: 
polyethylene glycol 4000 (PEG 4000) or Tween 80. No burst release nor a change in tablet 
size and geometry was detected for any of the formulations after dissolution testing. The total 
matrix porosity increased gradually upon drug release. Oral administration of TPUR did not 
affect the GI ecosystem (pH, bacterial count, short chain fatty acids), monitored via the 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME). The high drug load 
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(65wt.%) in combination with (in vitro and in vivo) controlled release capacity of the 
formulations, is noteworthy in the field of formulations produced via HME/IM. 
 
In chapter 5, the influence of several dicarboxylic acids on the release characteristics 
of polyurethane tablets with a high drug load was investigated. Mixtures of diprophylline 
(Dyph) and thermoplastic polyurethane (TPUR) (ratio: 50/50, 65/35 and 75/25 wt.%) were 
hot-melt extruded (HME) and injection molded (IM) with the addition of 1, 2.5, 5 and 10wt.% 
dicarboxylic acid as release modifier. Incorporating malonic, succinic, maleic and glutaric 
acid in the TPUR matrices enhanced drug release, in function of the dicarboxylic acid 
concentration in the formulation. No correlation was found between the water solubility, 
melting point, logP and pKa of the acids and their drug release modifying capacity. Succinic 
and maleic acid had the highest drug release modifying capacity which was linked to more 
intense molecular interactions with Dyph. A structural fit between the primary and secondary 
alcohol of Dyph and both carboxylic groups of the acids was at the origin of this enhanced 
interaction. 
 
It can be concluded that this doctoral thesis accentuated the need for a more rational 
design of polymer matrix excipients for drug formulation via hot melt extrusion and injection 
molding 
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SAMENVATTING 
 
Hot melt extrusie (HME) is een productieproces die nu bijna een eeuw wordt 
gehanteerd. De combinatie met spuitgieten (injection molding, IM) maakt het mogelijk om 
finale producten te bekomen met een hoge dimensionele nauwkeurigheid. Beide technieken 
resulteren in een homogeen systeem met behulp van een aanzienlijke energietoevoer, geleverd 
door de verhoogde temperatuur, de hoge afschuifkracht en druk. Ondanks verschillende 
studies en uitgebreid onderzoek de afgelopen jaren, is het aantal geproduceerde producten via 
HME en IM teleurstellend. Vandaar het doel van dit proefschrift om het gebruik van 
polymethacrylaten, gekwaterniseerde polymethacrylaten, structureel gewijzigde 
polymethacrylaten, polyoxazolines en polyurethanen te evalueren in de ontwikkeling van 
formulaties die zorgen voor een onmiddellijke en aanhoudende vrijstelling van het 
geneesmiddel. Wijzigingen werden aangebracht op farmaceutisch goedgekeurde polymeren 
en twee niet-conventionele polymeren werden geëvalueerd met als doel het aantal polymeren 
die momenteel gebruikt worden voor HME/IM uit te breiden. 
 
Hoofdstuk 1 evalueerde een polymethacrylaat polymeer, Eudragit E PO, als drug 
delivery matrix voor onmiddellijke geneesmiddel vrijstelling. De formulatie IBP/EudrE 30/70 
(wt.%) werd verwerkt via hot melt extrusie en spuitgieten, en vervolgens fysicochemisch 
gekarakteriseerd. Het vrijstellingsprofiel was echter pH-afhankelijk (alleen onmiddellijke 
geneesmiddelvrijstelling in zure milieus tot pH 3). Het doel was om een pH-onafhankelijke 
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geneesmiddelvrijstelling te bekomen via de kwaternisatie van het polymeer (protonatie van de 
aminefunctie van het polymeer) of via de creatie van een micromilieu met lage pH met behulp 
van dicarbonzuren (barnsteenzuur, glutaarzuur en adipinezuur). Beide modificaties 
resulteerden in een pH-onafhankelijke (tot pH 5) onmiddellijke geneesmiddelvrijstelling. De 
aanwezigheid van een positief geladen polymeer induceerde echter stabiliteitsproblemen 
(herkristallisatie van API) en de formulaties die dicarbonzuren bevatten werden als 
mechanisch onstabiel beschouwd. Verder onderzoek is daarom nodig om een pH-
onafhankelijke onmiddellijke geneesmiddelvrijstelling te bekomen via hot melt extrusie en 
spuitgieten. 
 
In hoofdstuk 2 werden verschillende Eudragit E PO analogen (n-butyl-, 
dimethylaminoethyl-, methyl-methacrylaat-terpolymer) gesynthetiseerd via vrije radicale 
polymerisatie. Deze polymeren werden verwerkt via hot melt extrusie en spuitgieten en 
geëvalueerd als carriers om tabletten te produceren die zorgden voor een onmiddellijke 
geneesmiddelenvrijgave. Drie chemische modificaties werden doorgevoerd om de 
glastransitietemperatuur (Tg) van het polymeer te verhogen: (a) de substitutie van de n-butyl 
groepen door t-butyl groepen, (b) een afname van het aantal dimethylaminoethyl methacrylaat 
(DMAEMA) groepen en (c) de toevoeging van extra component die sterische hinder 
induceert: isobornyl methacrylaat. Deze structurele modificaties toonden aan dat het mogelijk 
was om de mechanische stabiliteit van de tabletten te verhogen door de Tg van het polymeer 
te verhogen, zonder de geneesmiddelenvrijstelling te wijzigen. Het aantal DMAEMA 
eenheden in het polymeer bleek cruciaal te zijn met betrekking tot de geneesmiddel-polymeer 
interactie (essentieel om een ‘glassy solid solution’ te creëren) en de vrijstelling van het 
geneesmiddel. Bovendien accentueerden deze chemische modificaties de nood aan een meer 
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rationeel design van (methacrylaat)polymeren als carriërs voor verwerking via hot melt 
extrusie en spuitgieten. 
 
Hoofdstuk 3 evalueerde poly(2-ethyl-2-oxazoline)s (PEtOx) als matrix excipienten 
voor de productie van een orale vaste formulatie via hot melt extrusie (HME), gevolgd door 
spuitgieten (injection molding, IM). Door metoprolol tartrate te gebruiken als hydrofiel 
geneesmiddel, werd aangetoond dat de geneesmiddelvrijstellingssnelheid kan vertraagd 
worden via HME/IM met controle van de vrijstellingssnelheid via het moleculair gewicht van 
de PEtOx. Ook werd aangetoond dat, door fenofibraat te gebruiken als lipofiel geneesmiddel, 
de geneesmiddelvrijstellingssnelheid fors toenam. Bijgevolg vormen PEtOx polymeren een 
potentieel interessante klasse bruikbaar in farmaceutische formulaties. Verder onderzoek is 
echter noodzakelijk met de focus op: (a) toxiciteit analyse  van de PEtOx polymeren, (b) 
verdere optimalisatie van de vrijstellingsprofielen, door bijvoorbeeld de invloed van PEtOx 
met langere alkyl zijketens te onderzoeken, (c) stabiliteitsstudies en (d) de ontwikkeling van 
een farmaceutisch veilig PEtOx polymeer. 
 
Hoofdstuk 4 analyseerde de thermoplastische polyurethanen (TPUR) als matrix 
excipienten voor de productie van orale vaste formulaties via hot melt extrusie (HME) en 
spuitgieten (injection molding, IM). Er werd aangetoond dat de TPURs het toelieten om solid 
dispersions - kristallijn geneesmiddel in een kristallijne carrier - te produceren met een hoge 
geneesmiddelbelading (65wt.%) bij een procestemperatuur die lager ligt dan de 
smelttemperatuur van het geneesmiddel. De vrijstelling van metoprolol tartrate (MPT) werd 
gecontroleerd gedurende een periode van 24u, terwijl een volledige vrijstelling van 
diprophylline (Dyph) slechts mogelijk was met behulp van een additief: polyethylene glycol 
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4000 (PEG 4000) of Tween 80. Er werd geen burst vrijstelling of verandering in tablet 
geometrie en grootte gedetecteerd bij de tabletten na dissolutie. De totale matrix porositeit 
steeg gradueel in functie van het vrijgestelde geneesmiddel. Orale toediening van TPUR 
beïnvloedde het gastrointestinaal (GI) ecosysteem (pH, aantal bacteriën, korte vetzuren) niet, 
wat werd aangetoond door middel van SHIME (Simulator of the Human Intestional Microbial 
Ecosystem). De hoge geneesmiddelbelading (65wt.%) in combinatie met de (in vitro en in 
vivo) gecontroleerde vrijstellingsprofielen is noemenswaardig voor formulaties geproduceerd 
door middel van HME/IM. 
 
In hoofdstuk 5 werd de invloed van verschillende dicarbonzuren op de 
vrijstellingsprofielen van polyurethane tabletten met een hoge geneesmiddelbelading 
onderzocht. Formulaties van diprophylline (Dyph) en thermoplastisch polyurethane (TPUR) 
(ratio: 50/50, 65/35 and 75/25 wt.%) werden geproduceerd via hot melt extrusive (HME) en 
spuitgieten (injection molding, IM). Aan deze formulaties werd vervolgens 1, 2.5, 5 en 
10wt% dicarbonzuur toegevoegd om hun invloed op het vrijstellingsprofiel te onderzoeken. 
Door de incorporatie van malonzuur, barnsteenzuur, maleïnezuur en glutaarzuur in de TPUR 
matrices, nam de geneesmiddelvrijstellingssnelheid toe in functie van de concentratie van 
dicarbonzuur. Er werd geen correlatie vastgesteld tussen de wateroplosbaarheid, smeltpunt, 
logP en Pka van de dicarbonzuren en hun invloed op de geneesmiddelvrijstelling. 
Barnsteenzuur en maleïnezuur hadden de grootste invloed op het vrijstellingsprofiel van de 
formulatie. Een meer intense interactie tussen beide zuren en diprophylline lag aan de oorzaak 
hiervan door een structurele ‘fit’ tussen het primaire en de secundair alcohol van 
diprophylline en beide carbonzure groepen van de zuren. 
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Er kan worden geconcludeerd dat deze doctoraatsthesis de nood naar een meer 
rationeel design van polymeer matrix excipienten beklemtoont om verbeterde formulaties te 
produceren via hot melt extrusie en spuitgieten. 
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